

**CUMULATIVE
SUPPLEMENT 7
JULY 2003**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

23rd EDITION

Department of Health and Human Services

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2003

HYMAN, PHELPS
& McNAMARA, P.C.
WASHINGTON, DC

DEMCO

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

23RD EDITION

Cumulative Supplement 7

July 2003

CONTENTS

	PAGE
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Applicant Name Changes.....	iv
1.3 Nitroglycerin, Film, Extended Release; Transdermal 23 rd Annual Edition	v
1.4 Availability of the Edition.....	vi
1.5 Report of Counts for the Prescription Drug Product List.....	vii
1.6 Cumulative Supplement Change Legend	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List.....	1-1
OTC Drug Product List.....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms.....	B-1

the first time in the history of the world.

It is the first time in the history of the world.

It is the first time in the history of the world.

It is the first time in the history of the world.

It is the first time in the history of the world.

It is the first time in the history of the world.

It is the first time in the history of the world.

It is the first time in the history of the world.

It is the first time in the history of the world.

It is the first time in the history of the world.

It is the first time in the history of the world.

It is the first time in the history of the world.

It is the first time in the history of the world.

It is the first time in the history of the world.

It is the first time in the history of the world.

It is the first time in the history of the world.

It is the first time in the history of the world.

It is the first time in the history of the world.

It is the first time in the history of the world.

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

23rd EDITION

**CUMULATIVE SUPPLEMENT 7
July 2003**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 23rd Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 23rd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 24th Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section A, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**D**> (DELETE) to the left of the line. The information line with the >**D**> symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

AAIPHARMA INC (AAIPHARMA)	AAIPHARMA LLC (AAIPHARMA LLC)
BAYER CORP (BAYER)	BAYER PHARMACEUTICALS CORP (BAYER PHARMS)
BAYER CORP CONSUMER CARE DIV (BAYER CORP CONSUMER)	BAYER CORP CONSUMER CARE LLC (BAYER)
BAYER CORP PHARMACEUTICALS DIV (BAYER)	BAYER PHARMACEUTICALS CORP (BAYER PHARMS)
ESI LEDERLE INC (ESI LEDERLE)	CLONMEL HEALTHCARE INC (CLONMEL HEALTHCARE)
LEK SERVICES INC (LEK SVCS)	LEK PHARMACEUTICALS DD (LEK PHARM DD)
LEK LJUBLJANA PHARMACEUTICAL AND CHEMICAL CO (LEK LJUBLJANA)	LEK PHARMACEUTICALS DD (LEK PHARM DD)
LEK PHARMACEUTICAL AND CHEMICAL DD (LEK PHARM)	LEK PHARMACEUTICALS DD (LEK PHARM DD)
NEOSAN PHARMACEUTICALS (NEOSAN PHARMS)	AAIPHARMA LLC (AAIPHARMA LLC)
ORGANON INC (ORGANON INC)	ORGANON USA INC (ORGANON USA INC)
ORGANON INC SUB AKZO INC (ORGANON)	ORGANON USA INC (ORGANON USA INC)
ORGANON INC SUB AKZO NOBEL INC (ORGANON INC)	ORGANON USA INC (ORGANON USA INC)
SIDMAK LABORATORIES INC (SIDMAK LABS)	PLIVA INC (PLIVA)
SYNTEX (USA) INC LLC (SYNTEX USA INC)	ROCHE PALO ALTO LLC (ROCHE PALO)
WALLACE LABORATORIES DIV CARTER WALLACE INC (WALLACE LABS)	MEDPOINTE PHARMACEUTICALS MEDPOINTE HEALTHCARE INC (MEDPOINTE PHARM HLC)
WALLACE PHARMACEUTICALS DIV CARTER WALLACE INC (WALLACE PHARMS)	MEDPOINTE PHARMACEUTICALS MEDPOINTE HEALTHCARE INC (MEDPOINTE PHARM HLC)

1.3 NITROGLYCERIN, FILM, EXTENDED RELEASE; TRANSDERMAL 23RD ANNUAL EDITION

The *Approved Drug Products with Therapeutic Equivalence Evaluations 23rd annual edition*, page 3-265 omitted the 3 character Therapeutic Equivalence (TE) Codes for Nitroglycerin, Film, Extended Release; Transdermal products. The correct codes are listed below by product name, applicant holder, TE code, strength, NDA number, and product number.

PRODUCT NAME	APPLICANT	TE CODE	STRENGTH	NDA	PRODUCT
MINITRAN	3M	AB1	0.1MG/HR	N89771	001
MINITRAN	3M	AB1	0.2MG/HR	N89772	001
MINITRAN	3M	AB1	0.4MG/HR	N89773	001
MINITRAN	3M	AB1	0.6MG/HR	N89774	001
NITRO-DUR	KEY PHARMS	AB1	0.1MG/HR	N20145	001
NITRO-DUR	KEY PHARMS	AB1	0.2MG/HR	N20145	002
NITRO-DUR	KEY PHARMS	AB1	0.4MG/HR	N20145	004
NITRO-DUR	KEY PHARMS	AB1	0.6MG/HR	N20145	005
NITROGLYCERIN	HERCON LABS	AB2	0.2MG/HR	N89884	001
NITROGLYCERIN	HERCON LABS	AB2	0.4MG/HR	N89885	001
NITROGLYCERIN	HERCON LABS	AB2	0.6MG/HR	N89886	001

NITROGLYCERIN	MYLAN	AB2	0.1MG/HR	N75033	001
NITROGLYCERIN	MYLAN	AB2	0.2MG/HR	N74609	001
NITROGLYCERIN	MYLAN	AB2	0.4MG/HR	N74607	001

1.4 AVAILABILITY OF THE EDITION

The 23rd Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800 or toll free 866-512-1800. The cost is \$108.00 annually. A GPO Orange Book Subscription form is provided at the end of each cumulative supplement.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at <http://www.fda.gov/cder/ob>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the monthly cumulative supplements.

The Internet version of the Orange Book annual edition is at
<http://www.fda.gov/cder/orange/adp.htm>

The Internet version of the monthly supplement is at
<http://www.fda.gov/cder/orange/supplement/cspreface.htm>

There are ASCII text files of the Orange Book drug product data at
<http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 23rd annual edition of the 2002 Orange Book Patent and Exclusivity List is at
<http://www.fda.gov/cder.orange/23bookpub.pdf>

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at <http://www.fda.gov/cder/orange/supplement/patents.pdf>

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at
<http://www.fda.gov/cder/orange/docket.pdf>. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
<http://www.fda.gov/cder/orange/patdecl.pdf>
<http://www.fda.gov/cder/orange/patdecl.htm>

The current listing of the Orphan Product Designations and Approvals is available at
<http://www.fda.gov/orphan/designat/list.htm>

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2002) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2002</u>	<u>JUN 2003</u>	<u>SEP 2003</u>	<u>DEC 2003</u>
DRUG PRODUCTS LISTED	10465	10514		
SINGLE SOURCE	2420 (23.1%)	2417 (23.0%)		
MULTISOURCE	7939 (75.9%)	7989 (76.0%)		
THERAPEUTICALLY	7659 (73.2%)	7708 (73.3%)		
EQUIVALENT				
NOT THERAPEUTICALLY	280 (2.7%)	281 (2.7%)		
EQUIVALENT				
EXCEPTIONS ¹	106 (1.0%)	108 (1.0%)		
NEW MOLECULAR ENTITIES	6	6		
APPROVED				
NUMBER OF APPLICANTS	598	604		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.


New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

- WDAG Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
- WDRP Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.



PRESCRIPTION DRUG PRODUCT LIST - 23RD EDITION
RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2003

1-1

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

SOLUTION; ORAL

ACETAMINOPHEN AND BUTALBITAL AND CAFFEINE

+ MIKART	325MG/15ML;50MG/15ML;40MG/15ML	N40387 001 JAN 31, 2003 JAN NEWA
TABLET; ORAL		
BUTALBITAL, APAP, AND CAFFEINE		
AB AXIOM PHARM	325MG;50MG;40MG	N89536 001 FEB 16, 1988 MAY CAHN
FIORICET		
AB + WATSON PHARMS	325MG;50MG;40MG	N88616 001 NOV 09, 1984 APR CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

FIORICET W/ CODEINE

AB + WATSON PHARMS	325MG;50MG;40MG;30MG	N20232 001 JUL 30, 1992 MAR CAHN
--------------------	----------------------	----------------------------------

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

PHENAPHEN W/ CODEINE NO. 3

@ ROBINS AH	325MG;30MG	N84445 001 JUN DISC
-------------	------------	---------------------

PHENAPHEN W/ CODEINE NO. 4

@ ROBINS AH	325MG;60MG	N84446 001 JUN DISC
-------------	------------	---------------------

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPAHTE

AA ANDRX PHARMS	300MG;15MG	N40443 001 JAN 22, 2003 JAN NEWA
AA	300MG;30MG	N40443 002 JAN 22, 2003 JAN NEWA
AA	300MG;60MG	N40443 003 JAN 22, 2003 JAN NEWA
ACETAMINOPHEN AND CODEINE PHOSPHATE		
AA RANBAXY	300MG;60MG	N87083 001 JAN CAHN
ACETAMINOPHEN W/ CODEINE PHOSPHATE #3		
AA RANBAXY	300MG;30MG	N85868 001 JAN CAHN
CODRIX		
+ ANDRX PHARMS	500MG;30MG	N40441 001 MAR 27, 2003 MAR NEWA
+	500MG;15MG	N40447 001 FEB 26, 2003 FEB NEWA
+	500MG;60MG	N40488 001 MAR 28, 2003 MAR NEWA

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

AA ABLE	650MG;7.5MG	N40474 001 JAN 02, 2003 JAN NEWA
HYDROCODONE BITARTRATE AND ACETAMINOPHEN		
AA ABLE	500MG;7.5MG	N40490 001 MAY 21, 2003 MAY NEWA
AA ANDRX PHARMS	500MG;5MG	N40493 001 MAY 28, 2003 MAY NEWA
AA	660MG;10MG	N40495 001 MAY 28, 2003 MAY NEWA
AA	750MG;7.5MG	N40494 001 MAY 28, 2003 MAY NEWA
AA AXIOM PHARM	500MG;5MG	N40236 001 SEP 25, 1997 MAY CAHN
AA	650MG;10MG	N40240 001 NOV 26, 1997 MAY CAHN
AA	650MG;7.5MG	N40240 002 NOV 26, 1997 MAY CAHN
AA	750MG;7.5MG	N40236 002 SEP 25, 1997 MAY CAHN
AA MIKART	325MG;7.5MG	N40432 001 JAN 22, 2003 JAN NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL
OXYCODONE AND ACETAMINOPHEN
AA AXIOM PHARM 500MG;5MG N40219 001 JAN 22, 1998 MAY CAHN

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL
PROPOXYPHENE HCL AND ACETAMINOPHEN
>A> AA VINTAGE PHARMS 650MG;65MG N40507 001 JUL 30, 2003 JUL NEWA

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL			
DIAMOX			
@ DURAMED PHARM BARR	500MG	N12945 001	JUN CAHN
+	500MG	N12945 003	APR 25, 1995 JUN CAHN
TABLET; ORAL			
AB DURAMED PHARM BARR	125MG	N08943 001	JUN CAHN
AB +	250MG	N08943 002	JUN CAHN

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION
AP + DURAMED PHARM BARR EQ 500MG BASE/VIAL N09388 001 DEC 05, 1990 JUN CAHN

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS; OTIC
NEO-CORT-DOME
@ BAYER PHARMS 2%;1%;EQ 0.35% BASE N50238 001 JUN DISC

ACYCLOVIR

CAPSULE; ORAL			
ACYCLOVIR			
AB AAIPHARMA	200MG	N74833 001	APR 22, 1997 APR CAHN
TABLET; ORAL			
>D> AB CLONMEL HLTHCARE	400MG	N74834 001	APR 24, 1997 JUL DISC
>A> @	400MG	N74834 001	APR 24, 1997 JUL DISC
>D> AB	800MG	N74834 002	APR 24, 1997 JUL DISC
>A> @	800MG	N74834 002	APR 24, 1997 JUL DISC

ALBUMIN HUMAN

INJECTABLE; INJECTION
OPTISON
+ AMERSHAM HLTH 10MG/ML N20899 001 DEC 31, 1997 JUN CAHN

ALBUTEROL SULFATE

SOLUTION; INHALATION			
ALBUTEROL SULFATE			
AN NOVEX	EQ 0.5% BASE	N76391 001	APR 01, 2003 APR NEWA
TABLET; ORAL			
@ CLONMEL HLTHCARE	EQ 2MG BASE	N72859 001	DEC 20, 1989 JUN DISC
@	EQ 4MG BASE	N72860 001	DEC 20, 1989 JUN DISC

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

AP + AKORN

EQ 0.5MG BASE/ML

N19353 001 DEC 29, 1986 MAR CAHN

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

UROXATRAL

+ SANOFI SYN RES

10MG

N21287 001 JUN 12, 2003 JUN NEWA

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB VINTAGE PHARMS

100MG

AB 300MG

N75798 001 JUN 27, 2003 JUN NEWA

N75798 002 JUN 27, 2003 JUN NEWA

ALMOTRIPTAN MALATE

TABLET; ORAL

AXERT

JANSSEN ORTHO

EQ 6.25MG BASE

+ EQ 12.5MG BASE

N21001 001 MAY 07, 2001 APR CAHN

N21001 002 MAY 07, 2001 APR CAHN

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN;
DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE
SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+ SABEX 2002

2 IU/ML;40MG/ML;12UGM/ML;40

IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8MG/
ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660
IU/ML;0.03MG/ML

N21163 001 MAY 18, 2000 JUN CPOT

INJECTABLE; IV (INFUSION)

+ SABEX 2002

2 IU/ML;40MG/ML;12UGM/ML;40

IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8MG/
ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660
IU/ML;30UGM/ML

N21559 001 JUN 16, 2003 JUN NEWA

ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID;
NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

INJECTABLE; INJECTION

CERNEVIT-12

@ BAXTER HLTHCARE

11.2

IU/VIAL;125MG/VIAL;60UGM/VIAL;200
IU/VIAL;5.5MG/VIAL;414UGM/VIAL;46MG/
VIAL;17.25MG/VIAL;4.53MG/VIAL;4.14
MG/VIAL;3.51MG/VIAL;3,500 IU/VIAL

N20924 001 APR 06, 1999 MAR DISC

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

@ CLONMEL HLTHCARE

0.25MG

0.5MG

N74174 001 OCT 19, 1993 JUN DISC

N74174 002 OCT 19, 1993 JUN DISC

⑧	1MG	N74174 003	OCT 19, 1993	JUN	DISC
⑧	2MG	N74174 004	OCT 19, 1993	JUN	DISC
TABLET, EXTENDED RELEASE; ORAL					
XANAX XR					
PHARMACIA AND UPJOHN	0.5MG	N21434 001	JAN 17, 2003	JAN	NEWA
	1MG	N21434 002	JAN 17, 2003	JAN	NEWA
	2MG	N21434 003	JAN 17, 2003	JAN	NEWA
+	3MG	N21434 004	JAN 17, 2003	JAN	NEWA

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HCL

AB	GENEVA PHARMS	100MG	N71293 001	FEB 18, 1987	APR	CAHN
----	---------------	-------	------------	--------------	-----	------

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

AB	ALTANA	0.1%	N76065 001	MAY 15, 2003	MAY	NEWA
AB	TARO PHARM INDS	0.1%	N76229 001	MAY 31, 2002	MAY	CTEC
AT		0.1%	N76229 001	MAY 31, 2002	APR	NEWA
CYCLOCORT						
AT	+ FUJISAWA HLTHCARE	0.1%	N18116 002		APR	CFTG
AB	+	0.1%	N18116 002		MAY	CTEC
OINTMENT; TOPICAL						
AMCINONIDE						
AB	TARO PHARM INDS	0.1%	N76367 001	MAR 19, 2003	MAR	NEWA

AMINO ACIDS

INJECTABLE; INJECTION

PREMASOL 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	10% (10GM/100ML)	N75880 002	JUN 19, 2003	JUN	NEWA
PREMASOL 6% IN PLASTIC CONTAINER					
BAXTER HLTHCARE	6% (6GM/100ML)	N75880 001	JUN 19, 2003	JUN	NEWA

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

⑧ ELKINS SINK	250MG/ML	N18590 001	OCT 29, 1982	JUN	DISC
---------------	----------	------------	--------------	-----	------

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

AP	+	ABBOTT	25MG/ML	N87601 001	JUL 23, 1982	JUN	CRLD
⑧	ELKINS SINK	25MG/ML		N87239 001		JUN	DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HCL

AP	APOTEX	50MG/ML	N76394 001	APR 25, 2003	APR	NEWA	
CORDARONE							
AP	+	WYETH PHARMS INC	50MG/ML	N20377 001	AUG 03, 1995	MAR	CAHN
TABLET; ORAL							
AB	WYETH PHARMS INC	200MG	N18972 001	DEC 24, 1985	MAR	CAHN	

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE; ORAL

ENDEP

@ ROCHE

40MG/ML

N85749 001

JUN DISC

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

ETRAFON 2-10

@ SCHERING

10MG;2MG

N14713 007

MAR DISC

ETRAFON 2-25

@ SCHERING

25MG;2MG

N14713 004

MAR DISC

ETRAFON-FORTE

@ SCHERING

25MG;4MG

N14713 006

MAR DISC

AMLEXANOX

PASTE; DENTAL

APHTHASOL

>A>	+ ACCESS PHARMS	5%	N20511 001 DEC 17, 1996 JUL CAHN
>D>	+ GLAXOSMITHKLINE CONS	5%	N20511 001 DEC 17, 1996 JUL CAHN

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB	TARO	EQ 12% BASE	N75883 001 APR 10, 2003 APR NEWA
----	------	-------------	----------------------------------

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXIL

>D>	AB + GLAXOSMITHKLINE	50MG/ML	N62226 005 JUL CRLD
>A>	AB	50MG/ML	N62226 005 JUL CRLD
	WYMOX		
	@ WYETH AYERST	125MG/5ML	N62131 001 JUN DISC
	@	250MG/5ML	N62131 002 JUN DISC

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS; ORAL

PREVPAC

+ TAP PHARM

500MG;500MG;30MG

N50757 001 DEC 02, 1997 MAY CDFR

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	RANBAXY	200MG/5ML;EQ 28.5MG BASE/5ML	N65132 001 MAR 19, 2003 MAR NEWA
AB		400MG/5ML;EQ 57MG BASE/5ML	N65132 002 MAR 19, 2003 MAR NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE;DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

SHIRE LABS

2.5MG;2.5MG;2.5MG;2.5MG

N21303 001 OCT 11, 2001 JAN CAHN

ADDERALL XR 15

SHIRE LABS

3.75MG;3.75MG;3.75MG;3.75MG

N21303 006 MAY 22, 2002 JAN CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE;
DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL					
ADDERALL XR 20	SHIRE LABS	5MG;5MG;5MG;5MG	N21303 002	OCT 11, 2001	JAN CAHN
ADDERALL XR 25	SHIRE LABS	6.25MG;6.25MG;6.25MG;6.25MG	N21303 004	MAY 22, 2002	JAN CAHN
ADDERALL XR 30	SHIRE LABS	7.5MG;7.5MG;7.5MG;7.5MG	N21303 003	OCT 11, 2001	JAN CAHN
+ SHIRE LABS	ADDERALL XR 5	1.25MG;1.25MG;1.25MG;1.25MG	N21303 005	MAY 22, 2002	JAN CAHN
TABLET; ORAL					
ADDERALL 12.5	SHIRE LABS	3.125MG;3.125MG;3.125MG;3.125MG	N11522 012	AUG 31, 2000	MAR CFTG
AB ADDERALL 15	SHIRE LABS	3.75MG;3.75MG;3.75MG;3.75MG	N11522 013	AUG 31, 2000	MAR CFTG
AB ADDERALL 7.5	SHIRE LABS	1.875MG;1.875MG;1.875MG;1.875MG	N11522 011	AUG 31, 2000	MAR CFTG
AB DEXTROAMP SACCHARATE, AMP ASPARATE, DEXTROAMP SULFATE AND AMP SULFATE	WATSON LABS	1.25MG;1.25MG;1.25MG;1.25MG	N40456 001	MAY 06, 2003	MAY NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	N40456 002	MAY 06, 2003	MAY NEWA
AB		5MG;5MG;5MG;5MG	N40456 003	MAY 06, 2003	MAY NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	N40456 004	MAY 06, 2003	MAY NEWA
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE					
AB BARR		1.875MG;1.875MG;1.875MG;1.875MG	N40422 005	MAR 19, 2003	MAR NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	N40422 006	MAR 19, 2003	MAR NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	N40422 007	MAR 19, 2003	MAR NEWA

AMPICILLIN SODIUM

INJECTABLE; INJECTION					
OMNIPEN-N					
@ WYETH AYERST		EQ 125MG BASE/VIAL	N60626 001		JUN DISC
@		EQ 250MG BASE/VIAL	N60626 002		JUN DISC
@		EQ 500MG BASE/VIAL	N60626 003		JUN DISC
@		EQ 1GM BASE/VIAL	N60626 004		JUN DISC
@		EQ 2GM BASE/VIAL	N60626 005		JUN DISC
TOTACILLIN-N					
AP + GLAXOSMITHKLINE		EQ 125MG BASE/VIAL	N60677 001		JUN CRLD
AP +		EQ 250MG BASE/VIAL	N60677 002		JUN CRLD
AP +		EQ 500MG BASE/VIAL	N60677 003		JUN CRLD
AP +		EQ 1GM BASE/VIAL	N60677 004		JUN CRLD
AP +		EQ 2GM BASE/VIAL	N60677 005		JUN CRLD

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL					
OMNIPEN (AMPICILLIN)					
@ WYETH AYERST		250MG	N60624 001		JUN DISC
@		500MG	N60624 002		JUN DISC
FOR SUSPENSION; ORAL					
@ WYETH AYERST		100MG/ML	N60625 001		JUN DISC
@		125MG/5ML	N60625 002		JUN DISC

@	250MG/5ML	N60625 003	JUN DISC
PRINCIPEN			
APOTHECON	EQ 100MG BASE/ML	N61394 001	JUN CTEC

AMPRENAVIR

CAPSULE; ORAL			
AGENERASE			
GLAXOSMITHKLINE	50MG	N21007 001	APR 15, 1999 MAR CMFD
+	150MG	N21007 002	APR 15, 1999 MAR CMFD
SOLUTION; ORAL			
+ GLAXOSMITHKLINE	15MG/ML	N21039 001	APR 15, 1999 MAR CMFD

APREPITANT

CAPSULE; ORAL			
EMEND			
MERCK	80MG	N21549 001	MAR 26, 2003 MAR NEWA
+	125MG	N21549 002	MAR 26, 2003 MAR NEWA

ARGATROBAN

INJECTABLE; INJECTION			
ARGATROBAN			
+ ENCYSIVE	100MG/ML	N20883 001	JUN 30, 2000 JUN CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION			
M.V.I.-12			
+ AAIPHARMA	10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/ML;20IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.3MG/ML;330 UNITS/ML;1IU/ML	N08809 004	AUG 08, 1985 JUN CTEC

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL			
FIORINAL			
AB + WATSON PHARMS	325MG;50MG;40MG	N17534 005	APR 16, 1986 MAR CAHN
TABLET; ORAL			
AB + WATSON PHARMS	325MG;50MG;40MG	N17534 003	APR 16, 1986 MAR CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL			
FIORINAL W/CODEINE NO 3			
AB + WATSON PHARMS	325MG;50MG;40MG;30MG	N19429 003	OCT 26, 1990 MAR CAHN

ASPIRIN; MEPROBAMATE

TABLET; ORAL			
EQUAGESIC			
+ WOMEN FIRST HLTHCARE	325MG;200MG	N11702 003	DEC 29, 1983 JUN CTEC
MICRAININ			
@ MEDPOINTE PHARM HLC	325MG;200MG	N84978 001	JUN DISC

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

AB + IVAX PHARMS	325MG;400MG	N87211 001 DEC 22, 1982 JUN CRLD
ROBAXISAL		
@ ROBINS AH	325MG;400MG	N12281 001 JUN DISC

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

AA AXIOM PHARM	325MG;4.5MG;0.38MG	N40260 001 JUL 17, 1998 MAY CAHN
----------------	--------------------	----------------------------------

ASPIRIN; PRAVASTATIN SODIUM

TABLET; ORAL

PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB	81MG;20MG	N21387 001 JUN 24, 2003 JUN NEWA
	81MG;40MG	N21387 002 JUN 24, 2003 JUN NEWA
	81MG;80MG	N21387 003 JUN 24, 2003 JUN NEWA
	325MG;20MG	N21387 004 JUN 24, 2003 JUN NEWA
	325MG;40MG	N21387 005 JUN 24, 2003 JUN NEWA
+ ROBINS AH	325MG;80MG	N21387 006 JUN 24, 2003 JUN NEWA

>D ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

>D CAPSULE; ORAL

>D DARVON W/ ASA

>D + AAIPHARMA LLC 325MG;65MG

>A @ 325MG;65MG

N10996 005	JUL DISC
N10996 005	JUL DISC

ATAZANAVIR SULFATE

CAPSULE; ORAL

REYATAZ

BRISTOL MYERS SQUIBB	EQ 100MG BASE	N21567 001 JUN 20, 2003 JUN NEWA
	EQ 150MG BASE	N21567 002 JUN 20, 2003 JUN NEWA
+	EQ 200MG BASE	N21567 003 JUN 20, 2003 JUN NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

STRATTERA

@ LILLY 5MG

N21411 001 NOV 26, 2002 MAY DISC

ATROPINE

INJECTABLE; INJECTION

ATROPEN

>A + MERIDIAN MEDCL TECHN	EQ 0.5MG SULFATE/0.7ML	N17106 003 JUN 19, 2003 JUL NEWA
>A +	EQ 1MG SULFATE/0.7ML	N17106 002 JUN 19, 2003 JUL NEWA

AZATHIOPRINE

TABLET; ORAL

AZASAN

AB AAIPHARMA LLC	25MG	N75252 002 FEB 03, 2003 FEB NEWA
	50MG	N75252 001 JUN 07, 1999 FEB NEWA
	75MG	N75252 003 FEB 03, 2003 FEB NEWA

100MG

N75252 004 FEB 03, 2003 FEB NEWA

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OPTIVAR

+ MEDPOINTE 0.05%

N21127 001 MAY 22, 2000 APR CAHN

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

BECLOVENT

@ GLAXOSMITHKLINE 0.042MG/INH

N18153 001

MAR DISC

AEROSOL, METERED; NASAL

BECONASE

@ GLAXOSMITHKLINE 0.042MG/INH

N18584 001

MAR DISC

VANCENASE

@ SCHERING 0.042MG/INH

N18521 001

MAR DISC

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION

PRE-PEN

>A> + HOLLISTER STIER LABS 60UMOLAR
>D> + SCHWARZ PHARMA 60UMOLAR

N50114 001

JUL CAHN

N50114 001

JUL CAHN

BETAMETHASONE

TABLET; ORAL

CELESTONE

@ SCHERING 0.6MG

N12657 003

FEB DISC

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

ALPHATREX

AB + SAVAGE LABS EQ 0.05% BASE

N19138 001 JUN 26, 1984 MAY CRLD

DIPROSONE

@ SCHERING EQ 0.05% BASE

N17536 001

MAY DISC

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB ALTANA EQ 0.05% BASE

N75276 001 MAY 13, 2003 MAY NEWA

DIPROLENE

AB + SCHERING EQ 0.05% BASE

N19408 002 NOV 22, 1991 MAY CFTG

BISOPROLOL FUMARATE

TABLET; ORAL

ZEBETA

AB DURAMED PHARM BARR 5MG

N19982 002 JUL 31, 1992 JUN CAHN

AB + 10MG

N19982 001 JUL 31, 1992 JUN CAHN

AB WYETH PHARMS INC 5MG

N19982 002 JUL 31, 1992 MAR CAHN

AB + 10MG

N19982 001 JUL 31, 1992 MAR CAHN

BISOPROLOL FUMARATE; HYDROCHLORTIAZIDE

TABLET; ORAL

ZIAC

AB DURAMED PHARM BARR 2.5MG;6.25MG

N20186 003 MAR 26, 1993 JUN CAHN

AB 5MG;6.25MG

N20186 001 MAR 26, 1993 JUN CAHN

AB +	10MG;6.25MG	N20186 002	MAR 26, 1993	JUN	CAHN
AB WYETH PHARMS INC	2.5MG;6.25MG	N20186 003	MAR 26, 1993	MAR	CAHN
AB	5MG;6.25MG	N20186 001	MAR 26, 1993	MAR	CAHN
AB +	10MG;6.25MG	N20186 002	MAR 26, 1993	MAR	CAHN

BORTEZOMIB

INJECTABLE; INTRAVENOUS

VELCADE

+ MILLENNIUM PHARMS 3.5MG/VIAL

N21602 001 MAY 13, 2003 MAY NEWA

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

@ ELKINS SINK

@

50MG/ML

50MG/ML

N70545 001 MAY 14, 1986 JUN DISC
N70546 001 MAY 14, 1986 JUN DISCBRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE

+ BAUSCH AND LOMB

0.2%

N76260 001 MAY 28, 2003 MAY NEWA

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

DIMETANE-DX

@ ROBINS AH

MYPHETANE DX

AA + MORTON GROVE

2MG/5ML;10MG/5ML;30MG/5ML

N19279 001 AUG 24, 1984 MAR DISC

2MG/5ML;10MG/5ML;30MG/5ML

N88811 001 JUN 07, 1985 MAR CTEC

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DUOCAINE

+ AMPAHSTAR

0.375% (37.5MG/10ML);1%
(100MG/10ML)

N21496 001 MAY 23, 2003 MAY NEWA

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HCL

AB EGIS

15MG

N75119 003 JAN 23, 2003 JAN NEWA

BUSULFAN

INJECTABLE; INJECTION

BUSULFEX

+ ESP PHARMA

6MG/ML

N20954 001 FEB 04, 1999 JUN CAHN

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS, ORAL

CAF'CIT

+ MEAD JOHNSON

EQ 10MG BASE/ML

N20793 001 SEP 21, 1999 JUN CAHN

CALCITRIOL

INJECTABLE; INJECTION

CALCITRIOL

AP AAIPHARMA

0.001MG/ML

N75766 001 FEB 20, 2003 FEB NEWA

AP		0.002MG/ML	N75766 002	FEB 20, 2003	FEB	NEWA
AP	GENSIA SICOR PHARMS	0.001MG/ML	N75823 001	MAR 31, 2003	MAR	NEWA
AP		0.002MG/ML	N75823 002	MAR 31, 2003	MAR	NEWA
SOLUTION; ORAL						
>A>	AA ROXANE	1UGM/ML	N76242 001	JUL 18, 2003	JUL	NEWA
ROCALTROL						
>D>	+ ROCHE	1UGM/ML	N21068 001	NOV 20, 1998	JUL	CFTG
>A>	AA +	1UGM/ML	N21068 001	NOV 20, 1998	JUL	CFTG

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE;
SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL
ELLIOTTS B SOLUTION
+ QOL MEDCL

0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML
;1.9MG/ML;7.3MG/ML;0.2MG/ML

N20577 001 SEP 27, 1996 MAY CAHN

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL
STALEVO 100
+ ORION PHARMA INC

25MG;200MG;100MG

N21485 002 JUN 11, 2003 JUN NEWA

STALEVO 150
+ ORION PHARMA INC

37.5MG;200MG;150MG

N21485 003 JUN 11, 2003 JUN NEWA

STALEVO 50
ORION PHARMA INC

12.5MG;200MG;50MG

N21485 001 JUN 11, 2003 JUN NEWA

CARBINOXAMINE MALEATE

SOLUTION; ORAL
CARBINOXAMINE MALEATE
+ MIKART

4MG/5ML

N40458 001 APR 25, 2003 APR NEWA

TABLET; ORAL
+ MIKART

4MG

N40442 001 MAR 19, 2003 MAR NEWA

CARBOPLATIN

INJECTABLE; IV (INFUSION)

PARAPLATIN

>A> + BRISTOL MYERS SQUIBB 50MG /5ML(10MG/ML)
>A> + 150MG /15ML(10MG/ML)
>A> + 450MG /45ML(10MG/ML)

N20452 001 JUL 14, 2003 JUL NEWA

N20452 002 JUL 14, 2003 JUL NEWA

N20452 003 JUL 14, 2003 JUL NEWA

CARVEDILOL

TABLET; ORAL
COREG

+ GLAXOSMITHKLINE 12.5MG
25MG

N20297 002 SEP 14, 1995 APR CRLD

N20297 001 SEP 14, 1995 APR CRLD

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

CEFADROXIL

AB RANBAXY EQ 125MG BASE/5ML
AB EQ 250MG BASE/5ML
AB EQ 500MG BASE/5ML
AB DURICEF
AB WARNER CHILCOTT EQ 125MG BASE/5ML

N65115 001 MAR 26, 2003 MAR NEWA

N65115 002 MAR 26, 2003 MAR NEWA

N65115 003 MAR 26, 2003 MAR NEWA

N50527 002 MAR CFTG

AB	EQ 250MG BASE/5ML	N50527 003	MAR	CFTG
AB +	EQ 500MG BASE/5ML	N50527 001	MAR	CFTG

CEFDITOREN PIVOXIL

TABLET; ORAL SPECTRACEF + PURDUE PHARMA LP	200MG	N21222 001	AUG 29, 2001	MAY CAHN
--	-------	------------	--------------	----------

CEFIXIME

FOR SUSPENSION; ORAL SUPRAX @ LEDERLE	100MG/5ML	N50622 001	APR 28, 1989	APR DISC
TABLET; ORAL @ LEDERLE	200MG	N50621 001	APR 28, 1989	APR DISC
@	400MG	N50621 002	APR 28, 1989	APR DISC

CEFOXITIN SODIUM

INJECTABLE; INJECTION MEFOXIN IN PLASTIC CONTAINER + MERCK	EQ 20MG BASE/ML	N63182 001	JAN 25, 1993	MAR CRLD
+ @	EQ 40MG BASE/ML	N63182 002	JAN 25, 1993	MAR CRLD

CEFUROXIME AXETIL

TABLET; ORAL CEFUROXIME AXETIL >A> AB LUPIN	EQ 250MG BASE	N65135 001	JUL 25, 2003	JUL NEWA
	EQ 500MG BASE	N65135 002	JUL 25, 2003	JUL NEWA
>A> AB RANBAXY	EQ 125MG BASE	N65118 001	APR 25, 2003	APR NEWA
AB	EQ 250MG BASE	N65118 002	APR 25, 2003	APR NEWA
AB	EQ 500MG BASE	N65118 003	APR 25, 2003	APR NEWA

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION CEPHALOTHIN SODIUM + BRISTOL	EQ 1GM BASE/VIAL	N62464 001	MAY 07, 1984	MAR CRLD
+ @	EQ 2GM BASE/VIAL	N62464 002	MAY 07, 1984	MAR CRLD
+ @	EQ 4GM BASE/VIAL	N62464 003	MAY 07, 1984	MAR CRLD
KEFLIN @ LILLY	EQ 1GM BASE/VIAL	N50482 001		MAR DISC
@	EQ 2GM BASE/VIAL	N50482 002		MAR DISC
@	EQ 4GM BASE/VIAL	N50482 003		MAR DISC

CHLORAMPHENICOL

>D> CAPSULE; ORAL >D> MYCHEL				
>D> + ARMENPHARM	250MG	N60851 001		JUL DISC
>A> @	250MG	N60851 001		JUL DISC
OINTMENT; OPHTHALMIC CHLORAMPHENICOL AT + ALTANA	1%	N60133 001		MAY CRLD
CHLOROMYCETIN @ PARKADEALE	1%	N50156 001		MAY DISC

CHLORAMPHENICOL

OINTMENT; OPHTHALMIC CHLOROPTIC S.O.P.			
@ ALLERGAN	1%	N61187 001	JUN DISC
SOLUTION/DROPS; OPHTHALMIC CHLOROPTIC			
@ ALLERGAN	0.5%	N50091 001	JUN DISC
SOLUTION/DROPS; OTIC CHLOROMYCETIN			
@ PARKEDALE	0.5%	N50205 001	MAY DISC

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION CHLORAMPHENICOL SODIUM SUCCINATE			
>D> AP GRUPPO LEPETIT	EQ 1GM BASE/VIAL	N62278 001	JUL DISC
>A> @	EQ 1GM BASE/VIAL	N62278 001	JUL DISC

CHLOROQUINE HYDROCHLORIDE

INJECTABLE; INJECTION ARALEN HCL			
@ SANOFI SYNTHELABO	EQ 40MG BASE/ML	N06002 002	JUN DISC

CHLORTHIAZIDE; METHYLDOPA

TABLET; ORAL ALDOCLOR-150			
@ MERCK	150MG;250MG	N16016 001	MAY DISC
ALDOCLOR-250			
@ MERCK	250MG;250MG	N16016 002	MAY DISC

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION CHLORPROMAZINE HCL			
AP BAXTER HLTHCARE	25MG/ML	N83329 001	JUN CAHN
TABLET; ORAL @ LEDERLE	10MG	N84803 001	JUN DISC

CHLORTHALIDONE

TABLET; ORAL CHLORTHALIDONE			
>A> @ CLONMEL HLTHCARE	25MG	N87451 001	JUL CAHN
>A> @	50MG	N87450 001	JUL CAHN
>D> @ LEDERLE	25MG	N87451 001	JUL CAHN
>D> @	50MG	N87450 001	JUL CAHN
THALITONE @ MONARCH PHARMS	25MG	N19574 002 FEB 12, 1992	MAY DISC

CICLOPIROX

SHAMPOO; TOPICAL LOPROX			
+ MEDICIS	1%	N21159 001 FEB 28, 2003	FEB NEWA

>A> CIPROFLOXACIN; DEXAMETHASONE
 >A> SUSPENSION/DROPS; OTIC
 >A> CIPRODEX
 >A> + ALCON 0.3%;0.1% N21537 001 JUL 18, 2003 JUL NEWA

>D> CITRIC ACID; UREA, C-13
 >D> FOR SOLUTION; TABLET, FOR SOLUTION; ORAL
 >D> IDKIT:HP
 >D> + ORIDION 4GM;75MG N21314 001 DEC 17, 2002 JUL DISC
 >A> @ 4GM;75MG N21314 001 DEC 17, 2002 JUL DISC

CLADRIBINE
 INJECTABLE; INJECTION
 LEUSTATIN
 AP + ORTHO BIOTECH 1MG/ML N20229 001 FEB 26, 1993 APR CTEC

CLEMASTINE FUMARATE
 SYRUP; ORAL
 CLEMASTINE FUMARATE
 AA + TEVA EQ 0.5MG BASE/5ML N73399 001 JUN 30, 1994 JUN CRLD
 TAVIST
 @ NOVARTIS EQ 0.5MG BASE/5ML N18675 001 JUN 28, 1985 JUN DISC

CLINDAMYCIN HYDROCHLORIDE
 CAPSULE; ORAL
 CLINDAMYCIN HCL
 AB WATSON LABS EQ 300MG BASE N63083 002 MAR 18, 2003 MAR NEWA

CLOBETASOL PROPIONATE
 LOTION; TOPICAL
 >A> CLOBEX
 >A> + GALDERMA LABS LP 0.05% N21535 001 JUL 24, 2003 JUL NEWA

CLOFIBRATE
 CAPSULE; ORAL
 ATROMID-S
 @ WYETH AYERST 500MG N16099 002 JUN DISC

CLONAZEPAM
 TABLET, ORALLY DISINTEGRATING; ORAL
 KLOONOPIN RAPIDLY DISINTEGRATING
 ROCHE 0.125MG N20813 001 DEC 23, 1997 APR CMFD
 0.25MG N20813 002 DEC 23, 1997 APR CMFD
 0.5MG N20813 003 DEC 23, 1997 APR CMFD
 + 1MG N20813 004 DEC 23, 1997 APR CMFD
 2MG N20813 005 DEC 23, 1997 APR CMFD

CLORAZEPATE DIPOTASSIUM
 CAPSULE; ORAL
 CLORAZEPATE DIPOTASSIUM
 @ CLONMEL HLTHCARE 3.75MG N71742 001 DEC 14, 1987 JUN DISC
 @ 7.5MG N71743 001 DEC 14, 1987 JUN DISC

⑥	15MG	N71744 001 DEC 14, 1987 JUN DISC
<u>CLOZAPINE</u>		
TABLET; ORAL		
CLOZAPINE		
>A>	IVAX PHARMS	12.5MG
N74949 003 JUL 31, 2003 JUL NEWA		
<u>CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE</u>		
SYRUP; ORAL		
PHENERGAN VC W/ CODEINE		
⑥	WYETH AYERST	10MG/5ML;5MG/5ML;6.25MG/5ML
PROMETH VC W/ CODEINE		
AA +	ALPHARMA	10MG/5ML;5MG/5ML;6.25MG/5ML
N88764 001 OCT 31, 1984 JUN CRLD		
<u>CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE</u>		
SYRUP; ORAL		
PHENERGAN W/ CODEINE		
⑥	WYETH AYERST	10MG/5ML;6.25MG/5ML
PROMETH W/ CODEINE		
AA +	ALPHARMA	10MG/5ML;6.25MG/5ML
N88763 001 OCT 31, 1984 JUN CRLD		
<u>COLESTIPOL HYDROCHLORIDE</u>		
TABLET; ORAL		
COlestid		
+ PHARMACIA AND UPJOHN	1GM	N20222 001 JUL 19, 1994 MAY CRLD
<u>COPPER</u>		
INTRAUTERINE DEVICE; INTRAUTERINE		
COPPER T MODEL TCU 380A		
+ FEI	309MG/COPPER	N18680 001 NOV 15, 1984 MAR CAHN
<u>CORTISONE ACETATE</u>		
TABLET; ORAL		
CORTISONE ACETATE		
BP + PHARMACIA AND UPJOHN	25MG	N08126 001 APR CRLD
CORTONE		
⑥ MERCK	25MG	N07750 003 APR DISC
<u>COSYNTROPIN</u>		
INJECTABLE; INJECTION		
CORTROSYN		
+ AMPAHSTAR	0.25MG/VIAL	N16750 001 JUN CAHN
<u>CROMOLYN SODIUM</u>		
SOLUTION/DROPS; OPHTHALMIC		
CROMOPTIC		
⑥ KING PHARMS	4%	N75088 001 APR 27, 1999 MAY DISC
<u>CYANOCOBALAMIN</u>		
GEL, METERED; NASAL		
NASCOBAL		
+ QUESTCOR PHARMS	0.5MG/INH	N19722 001 NOV 05, 1996 JUN CAHN

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

@ ELKINS SINK	1MG/ML	N80515 002	JUN DISC
@ WYETH AYERST	0.1MG/ML	N80554 001	JUN DISC
@	1MG/ML	N80554 002	JUN DISC

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

FLEXERIL

AA MCNEIL CONS SPECLT	5MG	N17821 001	MAR CMFD
	5MG	N17821 001	APR CTEC

CYCLOSPORINE

CAPSULE; ORAL

GENGRAF

AB1 ABBOTT	25MG	N65003 001	MAY 12, 2000	FEB CTNA
BX	50MG	N65003 002	MAY 12, 2000	FEB CTNA
AB1	100MG	N65003 003	MAY 12, 2000	FEB CTNA
EMULSION; OPHTHALMIC				
RESTASIS				
+ ALLERGAN	0.05%	N50790 001	DEC 23, 2002	MAR CMS1

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

>D> AP GENSIA SICOR PHARMS	100MG/VIAL	N75206 001	DEC 30, 1998	JUL CAHN
>D> AP +	500MG/VIAL	N75206 002	DEC 30, 1998	JUL CAHN
>D> AP	1GM/VIAL	N75206 004	DEC 30, 1998	JUL CAHN
>D> AP	2GM/VIAL	N75206 003	DEC 30, 1998	JUL CAHN
>A> AP SICOR PHARMS	100MG/VIAL	N75206 001	DEC 30, 1998	JUL CAHN
>A> AP +	500MG/VIAL	N75206 002	DEC 30, 1998	JUL CAHN
>A> AP	1GM/VIAL	N75206 004	DEC 30, 1998	JUL CAHN
>A> AP	2GM/VIAL	N75206 003	DEC 30, 1998	JUL CAHN
CYTOSAR-U				
AP + GENSIA SICOR PHARMS	100MG/VIAL	N16793 001		JUN CAHN
AP +	500MG/VIAL	N16793 002		JUN CAHN
AP +	1GM/VIAL	N16793 003	DEC 21, 1987	JUN CAHN
AP +	2GM/VIAL	N16793 004	DEC 21, 1987	JUN CAHN

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

SYNERCID

+ KING PHARMS	350MG/VIAL;150MG/VIAL	N50748 001	SEP 21, 1999	FEB CAHN
@	420MG/VIAL;180MG/VIAL	N50748 002	AUG 24, 2000	FEB CAHN

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

@ WYETH PHARMS INC	75MG	N50261 001	MAR CAHN
	150MG	N50261 002	MAR CAHN

+ 300MG	N50261 003	MAR CAHN
<u>ESIRUDIN</u>		
INJECTABLE; SUBCUTANEOUS		
IPRIVASK		
+ AVENTIS PHARMS	15MG/VIAL	N21271 001 APR 04, 2003 APR NEWA
<u>ESMOPRESSIN ACETATE</u>		
SPRAY, METERED; NASAL		
DESMOPRESSIN ACETATE		
+ FERRING	0.01MG/SPRAY	N21333 001 SEP 16, 2002 MAY CMS1
MINIRIN		
+ FERRING	0.01MG/SPRAY	N21333 001 SEP 16, 2002 JUN CTNA
<u>ESOGESTREL; ETHINYLL ESTRADIOL</u>		
TABLET; ORAL-21		
ORTHO-CEPT		
@ ORTHO MCNEIL PHARM	0.15MG;0.03MG	N20301 001 DEC 14, 1992 MAR DISC
TABLET; ORAL-28		
+ ORTHO MCNEIL PHARM	0.15MG;0.03MG	N20301 002 DEC 14, 1992 MAR CRLD
<u>ESOXIMETASONE</u>		
CREAM; TOPICAL		
DESOXIMETASONE		
CLAY PARK	0.25%	N76510 001 JUL 01, 2003 JUL NEWA
<u>EXAMETHASONE</u>		
ELIXIR; ORAL		
DECADRON		
@ MERCK	0.5MG/5ML	N12376 002 APR DISC
HEXDROL		
+ ORGANON	0.5MG/5ML	N12674 001 APR CRLD
<u>EXAMETHASONE SODIUM PHOSPHATE</u>		
INJECTABLE; INJECTION		
DEXAMETHASONE SODIUM PHOSPHATE		
AM PHARM	EQ 10MG PHOSPHATE/ML	N40491 001 APR 11, 2003 APR NEWA
<u>EXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE</u>		
SOLUTION/DROPS; OPHTHALMIC		
NEODECADRON		
@ MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N50322 001 MAY DISC
<u>EXTROAMPHETAMINE SULFATE</u>		
CAPSULE, EXTENDED RELEASE; ORAL		
DEXEDRINE		
+ GLAXOSMITHKLINE	5MG	N17078 001 JUL CRLD
	5MG	N17078 001 JUL CRLD
+	10MG	N17078 002 JUL CRLD
	10MG	N17078 002 JUL CRLD
<u>DEXTROAMPHETAMINE SULFATE</u>		
MALLINCKRODT	5MG	N76353 001 MAY 06, 2003 MAY NEWA
	10MG	N76353 002 MAY 06, 2003 MAY NEWA

AB	15MG	N76353 003	MAY 06, 2003	MAY NEWA	
<u>DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE</u>					
SYRUP; ORAL					
PHENERGAN W/ DEXTROMETHORPHAN					
@ WYETH AYERST	15MG/5ML;6.25MG/5ML	N11265 002	APR 02, 1984	JUN DISC	
PROMETH W/ DEXTROMETHORPHAN					
AA + ALPHARMA	15MG/5ML;6.25MG/5ML	N88762 001	OCT 31, 1984	JUN CRLD	
<u>DIAZEPAM</u>					
INJECTABLE; INJECTION					
DIAZEPAM					
@ ELKINS SINK	5MG/ML	N70311 001	DEC 16, 1985	JUN DISC	
@	5MG/ML	N70312 001	DEC 16, 1985	JUN DISC	
@	5MG/ML	N70313 001	DEC 16, 1985	JUN DISC	
<u>DICHLORPHENAMIDE</u>					
TABLET; ORAL					
DARANIDE					
@ MERCK	50MG	N11366 001		MAY DISC	
<u>DICLOXAELLIN SODIUM</u>					
CAPSULE; ORAL					
PATHOCIL					
@ WYETH AYERST	EQ 250MG BASE	N50011 002		JUN DISC	
@	EQ 500MG BASE	N50011 003	MAR 28, 1983	JUN DISC	
FOR SUSPENSION; ORAL					
DICLOXAELLIN SODIUM					
+ APOTHECON	EQ 62.5MG BASE/5ML	N61455 001		JUN CTEC	
PATHOCIL					
@ WYETH AYERST	EQ 62.5MG BASE/5ML	N50092 001		JUN DISC	
<u>DICYCLOMINE HYDROCHLORIDE</u>					
INJECTABLE; INJECTION					
DICYCLOMINE HCL (PRESERVATIVE-FREE)					
AP BEDFORD	10MG/ML	N40465 001	JUN 30, 2003	JUN NEWA	
<u>DIGOXIN</u>					
CAPSULE; ORAL					
LANOXICAPS					
>D>	GLAXO WELLCOME	0.05MG	N18118 002	JUL 26, 1982	JUL CAHN
>D>		0.1MG	N18118 003	JUL 26, 1982	JUL CAHN
>D>	@	0.15MG	N18118 004	SEP 24, 1984	JUL CAHN
>D>	+	0.2MG	N18118 001	JUL 26, 1982	JUL CAHN
>A>	SMITHKLINE BEECHAM	0.05MG	N18118 002	JUL 26, 1982	JUL CAHN
>A>		0.1MG	N18118 003	JUL 26, 1982	JUL CAHN
>A>	@	0.15MG	N18118 004	SEP 24, 1984	JUL CAHN
>A>	+	0.2MG	N18118 001	JUL 26, 1982	JUL CAHN
INJECTABLE; INJECTION					
DIGOXIN					
@ WYETH AYERST	0.25MG/ML	N84386 001		JUN DISC	
TABLET; ORAL					
AB CARACO	0.125MG	N76363 001	JAN 31, 2003	JAN NEWA	

AB	0.25MG	N76363 002	JAN 31, 2003	JAN	NEWA
----	--------	------------	--------------	-----	------

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

AP + XCEL PHARMS	1MG/ML	N05929 001	APR	CFTG	
DIHYDROERGOTAMINE MESYLATE					
AP BEDFORD	1MG/ML	N40453 001	JUN 09, 2003	JUN	NEWA
DIHYDROERGOTAMINE MESYLATE					
AP PADDICK	1MG/ML	N40475 001	APR 28, 2003	APR	NEWA

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TAZTIA XT

AB4 ANDRX PHARMS	120MG	N75401 001	APR 10, 2003	APR	NEWA
AB4	180MG	N75401 002	APR 10, 2003	APR	NEWA
AB4	240MG	N75401 003	APR 10, 2003	APR	NEWA
AB4	300MG	N75401 004	APR 10, 2003	APR	NEWA
AB4	360MG	N75401 005	APR 10, 2003	APR	NEWA
TIAZAC					
AB4 + BIOVAIL	120MG	N20401 001	SEP 11, 1995	APR	CFTG
AB4 +	180MG	N20401 002	SEP 11, 1995	APR	CFTG
AB4 +	240MG	N20401 003	SEP 11, 1995	APR	CFTG
AB4 +	300MG	N20401 004	SEP 11, 1995	APR	CFTG
AB4 +	360MG	N20401 005	SEP 11, 1995	APR	CFTG

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

+ BIOVAIL	120MG	N21392 001	FEB 06, 2003	FEB	NEWA
+	180MG	N21392 002	FEB 06, 2003	FEB	NEWA
+	240MG	N21392 003	FEB 06, 2003	FEB	NEWA
+	300MG	N21392 004	FEB 06, 2003	FEB	NEWA
+	360MG	N21392 005	FEB 06, 2003	FEB	NEWA
+	420MG	N21392 006	FEB 06, 2003	FEB	NEWA

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL

TIAMATE

@ MERCK	EQ 120MG HCL	N20506 001	OCT 04, 1996	MAY	DISC
@	EQ 180MG HCL	N20506 002	OCT 04, 1996	MAY	DISC
@	EQ 240MG HCL	N20506 003	OCT 04, 1996	MAY	DISC

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

+ STERIS	50MG/ML	N80615 001	JUN	CTEC
@ WYETH AYERST	50MG/ML	N84316 001	JUN	DISC

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

RIMSO-50

>A> AT + EDWARDS LIFESCIENCES	50%	N17788 001	JUL	CAHN
>D> AT + RES IND'S	50%	N17788 001	JUL	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL
AP BAXTER HLTHCARE 50MG/ML N80817 002 JUN CAHN
@ WYETH AYERST 50MG/ML N80577 001 JUN DISC

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE
>A> AB CLONMEL HLTHCARE 25MG N88999 001 FEB 05, 1991 JUL CAHN
>A> AB 50MG N89000 001 FEB 05, 1991 JUL CAHN
>A> AB 75MG N89001 001 FEB 05, 1991 JUL CAHN
>D> AB LEDERLE 25MG N88999 001 FEB 05, 1991 JUL CAHN
>D> AB 50MG N89000 001 FEB 05, 1991 JUL CAHN
>D> AB 75MG N89001 001 FEB 05, 1991 JUL CAHN

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL
@ ELKINS SINK EQ 12.5MG BASE/ML N74381 001 SEP 26, 1996 JUN DISC

DOLASETRON MESYLATE MONOHYDRATE

INJECTABLE; INJECTION
ANZEMET
>D> AVENTIS PHARMS EQ 12.5MG BASE/ML N20624 002 SEP 11, 1997 JUL CPOT
>A> @ EQ 12.5MG BASE/0.625ML N20624 002 SEP 11, 1997 JUL CPOT

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL
@ BAXTER HLTHCARE 40MG/ML N18398 001 JUN DISC
@ 80MG/ML N18398 002 MAR 22, 1982 JUN DISC

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION
DOXAPRAM
AP + BAXTER HLTHCARE CORP 20MG/ML N14879 001 JAN CAHN
DOXAPRAM HCL
AP BEDFORD 20MG/ML N76266 001 JAN 10, 2003 JAN NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
ADRIAMYCIN RDF
>D> + PHARMACIA AND UPJOHN 150MG/VIAL N50467 004 JUL 22, 1987 JUL DISC
>A> @ 150MG/VIAL N50467 004 JUL 22, 1987 JUL DISC

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE
AB AXIOM PHARM EQ 50MG BASE N65041 001 APR 28, 2000 MAY CAHN
AB EQ 100MG BASE N65041 002 APR 28, 2000 MAY CAHN

DOXYCYCLINE HYCLATE

CAPSULE; ORAL			
DOXYCYCLINE HYCLATE			
AB AXIOM PHARM	EQ 50MG BASE	N61717 001	MAY CAHN
	EQ 100MG BASE	N61717 002	MAY CAHN
AB CAPSULE, COATED PELLETS; ORAL			
DORYX			
FAULDING	EQ 75MG BASE	N50582 002	AUG 13, 2001 FEB NEWA
INJECTABLE; INJECTION			
DOXY 100			
+ AM PHARM PARTNERS	EQ 100MG BASE/VIAL	N62475 001	DEC 09, 1983 MAR CRLD
DOXY 200			
+ AM PHARM PARTNERS	EQ 200MG BASE/VIAL	N62475 002	DEC 09, 1983 MAR CRLD
VIBRAMYCIN			
@ PFIZER	EQ 100MG BASE/VIAL	N50442 002	MAR DISC
@	EQ 200MG BASE/VIAL	N50442 001	MAR DISC
TABLET; ORAL			
DOXYCYCLINE HYCLATE			
AB AXIOM PHARM	EQ 100MG BASE	N62269 002	NOV 08, 1982 MAY CAHN
>A> AB WEST WARD	EQ 100MG BASE	N65095 001	JUL 02, 2003 JUL NEWA
DOXYCYCLINE HYLATE			
@ AXIOM PHARM	EQ 50MG BASE	N62269 003	MAY CAHN

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION			
REVERSOL			
@ ORGANON	10MG/ML	N89624 001	MAY 13, 1988 MAY DISC

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL			
RELPAX			
PFIZER IRELAND	EQ 20MG BASE	N21016 001	DEC 26, 2002 MAR CAHN
+	EQ 40MG BASE	N21016 002	DEC 26, 2002 MAR CAHN
>A> EMTRICITABINE			
>A> CAPSULE; ORAL			
>A> EMTRIVA			
>A> + GILEAD	200MG	N21500 001	JUL 02, 2003 JUL NEWA

ENALAPRIL MALEATE; HYDROCHLORTIAZIDE

TABLET; ORAL			
ENALAPRIL MALEATE AND HYDROCHLORTIAZIDE			
AB IVAX PHARMS	5MG;12.5MG	N75736 001	MAR 25, 2003 MAR NEWA
AB	10MG;25MG	N75736 002	MAR 25, 2003 MAR NEWA

ENFUVIRTIDE

INJECTABLE; SUBCUTANEOUS			
FUZEON			
+ ROCHE	90MG/VIAL	N21481 001	MAR 13, 2003 MAR NEWA

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX

+ AVENTIS

300MG/3ML

N20164 009 JAN 23, 2003 JAN NEWA

EPINEPHRINE

INJECTABLE; IM-SC

TWINJECT

+ HOLLISTER STIER LABS 0.3MG /DELIVERY

N20800 001 MAY 30, 2003 MAY NEWA

EPINEPHRINE BITARTRATE; ETIDOCaine HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

@ DENTSPLY PHARM

0.005MG/ML;1.5%

N21384 001

MAR DISC

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL AND EPINEPHRINE

@ ELKINS SINK 0.01MG/ML;1%

N80406 001

JUN DISC

@ 0.01MG/ML;2%

N80406 002

JUN DISC

EPROSARTAN MESYLATE

TABLET; ORAL

TEVETEN

>A>	BIOVAIL	EQ 300MG BASE	N20738 004 DEC 22, 1997 JUL CAHN
>A>		EQ 400MG BASE	N20738 005 DEC 22, 1997 JUL CAHN
>A>	+	EQ 600MG BASE	N20738 006 MAY 27, 1999 JUL CAHN
>D>	BIOVAIL PHARMS	EQ 300MG BASE	N20738 004 DEC 22, 1997 JUL CAHN
>D>		EQ 400MG BASE	N20738 005 DEC 22, 1997 JUL CAHN
>D>	+	EQ 600MG BASE	N20738 006 MAY 27, 1999 JUL CAHN

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEVETEN HCT

>A>	BIOVAIL	600MG;12.5MG	N21268 001 NOV 01, 2001 JUL CAHN
>A>	+	600MG;25MG	N21268 002 NOV 01, 2001 JUL CAHN
>D>	BIOVAIL PHARMS	600MG;12.5MG	N21268 001 NOV 01, 2001 JUL CAHN
>D>	+	600MG;25MG	N21268 002 NOV 01, 2001 JUL CAHN

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

ERGOMAR

+ HARVEST PHARMS

2MG

N87693 001 FEB 24, 1983 MAR CAHN

ERYTHROMYCIN

SOLUTION; TOPICAL

STATICIN

+ WESTWOOD SQUIBB

1.5%

N50526 001

APR CTEC

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROMYCIN

@ ELKINS SINK

@

EQ 500MG BASE/VIAL

EQ 1GM BASE/VIAL

N62563 001 MAR 28, 1985 JUN DISC

N62563 002 MAR 28, 1985 JUN DISC

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

+ BAXTER HLTHCARE CORP 10MG/ML

+ 20MG/ML

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

+ BAXTER HLTHCARE CORP 2GM/100ML

BREVIBLOC IN PLASTIC CONTAINER

+ BAXTER HLTHCARE CORP 1GM/100ML

N19386 006 FEB 25, 2003 JUN NEWA

N19386 007 MAY 28, 2003 JUN NEWA

N19386 005 JAN 27, 2003 MAR NEWA

N19386 004 FEB 16, 2001 MAR NEWA

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA

BX + BERLEX LABS 0.0375MG/24HR

+ 0.06MG/24HR

N20375 005 MAY 27, 2003 JUN NEWA

N20375 006 MAY 27, 2003 JUN NEWA

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING

GALEN LTD 0.05MG/24HR

+ 0.1MG/24HR

N21367 001 MAR 20, 2003 MAR NEWA

N21367 002 MAR 20, 2003 MAR NEWA

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTADIOL

@ PHARMACIA AND UPJOHN 2MG/ML;50MG/ML

N17968 001

MAY WDAG

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

PREFEST

+ KING PHARMS 1MG;1MG;0.09MG

N21040 001 OCT 22, 1999 MAY CTNA

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL

PREMARIN

+ WYETH PHARMS INC 0.625MG/GM

N20216 001 MAR CAHN

INJECTABLE; INJECTION

+ WYETH PHARMS INC 25MG/VIAL

N10402 001 MAR CAHN

TABLET; ORAL

WYETH PHARMS INC 0.3MG

N04782 003 MAR CAHN

0.45MG

N04782 006 JUL 16, 2003 JUL NEWA

>A>

0.625MG

N04782 004 MAR CAHN

0.9MG

N04782 005 JAN 26, 1984 MAR CAHN

1.25MG

N04782 001 MAR CAHN

2.5MG

N04782 002 MAR CAHN

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE (PREMARIN; CYCRIN 14/14)

@ WYETH PHARMS INC 0.625MG;0.625MG;5MG

N20303 002 DEC 30, 1994 MAR CAHN

PREMPHASE 14/14

+ WYETH PHARMS INC 0.625MG;0.625MG;5MG

N20527 002 NOV 17, 1995 MAR CAHN

PREMPRO

+ WYETH PHARMS INC 0.3MG;1.5MG

N20527 005 JUN 04, 2003 JUN NEWA

+ WYETH PHARMS INC 0.45MG;1.5MG

N20527 004 MAR 12, 2003 MAR NEWA

+ WYETH PHARMS INC 0.625MG;0.625MG;2.5MG;2.5MG

N20527 001 NOV 17, 1995 MAR CAHN

+ WYETH PHARMS INC 0.625MG;0.625MG;5MG;5MG

N20527 003 JAN 09, 1998 MAR CAHN

PREMPRO (PREMARIN; CYCRIN)

@ WYETH PHARMS INC 0.625MG;0.625MG;2.5MG;2.5MG

N20303 001 DEC 30, 1994 MAR CAHN

ESTROGENS, ESTERIFIED

TABLET; ORAL

MENEST

MONARCH PHARMS 0.3MG

N84951 001 JAN CRLD

ETHACRYNIC ACID

TABLET; ORAL

EDECIN

+ MERCK 25MG

N16092 001 MAY CRLD

@ 50MG

N16092 002 MAY DISC

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HCL

AB + WEST WARD 400MG

N75095 002 NOV 30, 1999 JUN CRLD

MYAMBUTOL

@ LEDERLE 100MG

N16320 001 JUN DISC

@ 400MG

N16320 003 JUN DISC

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

DEMULEN 1/35-28

>D> AB GD SEARLE LLC 0.035MG;1MG

N18160 001 JUL CRLD

>A> AB + 0.035MG;1MG

N18160 001 JUL CRLD

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL

NUVARING

+ ORGANON USA INC 0.015MG;0.12MG

N21187 001 OCT 03, 2001 JUN CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

ALESSE

AB1 + WYETH PHARMS INC 0.02MG;0.1MG

N20683 001 MAR 27, 1997 MAR CAHN

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1 BARR 0.02MG;0.1MG

N75862 001 APR 29, 2003 APR NEWA

NORDETTE-21

AB + WYETH PHARMS INC 0.03MG;0.15MG

N18668 001 MAY 10, 1982 MAR CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21
TRIPHASICL-21
AB + WYETH PHARMS INC 0.03MG;0.04MG;0.03MG;0.05MG;0.125MG
;0.075MG N19192 001 NOV 01, 1984 MAR CAHN

TABLET; ORAL-28
ALESSE
AB1 WYETH PHARMS INC 0.02MG;0.1MG N20683 002 MAR 27, 1997 MAR CAHN

LEVONORGESTREL AND ETHINYL ESTRADIOL
AB1 BARR 0.02MG;0.1MG N75862 002 APR 29, 2003 APR NEWA

NORDETTE-28
AB WYETH PHARMS INC 0.03MG;0.15MG N18782 001 JUL 21, 1982 MAR CAHN

TRIPHASICL-28
AB WYETH PHARMS INC 0.03MG;0.04MG;0.03MG;0.05MG;0.125MG
;0.075MG N19190 001 NOV 01, 1984 MAR CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
TRI-NORINYL 21-DAY
@ WATSON LABS 0.035MG,0.035MG,0.035MG;0.5MG,1MG,0
.5MG N18977 001 APR 13, 1984 MAR CPOT
0.035MG,0.035MG;0.5MG,1MG N18977 001 APR 13, 1984 FEB DISC

TABLET; ORAL-28
ORTHO-NOVUM 7/7/7-28
AB + ORTHO MCNEIL PHARM 0.035MG,0.035MG,0.035MG;0.5MG,1MG,0
.75MG N18985 002 APR 04, 1984 FEB CRLD

OVCON-35
+ WARNER CHILCOTT 0.035MG;0.4MG N17716 001 JAN CRLD

OVCON-50
+ WARNER CHILCOTT 0.05MG;1MG N17576 001 JAN CRLD

TRI-NORINYL 28-DAY
+ WATSON LABS 0.035MG,0.035MG,0.035MG;0.5MG,1MG,0
.5MG N18977 002 APR 13, 1984 MAR CPOT
0.035MG,0.035MG;0.5MG,1MG N18977 002 APR 13, 1984 JAN CRLD

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL
FEMHRT
+ GALEN CHEM 0.005MG;1MG N21065 002 OCT 15, 1999 MAY CAHN

TABLET; ORAL-21
ESTROSTEP 21
@ GALEN CHEM 0.02MG;0.03MG;0.035MG;1MG;1MG;1MG N20130 001 OCT 09, 1996 APR CAHN

JUNEL 1.5/30
AB BARR 0.03MG;1.5MG N76381 001 MAY 30, 2003 MAY NEWA

JUNEL 1/20
AB BARR 0.02MG;1MG N76380 001 MAY 30, 2003 MAY NEWA

LOESTRIN 21 1.5/30
+ GALEN CHEM 0.03MG;1.5MG N17875 001 APR CAHN
0.03MG;1.5MG N17875 001 MAY CFTG

AB +
LOESTRIN 21 1/20
+ GALEN CHEM 0.02MG;1MG N17876 001 APR CAHN

AB +	0.02MG;1MG	N17876 001	MAY	CFTG
TABLET; ORAL-28				
ESTROSTEP FE				
+ GALEN CHEM	0.02MG;0.03MG;0.035MG;1MG;1MG;1MG	N20130 002	OCT 09, 1996	APR CAHN
LOESTRIN FE 1.5/30				
AB + GALEN CHEM	0.03MG;1.5MG	N17355 001		APR CAHN
LOESTRIN FE 1/20				
AB + GALEN CHEM	0.02MG;1MG	N17354 001		APR CAHN

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21				
LO/OVRAL				
AB + WYETH PHARMS INC	0.03MG;0.3MG	N17612 001	MAR	CAHN
OGESTREL 0.5/50-21				
AB WATSON LABS	0.05MG;0.5MG	N75406 001	DEC 15, 1999	FEB CAHN
OVRAL				
AB + WYETH PHARMS INC	0.05MG;0.5MG	N16672 001	MAR	CAHN
TABLET; ORAL-28				
LO/OVRAL-28				
AB WYETH PHARMS INC	0.03MG;0.3MG	N17802 001	MAR	CAHN
OGESTREL 0.5/50-28				
AB WATSON LABS	0.05MG;0.5MG	N75406 002	DEC 15, 1999	FEB CAHN
OVRAL-28				
AB WYETH PHARMS INC	0.05MG;0.5MG	N16806 001	MAR	CAHN

ETHIONAMIDE

TABLET; ORAL				
TRECATOR-SC				
+ WYETH PHARMS INC	250MG	N13026 002	MAR	CAHN

ETHOTOKIN

TABLET; ORAL				
PEGANONE				
+ OVATION PHARMS	250MG	N10841 001	MAR	CAHN
@	500MG	N10841 003	MAR	CAHN

ETIDRONATE DISODIUM

TABLET; ORAL				
DIDRONEL				
>D>	PROCTER AND GAMBLE	200MG	N17831 001	JUL CTEC
>A> AB		200MG	N17831 001	JUL CTEC
>D>	+	400MG	N17831 002	JUL CTEC
>A> AB +		400MG	N17831 002	JUL CTEC
ETIDRONATE DISODIUM				
AB GENPHARM	200MG	N75800 001	JAN 24, 2003	JAN NEWA
AB	400MG	N75800 002	JAN 24, 2003	JAN NEWA

ETODOLAC

CAPSULE; ORAL				
LODINE				
AB WYETH PHARMS INC	200MG	N18922 002	JAN 31, 1991	MAR CAHN
AB +	300MG	N18922 003	JAN 31, 1991	MAR CAHN

ETODOLAC

TABLET; ORAL						
LODINE						
AB	WYETH PHARMS INC	400MG	N18922 004	JUL 29, 1993	MAR CAHN	
AB	+	500MG	N18922 005	JUN 28, 1996	MAR CAHN	
TABLET, EXTENDED RELEASE; ORAL						
ETODOLAC						
AB	TARO	400MG	N76174 001	MAR 13, 2003	MAR NEWA	
AB		500MG	N76174 002	MAR 13, 2003	MAR NEWA	
AB		600MG	N76174 003	MAR 13, 2003	MAR NEWA	
LODINE XL						
AB	+	WYETH PHARMS INC	400MG	N20584 001	OCT 25, 1996	MAR CAHN
AB	+		500MG	N20584 003	JAN 20, 1998	MAR CAHN
AB	+		600MG	N20584 002	OCT 25, 1996	MAR CAHN

ETOPOSIDE

INJECTABLE; INJECTION						
ETOPOSIDE						
>D>	AP	GENSIA SICOR PHARMS	20MG/ML	N74284 001	FEB 10, 1994	JUL CAHN
>D>	AP		20MG/ML	N74529 001	JUL 24, 1996	JUL CAHN
>A>	AP	SICOR PHARMS	20MG/ML	N74284 001	FEB 10, 1994	JUL CAHN
>A>	AP		20MG/ML	N74529 001	JUL 24, 1996	JUL CAHN
TOPOSAR						
>A>	AP	GENSIA SICOR PHARMS	20MG/ML	N74166 001	FEB 27, 1995	JUL CAHN
>D>	AP	PHARMACIA AND UPJOHN	20MG/ML	N74166 001	FEB 27, 1995	JUL CAHN

FAMOTIDINE

INJECTABLE; INJECTION					
FAMOTIDINE PRESERVATIVE FREE					
AP	BAXTER HLTHCARE	10MG/ML	N75486 001	APR 16, 2001	JUN CAHN

FELBAMATE

SUSPENSION; ORAL					
FELBATOL					
+>	MEDPOINTE	600MG/5ML	N20189 003	JUL 29, 1993	MAR CAHN
TABLET; ORAL					
+>	MEDPOINTE	400MG	N20189 001	JUL 29, 1993	MAR CAHN
+>		600MG	N20189 002	JUL 29, 1993	MAR CAHN

FENOFIBRATE

CAPSULE; ORAL					
FENOFIBRATE (MICRONIZED)					
TEVA		67MG	N75753 001	SEP 03, 2002	MAR CTEC
		134MG	N75753 002	APR 09, 2002	MAR CTEC
+		200MG	N75753 003	APR 09, 2002	MAR CRLD
TRICOR (MICRONIZED)					
@ ABBOTT		67MG	N19304 002	FEB 09, 1998	MAR DISC
@		134MG	N19304 003	JUN 30, 1999	MAR DISC
@		200MG	N19304 004	JUN 30, 1999	MAR DISC

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL
URISPAS
+ ORTHO MCNEIL PHARM

100MG

N16769 001

MAR CAHN

FLECAINIDE ACETATE

TABLET; ORAL
FLECAINIDE ACETATE

AB	GENEVA PHARMS	50MG	N76030 001	OCT 28, 2002	JUN	CAHN
AB		100MG	N76030 002	OCT 28, 2002	JUN	CAHN
AB		150MG	N76030 003	OCT 28, 2002	JUN	CAHN
AB	RANBAXY	50MG	N76421 001	MAR 28, 2003	MAR	NEWA
AB		100MG	N76421 002	MAR 28, 2003	MAR	NEWA
AB		150MG	N76421 003	MAR 28, 2003	MAR	NEWA
AB	ROXANE	50MG	N76278 001	JAN 14, 2003	JAN	NEWA
AB		100MG	N76278 002	JAN 14, 2003	JAN	NEWA
AB		150MG	N76278 003	JAN 14, 2003	JAN	NEWA

FLUDROCORTISONE ACETATE

TABLET; ORAL
FLUDROCORTISONE ACETATE

AB	BARR	0.1MG	N40425 001	JAN 21, 2003	JAN	NEWA
----	------	-------	------------	--------------	-----	------

FLUNISOLIDE

SPRAY, METERED; NASAL
NASAREL

>D>	BX + IVAX RES	0.025MG/SPRAY	N20409 001	MAR 08, 1995	JUL	CPOT
>A>	+	0.029MG/SPRAY	N20409 001	MAR 08, 1995	JUL	CPOT

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE

AB1	ALPHARMA US PHARM	0.05%	N73085 001	FEB 14, 1992	MAY	CTEC
AB1	FOUGERA	0.05%	N73030 001	OCT 17, 1994	MAY	CTEC
AB1	TARO	0.05%	N19117 001	JUN 26, 1984	MAY	CTEC
AB1		0.05%	N71500 001	JUN 10, 1987	MAY	CTEC
AB1	TEVA	0.05%	N72488 001	FEB 06, 1989	MAY	CTEC
	FLUOCINONIDE EMULSIFIED BASE					
AB2	ALPHARMA US PHARM	0.05%	N74204 001	JUN 13, 1995	MAY	CTEC
AB2	DRAXIS HLTH	0.05%	N72494 001	JAN 19, 1989	MAY	CTEC
AB2	TARO	0.05%	N72494 001	JAN 19, 1989	JUN	CAHN
AB2	TEVA	0.05%	N72490 001	FEB 07, 1989	MAY	CTEC
	LIDEX					
AB1 + MEDICIS		0.05%	N16908 002		MAY	CTEC
	LIDEX-E					
AB2 + MEDICIS		0.05%	N16908 003		MAY	CRLD

FLUORESCIN SODIUM

INJECTABLE; INJECTION

FUNDUSCEIN-25

@ NOVARTIS

25%

N17869 001

JAN DISC

FLUOROURACIL

INJECTABLE; INJECTION

ADRUCIL

>A>	AP	GENSIA SICOR PHARMS	50MG/ML	N40023 001	OCT 18, 1991	JUL	CAHN
>A>	AP	+	50MG/ML	N81225 001	AUG 28, 1991	JUL	CAHN
>D>	AP	PHARMACIA AND UPJOHN	50MG/ML	N40023 001	OCT 18, 1991	JUL	CAHN
>D>	AP	+	50MG/ML	N81225 001	AUG 28, 1991	JUL	CAHN
		FLUOROURACIL					
>D>	AP	GENSIA SICOR PHARMS	50MG/ML	N40333 001	JAN 27, 2000	JUL	CAHN
>D>	AP		50MG/ML	N40334 001	FEB 25, 2000	JUL	CAHN
>A>	AP	SICOR PHARMS	50MG/ML	N40333 001	JAN 27, 2000	JUL	CAHN
>A>	AP		50MG/ML	N40334 001	FEB 25, 2000	JUL	CAHN
		SOLUTION; TOPICAL					
		FLUOROPLEX					
	@	ALLERGAN HERBERT	1%	N16765 001		JUN	DISC

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

@ KING PHARMS

25MG/ML

N74966 001 APR 16, 1998 MAY DISC

FLURANDRENOLIDE

LOTION; TOPICAL

CORDRAN

+ OCLASSEN

0.05%

N13790 001 MAY CTEC

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB GENPHARM

125MG

N76224 001 MAY 09, 2003 MAY NEWA

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

AB GENEVA PHARMS

25MG

N75887 001 JAN 05, 2001 APR CAHN

AB

50MG

N75887 002 JAN 05, 2001 APR CAHN

AB

100MG

N75887 003 JAN 05, 2001 APR CAHN

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

AP + AM PHARM PARTNERS

5MG/ML

N89202 001 FEB 18, 1986 JUN CRLD

FOLVITE

AP + WYETH PHARMS INC

5MG/ML

N05897 008 MAR CAHN

@

5MG/ML

N05897 008 JUN DISC

TABLET; ORAL

@ WYETH PHARMS INC

1MG

N05897 004 MAR CAHN

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

@ BAXTER HLTHCARE

10MG/ML

N18267 001 JUN DISC

FUROSEMIDE

TABLET; ORAL

FUROSEMIDE

>A>	AB	CLONMEL HLTHCARE	20MG	N18415 001	JUL 27, 1982	JUL	CAHN
>A>	AB		40MG	N18415 002	JUL 27, 1982	JUL	CAHN
>A>	AB		80MG	N18415 003	NOV 26, 1984	JUL	CAHN
>D>	AB	LEDERLE	20MG	N18415 001	JUL 27, 1982	JUL	CAHN
>D>	AB		40MG	N18415 002	JUL 27, 1982	JUL	CAHN
>D>	AB		80MG	N18415 003	NOV 26, 1984	JUL	CAHN

GALANTAMINE HYDROBROMIDE

TABLET; ORAL

REMINYL

+ JANSSEN PHARMA		EQ 4MG BASE	N21169 001	FEB 28, 2001	APR	CRLD
		EQ 12MG BASE	N21169 003	FEB 28, 2001	APR	CRLD

GANCICLOVIR

CAPSULE; ORAL

CYTOVENE

AB	ROCHE PALO	250MG	N20460 001	DEC 22, 1994	JUN	CFTG
AB +		500MG	N20460 002	DEC 12, 1997	JUN	CFTG
	GANCICLOVIR					
AB	RANBAXY	250MG	N76457 001	JUN 27, 2003	JUN	NEWA
AB		500MG	N76457 002	JUN 27, 2003	JUN	NEWA

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

CYTOVENE IV

>D>	+ ROCHE PALO	EQ 500MG BASE/VIAL	N19661 001	JUN 23, 1989	JUL	CFTG
>A>	AP +	EQ 500MG BASE/VIAL	N19661 001	JUN 23, 1989	JUL	CFTG
>A>	GANCICLOVIR SODIUM					
>A>	AP BEDFORD	EQ 500MG BASE/VIAL	N76222 001	JUL 16, 2003	JUL	NEWA

GATIFLOXACIN

INJECTABLE; INJECTION

TEQUIN

+ BRISTOL MYERS SQUIBB	EQ 2MG /ML(200MG/100ML)	N21062 001	DEC 17, 1999	APR	CRLD
+	EQ 2MG /ML(400MG/200ML)	N21062 002	DEC 17, 1999	APR	CRLD
+	EQ 10MG /ML(200MG)	N21062 003	DEC 17, 1999	APR	CRLD

SOLUTION/DROPS; OPHTHALMIC

ZYMAR

+ ALLERGAN	0.3%	N21493 001	MAR 28, 2003	MAR	NEWA
------------	------	------------	--------------	-----	------

GEFITINIB

TABLET; ORAL

IRESSA

+ ASTRAZENECA	250MG	N21399 001	MAY 05, 2003	MAY	NEWA
---------------	-------	------------	--------------	-----	------

GEMIFLOXACIN MESYLATE

TABLET; ORAL
FACTIVE

+ GENESOFT PHARMS	EQ 320MG BASE	N21158 001 APR 04, 2003 MAY CAHN
+ LG LIFE	EQ 320MG BASE	N21158 001 APR 04, 2003 APR NEWA

GEMTUZUMAB OZOGAMICIN

INJECTABLE; INJECTION
MYLOTARG

+ WYETH PHARMS INC	5MG/VIAL	N21174 001 MAY 17, 2000 MAR CAHN
--------------------	----------	----------------------------------

GENTAMICIN SULFATE

CREAM; TOPICAL
GARAMYCIN

@ SCHERING	EQ 0.1% BASE	N60462 001 FEB DISC
------------	--------------	---------------------

GENTAMICIN SULFATE

AT + FOUGERA	EQ 0.1% BASE	N62531 001 JUL 05, 1984 FEB CRLD
--------------	--------------	----------------------------------

INJECTABLE; INJECTION

AP + AM PHARM PARTNERS	EQ 10MG BASE/ML	N62356 001 MAR 04, 1982 JUN CRLD
@ BAXTER HLTHCARE	EQ 10MG BASE/ML	N62251 002 JUN DISC
@	EQ 40MG BASE/ML	N62251 001 JUN DISC

OINTMENT; OPHTHALMIC
GARAMYCIN

@ SCHERING	EQ 0.3% BASE	N50425 001 APR DISC
------------	--------------	---------------------

GENTAMICIN SULFATE

+ AKORN	EQ 0.3% BASE	N64093 001 AUG 31, 1995 APR CRLD
---------	--------------	----------------------------------

GLIMEPIRIDE

TABLET; ORAL
AMARYL

+ AVENTIS PHARMS	1MG	N20496 001 NOV 30, 1995 JAN CRLD
	4MG	N20496 003 NOV 30, 1995 JAN CRLD

GLYBURIDE

TABLET; ORAL
GLYBURIDE (MICRONIZED)

>A> AB HIKMA	1.5MG	N75890 001 JUL 31, 2003 JUL NEWA
>A> AB	3MG	N75890 002 JUL 31, 2003 JUL NEWA
>A> AB	6MG	N75890 003 JUL 31, 2003 JUL NEWA

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION
FACTREL

+ BAXTER HLTHCARE CORP	EQ 0.1MG BASE/VIAL	N18123 001 SEP 30, 1982 MAY CAHN
@	EQ 0.2MG BASE/VIAL	N18123 002 SEP 30, 1982 MAY CAHN
@	EQ 0.5MG BASE/VIAL	N18123 003 SEP 30, 1982 MAY CAHN

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION
A.P.L.

>A> @ FERRING	5,000 UNITS/VIAL	N17055 001 JUL CAHN
>A> @	10,000 UNITS/VIAL	N17055 002 JUL CAHN

>A>	⑥	20,000 UNITS/VIAL	N17055 003	JUL CAHN
>D>	⑥ WYETH AYERST	5,000 UNITS/VIAL	N17055 001	JUL CAHN
	⑥	5,000 UNITS/VIAL	N17055 001	JUN DISC
>D>	⑥	10,000 UNITS/VIAL	N17055 002	JUL CAHN
	⑥	10,000 UNITS/VIAL	N17055 002	JUN DISC
>D>	⑥	20,000 UNITS/VIAL	N17055 003	JUL CAHN

GRANISETRON HYDROCHLORIDE

SOLUTION; ORAL	KYTRIL				
>D>	⑥ ROCHE	EQ 2MG BASE/10ML	N21238 001	JUN 27, 2001	JUL CMFD
>A>	+	EQ 2MG BASE/10ML	N21238 001	JUN 27, 2001	JUL CMFD

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL	RAXAR			
⑥ OTSUKA	EQ 200MG BASE	N20695 001	NOV 06, 1997	MAY DISC
⑥	EQ 400MG BASE	N20695 002	MAY 14, 1998	MAY DISC
⑥	EQ 600MG BASE	N20695 003	MAY 14, 1998	MAY DISC

GUANABENZ ACETATE

TABLET; ORAL	GUANABENZ ACETATE			
AB + WATSON LABS	EQ 8MG BASE	N74025 002	FEB 28, 1994	JUN CRLD
WYTENSIN				
⑥ WYETH AYERST	EQ 4MG BASE	N18587 001	SEP 07, 1982	JUN DISC
⑥	EQ 8MG BASE	N18587 002	SEP 07, 1982	JUN DISC

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION	HALOPERIDOL DECANOATE			
⑥ KING PHARMS	EQ 50MG BASE/ML	N75176 001	FEB 09, 2000	MAY DISC
⑥	EQ 100MG BASE/ML	N75176 002	FEB 09, 2000	MAY DISC

HEPARIN SODIUM

INJECTABLE; INJECTION	HEP-LOCK			
AP + BAXTER HLTHCARE	10 UNITS/ML	N17037 007	JUN CAHN	
AP +	100 UNITS/ML	N17037 006	JUN CAHN	
HEP-LOCK U/P				
AP BAXTER HLTHCARE	10 UNITS/ML	N17037 010	JUN 10, 1983	JUN CAHN
AP	100 UNITS/ML	N17037 011	JUN 10, 1983	JUN CAHN
HEPARIN LOCK FLUSH				
⑥ BAXTER HLTHCARE CORP	10 UNITS/ML	N17007 008	MAY CAHN	
⑥	100 UNITS/ML	N17007 009	MAY CAHN	
HEPARIN SODIUM				
AP BAXTER HLTHCARE	1,000 UNITS/ML	N17037 001	JUN CAHN	
AP	5,000 UNITS/ML	N17037 002	JUN CAHN	
AP	5,000 UNITS/0.5ML	N17037 013	APR 07, 1986	JUN CAHN
AP	10,000 UNITS/ML	N17037 003	JUN CAHN	
⑥ BAXTER HLTHCARE CORP	1,000 UNITS/ML	N17007 001	MAY CAHN	
⑥	2,500 UNITS/ML	N17007 007	MAY CAHN	
⑥	5,000 UNITS/ML	N17007 002	MAY CAHN	

⑥		5,000 UNITS/0.5ML	N17007 010	MAY CAHN
⑥		7,500 UNITS/ML	N17007 003	MAY CAHN
⑥		10,000 UNITS/ML	N17007 004	MAY CAHN
⑥		15,000 UNITS/ML	N17007 005	MAY CAHN
⑥		20,000 UNITS/ML	N17007 006	MAY CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA AXIOM PHARM 1.5MG/5ML;5MG/5ML N40285 001 JUL 19, 1999 MAY CAHN

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

>A>	AB	CLONMEL HLTHCARE	25MG	N87059 001	JUL CAHN
>A>	AB		50MG	N87068 001	JUL CAHN
>A>	⑥		100MG	N87060 001	JUL CAHN
>D>	AB	LEDERLE	25MG	N87059 001	JUL CAHN
>D>	AB		50MG	N87068 001	JUL CAHN
>D>	⑥		100MG	N87060 001	JUL CAHN

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

>D>	AB	CLONMEL HLTHCARE	15MG;250MG	N72507 001	JUN 02, 1989	JUL	DISC
>A>	⑥		15MG;250MG	N72507 001	JUN 02, 1989	JUL	DISC
>D>	AB		25MG;250MG	N72508 001	JUN 02, 1989	JUL	DISC
>A>	⑥		25MG;250MG	N72508 001	JUN 02, 1989	JUL	DISC
>D>	⑥		30MG;500MG	N72509 001	JUN 02, 1989	JUL	DISC
>A>	⑥		30MG;500MG	N72509 001	JUN 02, 1989	JUL	DISC
>D>	AB		50MG;500MG	N72510 001	JUN 02, 1989	JUL	DISC
>A>	⑥		50MG;500MG	N72510 001	JUN 02, 1989	JUL	DISC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR HCT

SANKYO		12.5MG;20MG	N21532 002	JUN 05, 2003	JUN	NEWA
		12.5MG;40MG	N21532 003	JUN 05, 2003	JUN	NEWA
+		25MG;40MG	N21532 005	JUN 05, 2003	JUN	NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERIDE-40/25

AB	WYETH PHARMS INC	25MG;40MG	N18031 001	MAR	CAHN
AB	+ WYETH PHARMS INC	25MG;80MG	N18031 002	MAR	CAHN

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

>A>	NOVARTIS	25MG;160MG	N20818 003	JAN 17, 2002	JUL	NEWA
-----	----------	------------	------------	--------------	-----	------

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB	TEVA	7.5MG;200MG	N76023 001 APR 11, 2003 APR NEWA
	VICOPROFEN		
AB	ABBOTT	7.5MG;200MG	N20716 001 SEP 23, 1997 APR CFTG

HYDROCORTISONE

LOTION; TOPICAL

HYDROCORTISONE

>A>	AT	VINTAGE PHARMS	2.5%	N40417 001 JUL 30, 2003 JUL NEWA
-----	----	----------------	------	----------------------------------

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDROCORTONE

@ MERCK EQ 50MG BASE/ML

N12052 001 APR DISC

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORT-DOME

@ BAYER PHARMS 0.5%;EQ 3.5MG BASE/GM

N50237 006 JUN 05, 1984 JUN DISC

@ 1%;EQ 3.5MG BASE/GM

N50237 005 JUN 05, 1984 JUN DISC

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	ALCON	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62423 001 AUG 25, 1983 FEB CMFD
	SUSPENSION/DROPS; OPHTHALMIC		

AT	ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62874 001 MAY 11, 1988 FEB CMFD
	SUSPENSION/DROPS; OTIC		

AT	ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62488 001 NOV 06, 1985 FEB CMFD
----	-----------------	-------------------------------------	----------------------------------

HYDROFLUMETHIAZIDE

TABLET; ORAL

DIUCARDIN

@ WYETH AYERST 50MG

N83383 001 JUN DISC

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

SALUTENSIN

+ SHIRE LABS 50MG;0.125MG

N12359 003 JUL DISC

>A> @ 50MG;0.125MG

N12359 003 JUL DISC

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROMORPHONE HCL

AP FAULDING 10MG/ML

N76444 001 APR 25, 2003 APR NEWA

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE

@ ELKINS SINK 50MG/ML

N85551 002 JUN DISC

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HCL

② ELKINS SINK	25MG/ML	N85551 001	JUN	DISC
TABLET; ORAL				
ATARAX				
② PFIZER	10MG	N10392 001	FEB	DISC
②	25MG	N10392 004	FEB	DISC
②	50MG	N10392 006	FEB	DISC
②	100MG	N10392 005	FEB	DISC
HYDROXYZINE HCL				
AB + SIDMAK LABS NJ	10MG	N88617 001	JAN 10, 1986	FEB CRLD
AB +	25MG	N88618 001	JAN 10, 1986	FEB CRLD
AB +	50MG	N88619 001	JAN 10, 1986	FEB CRLD
②	100MG	N81054 001	SEP 25, 1995	FEB DISC

>D> IBANDRONATE SODIUM

>D> TABLET; ORAL

>D> BONIVA

>D> + ROCHE	EQ 2.5MG BASE	N21455 001	MAY 16, 2003	JUL	DISC
>A> ②	EQ 2.5MG BASE	N21455 001	MAY 16, 2003	JUL	DISC
>A> +	EQ 2.5MG BASE	N21455 001	MAY 16, 2003	MAY	NEWA

IMATINIB MESYLATE

CAPSULE; ORAL

GLEEVEC

② NOVARTIS	50MG	N21335 001	MAY 10, 2001	JUN	DISC
TABLET; ORAL					
NOVARTIS	100MG	N21588 001	APR 18, 2003	APR	NEWA
+	400MG	N21588 002	APR 18, 2003	APR	NEWA

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL

② ELKINS SINK PHARM	41%	N74629 001	NOV 06, 1996	JUN	DISC
②	51%	N74629 004	MAR 31, 1998	JUN	DISC
②	61%	N74629 002	NOV 06, 1996	JUN	DISC
②	76%	N74629 003	NOV 06, 1996	JUN	DISC

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 240

② MALLINCKRODT	51%	N20923 001	MAY 28, 1998	JUN	DISC
OPTIRAY 300					
+ MALLINCKRODT	64%	N20923 004	MAY 13, 1999	JUN	NEWA
OPTIRAY 320		N20923 002	MAY 29, 1998	JUN	DISC
② MALLINCKRODT	68%				

IPRATROPIUM BROMIDE

SPRAY, METERED; NASAL					
ATROVENT					
AB + BOEHRINGER INGELHEIM	0.021MG/SPRAY	N20393	001	OCT 20, 1995	MAR CFTG
AB +	0.042MG/SPRAY	N20394	001	OCT 20, 1995	MAR CFTG
<u>IPRATROPIUM BROMIDE</u>					
AB BAUSCH AND LOMB	0.021MG/SPRAY	N76025	001	MAR 31, 2003	MAR NEWA
AB	0.042MG/SPRAY	N76103	001	MAR 31, 2003	MAR NEWA
AB DEY	0.021MG/SPRAY	N75552	001	MAR 31, 2003	MAR NEWA
AB	0.042MG/SPRAY	N75553	001	MAR 31, 2003	MAR NEWA
AB NOVEX	0.021MG/SPRAY	N76156	001	APR 18, 2003	APR NEWA
AB	0.042MG/SPRAY	N76155	001	APR 18, 2003	APR NEWA

ISONIAZID

TABLET; ORAL					
ISONIAZID					
@ AXIOM PHARM	100MG	N80136	001		MAY CAHN
AA	300MG	N83633	001		MAY CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION					
ISOPROTERENOL HCL					
@ BAXTER HLTHCARE	0.2MG/ML	N83486	001		JUN DISC

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL					
DILATRATE-SR					
>D> BC + SCHWARZ PHARMA	40MG	N19790	001	SEP 02, 1988	JUL CTEC
>A> +	40MG	N19790	001	SEP 02, 1988	JUL CTEC
BC +	40MG	N19790	001	SEP 02, 1988	JUN CRLD
<u>ISORDIL</u>					
@ WYETH AYERST	40MG	N12882	002	JUL 29, 1988	JUN DISC
TABLET; ORAL					
AB BIOVAIR	5MG	N12093	007	JUL 29, 1988	JUN CAHN
AB	10MG	N12093	002	JUL 29, 1988	JUN CAHN
AB	20MG	N12093	006	JUL 29, 1988	JUN CAHN
AB +	30MG	N12093	005	JUL 29, 1988	JUN CAHN
AB	40MG	N12093	001	JUL 29, 1988	JUN CAHN
AB WYETH PHARMS INC	5MG	N12093	007	JUL 29, 1988	JUN CAHN
AB	10MG	N12093	002	JUL 29, 1988	MAR CAHN
AB	20MG	N12093	006	JUL 29, 1988	MAR CAHN
AB +	30MG	N12093	005	JUL 29, 1988	MAR CAHN
AB	40MG	N12093	001	JUL 29, 1988	MAR CAHN
<u>TABLET; SUBLINGUAL</u>					
AB BIOVAIR	2.5MG	N12940	004	JUL 29, 1988	JUN CAHN
AB	5MG	N12940	003	JUL 29, 1988	JUN CAHN
+	10MG	N12940	005	JUL 29, 1988	JUN CAHN
AB WYETH PHARMS INC	2.5MG	N12940	004	JUL 29, 1988	MAR CAHN
AB	5MG	N12940	003	JUL 29, 1988	MAR CAHN
+	10MG	N12940	005	JUL 29, 1988	MAR CAHN

ISOTRETINOIN

CAPSULE; ORAL
CLARAVIS

AB	BARR	10MG	N76356 001	APR 11, 2003	APR	NEWA
AB		20MG	N76135 002	APR 11, 2003	APR	NEWA
AB		40MG	N76135 001	APR 11, 2003	APR	NEWA
	SOTRET					
	RANBAXY	30MG	N76503 001	JUN 20, 2003	JUN	NEWA

ISRADIPINE

CAPSULE; ORAL
DYNACIRC

	RELIANT PHARMS	2.5MG	N19546 001	DEC 20, 1990	MAY	CAHN
+		5MG	N19546 002	DEC 20, 1990	MAY	CAHN
	TABLET, EXTENDED RELEASE; ORAL					
	DYNACIRC CR					
+	RELIANT PHARMS	5MG	N20336 001	JUN 01, 1994	MAY	CAHN
+		10MG	N20336 002	JUN 01, 1994	MAY	CAHN

KETOPROFEN

CAPSULE; ORAL
KETOPROFEN

AB	CLONMEL HLTHCARE	75MG	N74014 003	JAN 29, 1993	JUN	CAHN
AB +	TEVA	75MG	N73517 001	DEC 22, 1992	JUN	CRLD
	ORUDIS					
@	WYETH AYERST	25MG	N18754 001	JUL 31, 1987	JUN	DISC
@		50MG	N18754 002	JAN 09, 1986	JUN	DISC
@		75MG	N18754 003	JAN 09, 1986	JUN	DISC
	CAPSULE, EXTENDED RELEASE; ORAL					
	ORUVAIL					
AB	WYETH PHARMS INC	100MG	N19816 003	FEB 08, 1995	MAR	CAHN
AB		150MG	N19816 002	FEB 08, 1995	MAR	CAHN
AB +		200MG	N19816 001	SEP 24, 1993	MAR	CAHN

KETOROLAC TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC
ACULAR LS

+	ALLERGAN	0.4%	N21528 001	MAY 30, 2003	MAY	NEWA
---	----------	------	------------	--------------	-----	------

LACTULOSE

SOLUTION; ORAL
LACTULOSE

AA	VISTAPHARM	10GM/15ML	N74138 001	SEP 30, 1992	MAR	CAHN
	SOLUTION; ORAL, RECTAL					
>A>	AA NOVEX	10GM/15ML	N76645 001	JUL 28, 2003	JUL	NEWA

LEFLUNOMIDE

TABLET; ORAL
ARAVA

+	AVENTIS PHARMS	20MG	N20905 002	SEP 10, 1998	MAR	CRLD
@		100MG	N20905 003	SEP 10, 1998	MAR	DISC

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

@ ELKINS SINK	EQ 50MG BASE/VIAL	N70480 001	JAN 02, 1987	JUN	DISC
@	EQ 100MG BASE/VIAL	N81224 001	JUN 03, 1994	JUN	DISC

LEUPROLIDE ACETATE

INJECTABLE; SUBCUTANEOUS

ELIGARD

+ ATRIX	30MG/VIAL	N21488 001	FEB 13, 2003	FEB	NEWA
---------	-----------	------------	--------------	-----	------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

XOPENEX

>A> + SEPRACOR	EQ 0.0103% BASE	N20837 003	JAN 30, 2002	JUL	CPOT
>D> +	EQ 0.0105% BASE	N20837 003	JAN 30, 2002	JUL	CPOT
>A> +	EQ 0.25% BASE	N20837 004	JUL 18, 2003	JUL	NEWA

LEVETIRACETAM

>A>	SOLUTION; ORAL	N21505 001	JUL 15, 2003	JUL	NEWA
>A>	KEPPRA				
>A>	+ UCB	100MG/ML			

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETAXON

>A> @ ALCON	EQ 0.5% BASE	N21114 001	FEB 23, 2000	JUL	CAHN
>D> + MEDPOINTE	EQ 0.5% BASE	N21114 001	FEB 23, 2000	JUL	CAHN
+ @	EQ 0.5% BASE	N21114 001	FEB 23, 2000	MAR	CAHN

LEVONORGESTREL

IMPLANT; IMPLANTATION

LEVONORGESTREL

BX + WYETH PHARMS INC	75MG/IMPLANT	N20627 001	AUG 15, 1996	MAR	CAHN
@	75MG/IMPLANT	N20627 001	AUG 15, 1996	JUN	DISC
NORPLANT II					
BX + POPULATION COUNCIL	75MG/IMPLANT	N20544 001	NOV 01, 1996	JUN	CRLD
NORPLANT SYSTEM IN PLASTIC CONTAINER					
+ WYETH PHARMS INC	36MG/IMPLANT	N20088 001	DEC 10, 1990	MAR	CAHN
@	36MG/IMPLANT	N20088 001	DEC 10, 1990	JUN	DISC

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVO-DROMORAN

@ ICN

2MG

N08720 001 DEC 19, 1991 FEB DISC

LEVORPHANOL TARTRATE

+ ROXANE

2MG

N74278 001 MAR 31, 2000 FEB CRLD

LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVO-T

BX ALARA PHARM

0.025MG

N21342 001 MAR 01, 2002 APR CAHN

BX		0.05MG	N21342 002	MAR 01, 2002	APR	CAHN
BX		0.075MG	N21342 003	MAR 01, 2002	APR	CAHN
BX		0.088MG	N21342 004	MAR 01, 2002	APR	CAHN
BX		0.1MG	N21342 005	MAR 01, 2002	APR	CAHN
BX		0.112MG	N21342 006	MAR 01, 2002	APR	CAHN
BX		0.125MG	N21342 007	MAR 01, 2002	APR	CAHN
BX		0.15MG	N21342 008	MAR 01, 2002	APR	CAHN
BX		0.175MG	N21342 009	MAR 01, 2002	APR	CAHN
BX		0.2MG	N21342 010	MAR 01, 2002	APR	CAHN
BX +		0.3MG	N21342 011	MAR 01, 2002	APR	CAHN
LEVOLET						
BX	VINTAGE PHARMS	0.025MG	N21137 001	JUN 06, 2003	JUN	NEWA
BX		0.05MG	N21137 002	JUN 06, 2003	JUN	NEWA
BX		0.075MG	N21137 003	JUN 06, 2003	JUN	NEWA
BX		0.088MG	N21137 004	JUN 06, 2003	JUN	NEWA
BX		0.1MG	N21137 005	JUN 06, 2003	JUN	NEWA
BX		0.112MG	N21137 006	JUN 06, 2003	JUN	NEWA
BX		0.125MG	N21137 007	JUN 06, 2003	JUN	NEWA
BX		0.137MG	N21137 008	JUN 06, 2003	JUN	NEWA
BX		0.15MG	N21137 009	JUN 06, 2003	JUN	NEWA
BX		0.175MG	N21137 010	JUN 06, 2003	JUN	NEWA
BX		0.2MG	N21137 011	JUN 06, 2003	JUN	NEWA
BX		0.3MG	N21137 012	JUN 06, 2003	JUN	NEWA

LIDOCAINE HYDROCHLORIDE**INJECTABLE; INJECTION****LIDOCAINE HCL**

Ⓐ ELKINS SINK	1%	N80407 001	JUN	DISC
Ⓑ	2%	N80407 002	JUN	DISC
Ⓒ WYETH AYERST	1%	N83083 001	JUN	DISC
Ⓓ	2%	N83083 002	JUN	DISC

LIDOCAINE HCL PRESERVATIVE FREE

Ⓐ ELKINS SINK	1%	N84625 001	JUN	DISC
Ⓓ	2%	N84625 002	JUN	DISC

JELLY; TOPICAL**LIDOCAINE HCL**

AT	AKORN	2%	N40433 001	FEB 12, 2003	FEB	NEWA
----	-------	----	------------	--------------	-----	------

LISINOPRIL**TABLET; ORAL****LISINOPRIL**

AB	RANBAXY	30MG	N75944 006	FEB 11, 2003	FEB	NEWA
AB	WEST WARD	30MG	N76063 006	JUN 27, 2003	JUN	NEWA
ZESTRIL						
AB	ASTRAZENECA	30MG	N19777 006	JAN 20, 1999	APR	CRLD

LITHIUM CARBONATE**CAPSULE; ORAL****LITHIUM CARBONATE**

AB	ROXANE	150MG	N17812 002	JAN 28, 1987	FEB	CTEC
AB	WEST WARD	150MG	N76243 002	FEB 24, 2003	FEB	NEWA

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL			
ESKALITH CR			
AB +	GLAXOSMITHKLINE	450MG	N18152 001 MAR 29, 1982 JUN CFTG
LITHIUM CARBONATE			
AB	ABLE	300MG	N76382 001 APR 21, 2003 APR NEWA
AB	WEST WARD	450MG	N76490 001 JUN 17, 2003 JUN NEWA

LORATADINE

SYRUP; ORAL			
CLARITIN			
@ SCHERING		1MG/ML	N20641 001 OCT 10, 1996 MAY DISC
TABLET; ORAL			
@ SCHERING		10MG	N19658 001 APR 12, 1993 MAY DISC
TABLET, ORALLY DISINTEGRATING; ORAL			
CLARITIN REDITABS			
@ SCHERING		10MG	N20704 001 DEC 23, 1996 MAY DISC

LORAZEPAM

CONCENTRATE; ORAL			
LORAZEPAM INTENSOL			
+ ROXANE		2MG/ML	N72755 001 JUN 28, 1991 MAY CRLD
INJECTABLE; INJECTION			
ATIVAN			
AP +	BAXTER HLTHCARE CORP	2MG/ML	N18140 001 FEB CAHN
AP +		4MG/ML	N18140 002 FEB CAHN
TABLET; ORAL			
AB	BIOVAIL	0.5MG	N17794 001 JUN CAHN
AB		1MG	N17794 002 JUN CAHN
AB +		2MG	N17794 003 JUN CAHN

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL			
INVERSINE			
+ TARGACEPT		2.5MG	N10251 001 APR CAHN

MECLOFENAMATE SODIUM

CAPSULE; ORAL			
MECLOFENAMATE SODIUM			
AB +	MYLAN	EQ 100MG BASE	N71081 001 SEP 03, 1986 MAY CRLD
MECLOMEN			
@ PARKE DAVIS		EQ 50MG BASE	N18006 001 MAY DISC
@		EQ 100MG BASE	N18006 002 MAY DISC

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL			
MEFLOQUINE HCL			
AB	GENEVA PHARMS	250MG	N76175 001 FEB 20, 2002 APR CAHN

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

AB COBLEY PHARM 40MG/ML

N75681 001 MAY 05, 2003 MAY NEWA

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

REPRONEX

BX + FERRING 75 IU/VIAL;75 IU/VIAL
@ 150 IU/VIAL;150 IU/VIALN21047 001 AUG 27, 1999 MAY CRLD
N21047 002 AUG 27, 1999 MAY DISCMEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HCL

AP BAXTER HLTHCARE CORP 25MG/ML
AP 50MG/ML
AP 75MG/ML
AP 100MG/MLN80455 007 MAY CAHN
N80455 008 MAY CAHN
N80455 009 MAY CAHN
N80455 010 MAY CAHNTABLET; ORAL
AA AXIOM PHARM 50MG
AA 100MG
@ WYETH AYERST 50MGN80448 001 MAY CAHN
N80448 002 MAY CAHN
N80454 001 JUN DISCMEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

@ BAXTER HLTHCARE CORP 25MG/ML;25MG/ML

N11730 001 MAY CAHN

MEPHENENTERMINE SULFATE

INJECTABLE; INJECTION

WYAMINE SULFATE

@ BAXTER HLTHCARE CORP EQ 15MG BASE/ML
@ EQ 30MG BASE/MLN08248 002 FEB CAHN
N08248 001 FEB CAHNMEPROBAMATE

TABLET; ORAL

EQUANIL

@ WYETH AYERST 200MG
@ 400MGN10028 005 JUN DISC
N10028 004 JUN DISC

MEPROBAMATE

+ ROXANE 600MG
MILTOWN

N84332 001 JUN CRLD

AA + MEDPOINTE 600MG
@ MEDPOINTE PHARM HLC 600MGN83919 001 APR CAHN
N83919 001 JUN DISCMESORIDAZINE BESYLATE

TABLET; ORAL

SERENTIL

@ NOVARTIS EQ 10MG BASE
@ EQ 50MG BASEN16774 001 JUN DISC
N16774 003 JUN DISC

METAXALONE

TABLET; ORAL						
SKELAXIN						
JONES PHARMA INC	400MG		N13217 001	JUN	CAHN	
+	800MG		N13217 003	AUG 30, 2002	JUN	CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL							
METFORMIN HCL							
AB PUREPAC PHARM	1GM		N76033 003	JAN 24, 2002	FEB	CMS1	
TABLET, EXTENDED RELEASE; ORAL							
GLUCOPHAGE XR							
+	BRISTOL MYERS SQUIBB	750MG		N21202 004	APR 11, 2003	APR	NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL						
AVANDAMET						
SB PHARMCO	500MG;EQ 1MG BASE		N21410 001	OCT 10, 2002	APR	CAHN
	500MG;EQ 2MG BASE		N21410 002	OCT 10, 2002	APR	CAHN
+	500MG;EQ 4MG BASE		N21410 003	OCT 10, 2002	APR	CAHN

METHADONE HYDROCHLORIDE

INJECTABLE; INJECTION						
DOLOPHINE HCL						
+	AAIPHARMA	10MG/ML		N21624 001	APR	CAHN
+	ROXANE	10MG/ML		N21624 001	FEB	CMS1

METHAZOLAMIDE

TABLET; ORAL						
METHAZOLAMIDE						
AB + MIKART	50MG		N40062 002	JAN 27, 1994	JUN	CRDL
NEPTAZANE						
AB LEDERLE	25MG		N11721 002	NOV 25, 1991	JUN	DISC
AB	50MG		N11721 001		JUN	DISC

METHENAMINE HIPPURATE

TABLET; ORAL						
METHENAMINE HIPPURATE						
AB COREPHARMA	1GM		N76411 001	JUN 20, 2003	JUN	NEWA

METHIMAZOLE

TABLET; ORAL						
TAPAZOLE						
AB LILLY	10MG		N07517 004		JUN	CRDL

METHOCARBAMOL

TABLET; ORAL						
METHOCARBAMOL						
AA ABLE	500MG		N40413 001	MAR 17, 2003	MAR	NEWA
AA	750MG		N40413 002	MAR 17, 2003	MAR	NEWA
AB CLONMEL HLTHCARE	500MG		N85961 001		JUN	DISC
AB	750MG		N85963 001		JUN	DISC

AA	LANNETT	500MG	N84756 002	MAR 31, 2003	MAR NEWA
AA	VINTAGE PHARMS	500MG	N40489 001	JAN 29, 2003	JAN NEWA
AA		750MG	N40489 002	JAN 29, 2003	JAN NEWA

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE LPF

AP +	WYETH PHARMS INC	EQ 25MG BASE/ML	N11719 007	MAR 31, 1982	MAR CAHN
	METHOTREXATE SODIUM		N11719 004		MAR CAHN
	@ WYETH PHARMS INC	EQ 2.5MG BASE/ML	N11719 001		MAR CAHN
		EQ 20MG BASE/VIAL	N11719 005		MAR CAHN
AP +		EQ 25MG BASE/ML	N11719 003		MAR CAHN
	@	EQ 50MG BASE/VIAL	N11719 006		MAR CAHN
	@	EQ 100MG BASE/VIAL	N11719 009	APR 07, 1988	MAR CAHN
AP +	WYETH PHARMS INC	EQ 1GM BASE/VIAL			

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

PAMINE FORTE

+ BRADLEY PHARMS 5MG

N08848 002 MAR 25, 2003 MAR NEWA

METHYCLOTHIAZIDE

TABLET; ORAL

AQUATENSEN

@ MEDPOINTE PHARM HLC 5MG

N17364 001 JUN DISC

METHYLDOPA

TABLET; ORAL

ALDOMET

@ MERCK 125MG
@ 250MGN13400 003 MAY DISC
N13400 001 MAY DISCMETHYLDOPA
@ CLONMEL HLTHCARE 125MG

N70070 003 OCT 15, 1985 JUN DISC

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HCL

@ ELKINS SINK 50MG/ML

N70291 001 JUL 01, 1986 JUN DISC

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

>A>	CELLTECH PHARMS	10MG	N21259 003	MAY 27, 2003	JUL NEWA
>D>	BX +	20MG	N21259 001	APR 03, 2001	JUL CRLD
>A>	BX	20MG	N21259 001	APR 03, 2001	JUL CRLD
>D>	+	30MG	N21259 002	JUN 19, 2003	JUL CTEC
>A>	BX +	30MG	N21259 002	JUN 19, 2003	JUL CTEC
	+	30MG	N21259 002	JUN 19, 2003	JUN NEWA
	RITALIN LA		N21284 002	JUN 05, 2002	JUL CTEC
>D>	NOVARTIS	30MG	N21284 002	JUN 05, 2002	JUL CTEC
>A>	BX	30MG			

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 7 - JUL 2003

METHYLPHENIDATE HYDROCHLORIDE

TABLET, CHEWABLE; ORAL

METHYLIN

MALLINCKRODT

2.5MG

5MG

10MG

+

TABLET, EXTENDED RELEASE; ORAL

CONCERTA

+ MCNEIL CONS SPECLT

18MG

+
+
+
+

27MG

36MG

54MG

N21475 001 APR 15, 2003 APR NEWA
N21475 002 APR 15, 2003 APR NEWA
N21475 003 APR 15, 2003 APR NEWAMETHYLPREDNISOLONE

TABLET; ORAL

MEDROL

>D> PHARMACIA AND UPJOHN

2MG

>A>

@

2MG

N11153 002 JUL DISC
N11153 002 JUL DISCMETHYLPREDNISOLONE ACETATE

OINTMENT; TOPICAL

MEDROL ACETATE

>A @ PHARMACIA AND UPJOHN

0.25%

N12421 001

JUN DISC

METHYSERGIDE MALEATE

TABLET; ORAL

SANSERT

>A NOVARTIS

2MG

N12516 001

JUN DISC

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL

METOCLOPRAMIDE

AA

VISTAPHARM

EQ 5MG BASE/5ML

N75051 001 JAN 26, 2001 APR CAHN

TABLET; ORAL

METOCLOPRAMIDE HCL

>A @ CLONMEL HLTHCARE

EQ 10MG BASE

N72639 001 MAY 09, 1991 JUN DISC

METOLAZONE

TABLET; ORAL

ZAROXOLYN

>D>

+ CELLTECH PHARMS

2.5MG

>A>

2.5MG

>D>

5MG

>A> +

5MG

N17386 001

JUL CRLD

N17386 001

JUL CRLD

N17386 002

JUL CRLD

N17386 002

JUL CRLD

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

>A> AP BEDFORD LABS

1MG/ML

N76495 001 JUL 07, 2003 JUL NEWA

METRONIDAZOLE

TABLET; ORAL					
METRONIDAZOLE					
AB	ABLE	250MG		N76519 001	JUN 27, 2003
AB		500MG		N76519 002	JUN 27, 2003
TABLET, EXTENDED RELEASE; ORAL					
FLAGYL ER				N20868 001	NOV 26, 1997
AB	+ GD SEARLE LLC	750MG			JUN CFTG
METRONIDAZOLE				N76462 001	JUN 25, 2003
AB	ABLE	750MG			JUN NEWA

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

MEZLIN					
ø	BAYER PHARMS	EQ 1GM BASE/VIAL		N50549 001	JUN DISC
ø		EQ 2GM BASE/VIAL		N50549 002	JUN DISC
ø		EQ 3GM BASE/VIAL		N50549 003	JUN DISC
ø		EQ 4GM BASE/VIAL		N50549 004	JUN DISC
ø		EQ 20GM BASE/VIAL		N50549 005	MAR 02, 1988 JUN DISC

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION					
MIDAZOLAM HCL				N75243 001	JUN 20, 2000 JUN CAHN
AP	BAXTER HLTHCARE	EQ 1MG BASE/ML		N75243 002	JUN 20, 2000 JUN CAHN
AP		EQ 5MG BASE/ML			

>A> MIGLUSTAT

>A>	CAPSULE; ORAL				
>A>	ZAVESCA			N21348 001	JUL 31, 2003 JUL NEWA
>A>	+ ACTELION PHARMS	100MG			

MILRINONE LACTATE

INJECTABLE; INJECTION					
MILRINONE LACTATE				N75530 001	MAY 28, 2002 JUN CAHN
AP	BAXTER HLTHCARE	EQ 1MG BASE/ML		N76428 001	JUN 16, 2003 JUN NEWA
AP	BIONICHE (CANADA)	EQ 1MG BASE/ML		N20343 003	AUG 09, 1994 MAY CRLD
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	+ SANOFI SYNTHELABO	EQ 20MG BASE/100ML			

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL					
MINOCIN				N50649 001	MAY 31, 1990 MAR CAHN
AB	WYETH PHARMS INC	EQ 50MG BASE		N50649 003	FEB 12, 2001 MAR CAHN
AB		EQ 75MG BASE		N50649 002	MAY 31, 1990 MAR CAHN
AB	+	EQ 100MG BASE		N50444 001	MAR CAHN
INJECTABLE; INJECTION					
+ WYETH PHARMS INC		EQ 100MG BASE/VIAL		N65131 001	APR 16, 2003 APR NEWA
TABLET; ORAL				N65131 002	APR 16, 2003 APR NEWA
MINOCYCLINE HCL				N65131 003	APR 16, 2003 APR NEWA
PAR PHARM		EQ 50MG BASE			
		EQ 75MG BASE			
		EQ 100MG BASE			

MIRTAZAPINE

AB	ALPHAPHARM	15MG	N76176 001	JUN 19, 2003	JUN	NEWA
AB		30MG	N76176 002	JUN 19, 2003	JUN	NEWA
AB		45MG	N76176 003	JUN 19, 2003	JUN	NEWA
AB	AMIDE PHARM	15MG	N76241 001	JUN 25, 2003	JUN	NEWA
AB		30MG	N76241 002	JUN 25, 2003	JUN	NEWA
AB		45MG	N76241 003	JUN 25, 2003	JUN	NEWA
AB	ANDRX PHARMS	15MG	N76336 001	JUN 20, 2003	JUN	NEWA
AB		30MG	N76336 002	JUN 20, 2003	JUN	NEWA
AB		45MG	N76336 003	JUN 20, 2003	JUN	NEWA
AB	EON	15MG	N76219 001	JUN 19, 2003	JUN	NEWA
AB		30MG	N76219 002	JUN 19, 2003	JUN	NEWA
AB		45MG	N76219 003	JUN 19, 2003	JUN	NEWA
AB	GENEVA PHARMS	15MG	N76189 001	JUN 19, 2003	JUN	NEWA
AB		30MG	N76189 002	JUN 19, 2003	JUN	NEWA
AB		45MG	N76189 003	JUN 19, 2003	JUN	NEWA
AB	MYLAN	15MG	N76122 001	JUN 19, 2003	JUN	NEWA
AB		30MG	N76122 002	JUN 19, 2003	JUN	NEWA
AB		45MG	N76122 003	JUN 19, 2003	JUN	NEWA
AB	PUREPAC PHARM	15MG	N76308 001	JUN 20, 2003	JUN	NEWA
AB		30MG	N76308 002	JUN 20, 2003	JUN	NEWA
AB		45MG	N76308 003	JUN 20, 2003	JUN	NEWA
AB	ROXANE	15MG	N76270 001	JUN 19, 2003	JUN	NEWA
AB		30MG	N76270 002	JUN 19, 2003	JUN	NEWA
AB		45MG	N76270 003	JUN 19, 2003	JUN	NEWA
AB	TEVA	15MG	N76119 001	JAN 24, 2003	JAN	NEWA
AB		30MG	N76119 002	JAN 24, 2003	JAN	NEWA
AB		45MG	N76119 003	JUN 19, 2003	JUN	NEWA
AB	WATSON LABS	15MG	N76312 001	JUN 19, 2003	JUN	NEWA
AB		30MG	N76312 002	JUN 19, 2003	JUN	NEWA
AB		45MG	N76312 003	JUN 19, 2003	JUN	NEWA
	REMERON					
AB	+ ORGANON	15MG	N20415 001	JUN 14, 1996	JAN	CFTG
AB		30MG	N20415 002	JUN 14, 1996	JAN	CFTG

MOEXIPRIL HYDROCHLORIDE

AB	TEVA	7.5MG	N76204 001	MAY 08, 2003	MAY	NEWA
AB		15MG	N76204 002	MAY 08, 2003	MAY	NEWA
	UNIVASC					
AB	SCHWARZ PHARMA	7.5MG	N20312 001	APR 19, 1995	MAY	CFTG
AB	+ LIGAND	15MG	N20312 002	APR 19, 1995	MAY	CFTG

MORPHINE SULFATE

AB	AVINZA					
BX	+ LIGAND	30MG	N21260 001	MAR 20, 2002	JUN	CAHN
BX	+ LIGAND	60MG	N21260 002	MAR 20, 2002	JUN	CAHN
	+ LIGAND	90MG	N21260 003	MAR 20, 2002	JUN	CAHN

+		120MG	N21260	004	MAR 20, 2002	JUN	CAHN	
<u>TABLET, EXTENDED RELEASE; ORAL</u>								
<u>MORPHINE SULFATE</u>								
>D>	AB	CLONMEL HLTHCARE	15MG	N75407	001	JAN 28, 2000	JUL	DISC
>A>	@		15MG	N75407	001	JAN 28, 2000	JUL	DISC
>A>	AB	MALLINCKRODT	15MG	N76412	001	JUL 31, 2003	JUL	NEWA
>A>	AB		30MG	N76412	002	JUL 31, 2003	JUL	NEWA
>A>	AB		60MG	N76412	003	JUL 31, 2003	JUL	NEWA
>A>	AB		100MG	N76438	001	JUL 03, 2003	JUL	NEWA
>A>	AB		200MG	N76438	002	JUL 03, 2003	JUL	NEWA
<u>MOXIFLOXACIN HYDROCHLORIDE</u>								
<u>SOLUTION/DROPS; OPHTHALMIC</u>								
<u>VIGAMOX</u>								
+	ALCON		0.5%	N21598	001	APR 15, 2003	APR	NEWA
<u>MUPIROCIN</u>								
<u>ointment; topical</u>								
<u>MUPIROCIN</u>								
BX	CLAY PARK LABS		2%	N50788	001	DEC 04, 2002	JAN	CTEC
BX	JOHNSON AND JOHNSON		2%	N50788	001	DEC 04, 2002	APR	CAHN
<u>MYCOPHENOLATE MOFETIL</u>								
<u>CAPSULE; ORAL</u>								
<u>CELLCEPT</u>								
+	ROCHE PALO		250MG	N50722	001	MAY 03, 1995	FEB	CAHN
<u>SUSPENSION; ORAL</u>								
+	ROCHE PALO		200MG/ML	N50759	001	OCT 01, 1998	FEB	CAHN
<u>TABLET; ORAL</u>								
+	ROCHE PALO		500MG	N50723	001	JUN 19, 1997	FEB	CAHN
<u>MYCOPHENOLATE MOFETIL HYDROCHLORIDE</u>								
<u>INJECTABLE; INJECTION</u>								
+	ROCHE PALO		500MG/VIAL	N50758	001	AUG 12, 1998	FEB	CAHN
<u>NABUMETONE</u>								
<u>TABLET; ORAL</u>								
<u>NABUMETONE</u>								
AB	IVAX PHARMS		500MG	N76009	001	JAN 24, 2003	JAN	NEWA
AB			750MG	N76009	002	JAN 24, 2003	JAN	NEWA
<u>NAFTIFINE HYDROCHLORIDE</u>								
<u>CREAM; TOPICAL</u>								
<u>NAFTIN</u>								
@	ALLERGAN HERBERT		1%	N19599	001	FEB 29, 1988	JUN	DISC
<u>GEL; TOPICAL</u>								
@	ALLERGAN HERBERT		1%	N19356	001	JUN 18, 1990	JUN	DISC
<u>NALBUPHINE HYDROCHLORIDE</u>								
<u>INJECTABLE; INJECTION</u>								
<u>NALBUPHINE HCL</u>								
@	KING PHARMS		10MG/ML	N74471	001	MAR 19, 1998	MAY	DISC
@			20MG/ML	N74471	002	MAR 19, 1998	MAY	DISC

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

@ ELKINS SINK	0.4MG/ML	N70299 001	SEP 24, 1986	JUN	DISC
@ ELKINS SINK PHARM	0.4MG/ML	N70298 001	SEP 24, 1986	JUN	DISC
NALOXONE HCL					
@ ELKINS SINK	0.02MG/ML	N71272 001	MAY 24, 1988	JUN	DISC
@	1MG/ML	N71273 001	MAY 24, 1988	JUN	DISC
@	1MG/ML	N71274 001	MAY 24, 1988	JUN	DISC
@	1MG/ML	N71287 001	MAY 24, 1988	JUN	DISC

NANDROLONE DECANOATE

INJECTABLE; INJECTION

DECA-DURABOLIN

@ ORGANON USA INC	50MG/ML	N13132 001	JUN 12, 1986	MAY	DISC
@	100MG/ML	N13132 002	JUN 12, 1986	MAY	DISC
@	200MG/ML	N13132 003	JUN 12, 1986	MAY	DISC

NANDROLONE DECANOATE

+ STERIS	50MG/ML	N86385 001	JAN 13, 1984	MAY	CRLD
+ STERIS	100MG/ML	N86598 001	JAN 13, 1984	MAY	CRLD
+	200MG/ML	N88128 001	DEC 05, 1983	MAY	CRLD

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

AB + ELAN PHARM	EQ 375MG BASE	N20353 001	JAN 05, 1996	APR	CFTG
AB +	EQ 500MG BASE	N20353 002	JAN 05, 1996	MAR	CFTG
AB + ELAN PHARMA	EQ 375MG BASE	N20353 001	JAN 05, 1996	JUN	CAHN
AB +	EQ 500MG BASE	N20353 002	JAN 05, 1996	JUN	CAHN
@	EQ 750MG BASE	N20353 003	JAN 05, 1996	JUN	CAHN
NAPROXEN SODIUM					
AB ANDRX PHARMS	EQ 375MG BASE	N75416 002	APR 23, 2003	APR	NEWA
AB	EQ 500MG BASE	N75416 001	AUG 27, 2002	MAR	NEWA

NELFINAVIR MESYLATE

TABLET; ORAL

VIRACEPT

+ AGOURON	EQ 625MG BASE	N21503 001	APR 30, 2003	APR	NEWA
-----------	---------------	------------	--------------	-----	------

NIFEDIPINE

CAPSULE; ORAL

ADALAT

@ BAYER PHARMS	10MG	N19478 001	NOV 27, 1985	JUN	DISC
@	20MG	N19478 002	SEP 17, 1986	JUN	DISC

TABLET, EXTENDED RELEASE; ORAL

PROCARDIA XL

>D> AB2 + PFIZER	30MG	N19684 001	SEP 06, 1989	JUL	CRLD
>A> AB2	30MG	N19684 001	SEP 06, 1989	JUL	CRLD
>D> AB2 +	60MG	N19684 002	SEP 06, 1989	JUL	CRLD
>A> AB2	60MG	N19684 002	SEP 06, 1989	JUL	CRLD

NITROFURANTOIN

TABLET; ORAL

FURADANTIN

@ PROCTER AND GAMBLE	50MG	N08693 001	APR	DISC
@	100MG	N08693 002	APR	DISC
NITROFURANTOIN				
@ WATSON LAB	50MG	N80447 001	APR	DISC
@ WHITEWORTH TOWN PLSN	100MG	N84085 002	APR	DISC

NITROFURAZONE

OINTMENT; TOPICAL

FURACIN

@ SHIRE PHARM	0.2%	N05795 001	MAR	DISC
---------------	------	------------	-----	------

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL*

NITROGLYCERIN

AB2	MYLAN TECHNOLOGIES	0.1MG/HR	N75033 001	FEB 06, 1998	APR	CAHN
AB2		0.2MG/HR	N74609 001	AUG 30, 1996	APR	CAHN
AB2		0.4MG/HR	N74607 001	AUG 30, 1996	APR	CAHN
AB2		0.6MG/HR	N74559 001	AUG 30, 1996	APR	CAHN

INJECTABLE; INJECTION

TRIDIL

@ FAULDING	0.5MG/ML	N18537 002	JUN 16, 1983	MAY	DISC
@	5MG/ML	N18537 001		MAY	DISC

OINTMENT; TRANSDERMAL

NITROGLYCERIN

+ FOUGERA	2%	N87355 001	JUL 08, 1988	APR	CAHN
-----------	----	------------	--------------	-----	------

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

AB	TORPHARM	150MG	N76383 001	JAN 23, 2003	JAN	NEWA
AB		300MG	N76383 002	JAN 23, 2003	JAN	NEWA

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

LEVOPHED

AP + ABBOTT	EQ 1MG BASE/ML	N07513 001		MAR	CFTG
AP GENSIA SICOR PHARMS	EQ 1MG BASE/ML	N40455 001	MAR 03, 2003	MAR	NEWA

NORETHINDRONE ACETATE

TABLET; ORAL

AYGESTIN

AB + DURAMED PHARM BARR	5MG	N18405 001	APR 21, 1982	JUN	CAHN
AB + WYETH PHARMS INC	5MG	N18405 001	APR 21, 1982	MAR	CAHN

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

CHIBROXIN

@ MERCK	0.3%	N19757 001	JUN 17, 1991	MAY	DISC
---------	------	------------	--------------	-----	------

* SEE SECTION 1.3 NITROGLYCERIN, FILM, EXTENDED RELEASE; TRANSDERMAL

NORGESTREL

TABLET; ORAL
OVRETTE
+ WYETH PHARMS INC 0.075MG

N17031 001

MAR CAHN

NYSTATIN

POWDER; ORAL
>D> NILSTAT
>D> AA + CLONMEL HLTHCARE 100% N50576 001 DEC 22, 1983 JUL DISC
>A> @ 100% N50576 001 DEC 22, 1983 JUL DISC
NYSTATIN
>D> AA PADDOCK 100% N62613 001 NOV 26, 1985 JUL CRLD
>A> + 100% N62613 001 NOV 26, 1985 JUL CRLD

OLANZAPINE

TABLET; ORAL
ZYPREXA
+ LILLY 5MG N20592 002 SEP 30, 1996 MAY CRLD
20MG N20592 006 SEP 09, 1997 MAY CRLD

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
OMEPRAZOLE
AB LEK SVCS 10MG N75757 001 JAN 28, 2003 JAN NEWA
AB 20MG N75757 002 JAN 28, 2003 JAN NEWA
AB MYLAN 10MG N75876 001 MAY 29, 2003 MAY NEWA
AB 20MG N75876 002 MAY 29, 2003 MAY NEWA

ORPHENADRINE CITRATE

INJECTABLE; INJECTION
ORPHENADRINE CITRATE
AP BEDFORD LABS 30MG/ML N40463 001 MAR 04, 2003 MAR NEWA

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL
OXYTROL
+ WATSON LABS (UTAH) 3.9MG/24HR

N21351 002 FEB 26, 2003 FEB NEWA

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE; ORAL
DITROPAN XL
ALZA 5MG N20897 001 DEC 16, 1998 MAY CRLD
10MG N20897 002 DEC 16, 1998 MAY CRLD

OXYTOCIN

INJECTABLE; INJECTION
OXYTOCIN
@ BAXTER HLTHCARE CORP 10USP UNITS/ML

N18243 001 MAY CAHN

>A> PALONOSERTRON HYDROCHLORIDE

>A> INJECTABLE; INTRAVENOUS

>A> ALOXI

>A> + HELSINN HLTHCARE EQ 0.25MG BASE/5ML(EQ 0.05MG BASE/ML) N21372 001 JUL 25, 2003 JUL NEWA

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

AP + GENSIA SICOR PHARMS	1MG/ML	N72759 001	JUL 31, 1990	MAY	CRLD
AP +	2MG/ML	N72760 001	JUL 31, 1990	MAY	CRLD
PAVULON					
@ ORGANON	1MG/ML	N17015 002		MAY	DISC
@	2MG/ML	N17015 001		MAY	DISC

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)

PROTONIX IV

+ WYETH PHARMS INC EQ 40MG BASE/VIAL

TABLET, DELAYED RELEASE; ORAL

PROTONIX

+ WYETH PHARMS INC	EQ 20MG BASE	N20987 002	JUN 12, 2001	MAR	CAHN
	EQ 20MG BASE	N20987 002	JUN 12, 2001	APR	CRLD
+	EQ 40MG BASE	N20987 001	FEB 02, 2000	MAR	CAHN

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

AA + KING PHARMS	EQ 250MG BASE	N62310 001		MAY	CAHN
------------------	---------------	------------	--	-----	------

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HCL

>A> AB TORPHARM	EQ 10MG BASE	N75356 001	JUL 30, 2003	JUL	NEWA
>A> AB	EQ 20MG BASE	N75356 002	JUL 30, 2003	JUL	NEWA
>A> AB	EQ 30MG BASE	N75356 003	JUL 30, 2003	JUL	NEWA
>A> AB	EQ 40MG BASE	N75356 004	JUL 30, 2003	JUL	NEWA

PAXIL

>D> GLAXOSMITHKLINE	EQ 10MG BASE	N20031 001	DEC 29, 1992	JUL	CFTG
>A> AB	EQ 10MG BASE	N20031 001	DEC 29, 1992	JUL	CFTG
>D>	EQ 20MG BASE	N20031 002	DEC 29, 1992	JUL	CFTG
>A> AB	EQ 20MG BASE	N20031 002	DEC 29, 1992	JUL	CFTG
>D>	EQ 30MG BASE	N20031 003	DEC 29, 1992	JUL	CFTG
>A> AB	EQ 30MG BASE	N20031 003	DEC 29, 1992	JUL	CFTG
>D> +	EQ 40MG BASE	N20031 005	DEC 29, 1992	JUL	CFTG
>A> AB +	EQ 40MG BASE	N20031 005	DEC 29, 1992	JUL	CFTG

PAROXETINE MESYLATE

TABLET; ORAL

PAROXETINE MESYLATE

>A> SYNTHON PHARMS	EQ 10MG BASE	N21299 001	JUL 03, 2003	JUL	NEWA
>A>	EQ 20MG BASE	N21299 002	JUL 03, 2003	JUL	NEWA
>A>	EQ 30MG BASE	N21299 003	JUL 03, 2003	JUL	NEWA

>A>	+	EQ 40MG BASE	N21299 004	JUL 03, 2003	JUL	NEWA
<u>PEGVISOMANT</u>						
INJECTABLE; SUBCUTANEOUS						
SOMAVERT						
+ PHARMACIA AND UPJOHN		10MG/VIAL	N21106 001	MAR 25, 2003	MAR	NEWA
+ PHARMACIA AND UPJOHN		15MG/VIAL	N21106 002	MAR 25, 2003	MAR	NEWA
+ PHARMACIA AND UPJOHN		20MG/VIAL	N21106 003	MAR 25, 2003	MAR	NEWA
<u>PENICILLIN G POTASSIUM</u>						
INJECTABLE; INJECTION						
PENICILLIN G POTASSIUM						
>D> AP MARSAM PHARMS LLC		1,000,000 UNITS/VIAL	N62991 001	SEP 13, 1988	JUL	DISC
>A> @		1,000,000 UNITS/VIAL	N62991 001	SEP 13, 1988	JUL	DISC
>D> AP		5,000,000 UNITS/VIAL	N62991 002	SEP 13, 1988	JUL	DISC
>A> @		5,000,000 UNITS/VIAL	N62991 002	SEP 13, 1988	JUL	DISC
>D> AP		10,000,000 UNITS/VIAL	N62991 003	SEP 13, 1988	JUL	DISC
>A> @		10,000,000 UNITS/VIAL	N62991 003	SEP 13, 1988	JUL	DISC
>D> AP		20,000,000 UNITS/VIAL	N62991 004	SEP 13, 1988	JUL	DISC
>A> @		20,000,000 UNITS/VIAL	N62991 004	SEP 13, 1988	JUL	DISC
TABLET; ORAL						
@ WYETH AYERST		200,000 UNITS	N60413 001		JUN	DISC
@ WYETH AYERST		250,000 UNITS	N60413 002		JUN	DISC
@ WYETH AYERST		400,000 UNITS	N60413 003		JUN	DISC
<u>PENICILLIN V POTASSIUM</u>						
FOR SOLUTION; ORAL						
LEDERCILLIN VK						
@ LEDERLE		EQ 125MG BASE/5ML	N60136 001		JUN	DISC
@ LEDERLE		EQ 250MG BASE/5ML	N60136 002		JUN	DISC
TABLET; ORAL						
@ LEDERLE		EQ 250MG BASE	N60134 001		JUN	DISC
@ LEDERLE		EQ 500MG BASE	N60134 002		JUN	DISC
PEN-VEE K						
@ WYETH AYERST		EQ 250MG BASE	N60006 002		JUN	DISC
@ WYETH AYERST		EQ 500MG BASE	N60006 003		JUN	DISC
<u>PENTAMIDINE ISETHIONATE</u>						
INJECTABLE; INJECTION						
PENTAMIDINE ISETHIONATE						
@ ELKINS SINK		300MG/VIAL	N73617 001	DEC 18, 1995	JUN	DISC
<u>PENTOBARBITAL SODIUM</u>						
INJECTABLE; INJECTION						
NEMBUTAL SODIUM						
+ ABBOTT		50MG/ML	N83246 001		JUN	CTEC
SODIUM PENTOBARBITAL						
@ WYETH AYERST		50MG/ML	N83261 001		JUN	DISC
<u>PERMETHRIN</u>						
CREAM; TOPICAL						
PERMETHRIN						
AB CLAY PARK		5%	N76369 001	APR 21, 2003	APR	NEWA

PERPHENAZINE

TABLET; ORAL					
PERPHENAZINE					
AB + IVAX PHARMS	16MG		N89457 001	SEP 10, 1987	FEB CRLD
TRILAFON					
@ SCHERING	2MG		N10775 001		FEB DISC
@	4MG		N10775 002		FEB DISC
@	8MG		N10775 003		FEB DISC
@	16MG		N10775 004		FEB DISC

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL					
PHENTERMINE HCL					
AA ABLE	15MG		N40497 001	MAR 13, 2003	MAR NEWA
AA AMBI PHARMS	30MG		N40083 001	MAR 07, 1997	MAY CAHN
AA AMIDE PHARM	15MG		N40460 001	JAN 14, 2003	JAN NEWA
AA	30MG		N40448 001	JAN 22, 2003	JAN NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL					
PHENERGAN VC					
@ WYETH AYERST	5MG/5ML;6.25MG/5ML		N08604 003	APR 02, 1984	APR DISC
PROMETH VC PLAIN					
AA + ALPHARMA	5MG/5ML;6.25MG/5ML		N88761 001	NOV 08, 1984	APR CRLD

PHENYTOIN

SUSPENSION; ORAL					
PHENYTOIN					
AB VISTAPHARM	125MG/5ML		N40342 001	JAN 31, 2001	MAR CAHN

PHENYTOIN SODIUM

INJECTABLE; INJECTION					
DILANTIN					
@ PARKE DAVIS	50MG/ML		N10151 001		MAR DISC
PHENYTOIN					
+ ELKINS SINK	50MG/ML		N84307 001		MAR CRLD
PHENYTOIN SODIUM					
@ ABBOTT	50MG/ML		N89521 001	MAR 17, 1987	MAR DISC
@	50MG/ML		N89744 001	DEC 18, 1987	MAR DISC

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL					
DILANTIN					
PARKE DAVIS	30MG		N84349 001		FEB CRLD
+	30MG		N84349 001		JUN CRLD
EXTENDED PHENYTOIN SODIUM					
AB BARR	100MG		N40435 001	JUN 20, 2003	JUN NEWA

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL					
SALAGEN					
MGI PHARMA INC	5MG		N20237 001	MAR 22, 1994	APR CRLD

+ 7.5MG

N20237 002 APR 18, 2003 APR NEWA

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPRACIL

+ WYETH PHARMS INC	EQ 2GM BASE/VIAL	N50545 002	MAR	CAHN	
@	EQ 2GM BASE/VIAL	N50545 002	JUN	DISC	
@	EQ 2GM BASE/VIAL	N62750 001	OCT 13, 1987	MAR	CAHN
@	EQ 2GM BASE/VIAL	N62750 001	OCT 13, 1987	JUN	DISC
+	EQ 3GM BASE/VIAL	N50545 003	MAR	CAHN	
@	EQ 3GM BASE/VIAL	N50545 003	JUN	DISC	
@	EQ 3GM BASE/VIAL	N62750 002	OCT 13, 1987	MAR	CAHN
+	EQ 3GM BASE/VIAL	N62750 002	OCT 13, 1987	JUN	DISC
@	EQ 4GM BASE/VIAL	N50545 004	MAR	CAHN	
@	EQ 4GM BASE/VIAL	N50545 004	JUN	DISC	
@	EQ 4GM BASE/VIAL	N62750 003	OCT 13, 1987	MAR	CAHN
@	EQ 4GM BASE/VIAL	N62750 003	OCT 13, 1987	JUN	DISC
@	EQ 40GM BASE/VIAL	N50545 006	SEP 30, 1985	MAR	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

ZOSYN

+ WYETH PHARMS INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N50684 001	OCT 22, 1993	MAR	CAHN
+	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N50684 002	OCT 22, 1993	MAR	CAHN
+	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N50684 003	OCT 22, 1993	MAR	CAHN
+	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	N50684 004	OCT 22, 1993	MAR	CAHN
ZOSYN IN PLASTIC CONTAINER					
+ WYETH PHARMS INC	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N50750 001	FEB 24, 1998	MAR	CAHN
+	EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N50750 002	FEB 24, 1998	MAR	CAHN
+	EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N50750 003	FEB 24, 1998	MAR	CAHN

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

@ 3M

EQ 0.2MG BASE/INH

N19009 001 DEC 30, 1986 MAY DISC

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON M15

UPSHER SMITH

15MEQ

N74726 003 JUN 06, 2003 JUN NEWA

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

@ BAXTER HLTHCARE CORP 300MG/ML
PROTOPAM CHLORIDE>A> + BAXTER HLTHCARE CORP 1GM/VIAL
>D> + WYETH AYERST 1GM/VIAL

N18799 001 DEC 13, 1982 MAR CAHN

N14134 001 JUL CAHN
N14134 001 JUL CAHN

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HCL

>D>	AB	CLONMEL HLTHCARE	EQ 2MG BASE	N72706 001	MAY 16, 1989	JUL	DISC
>A>	@		EQ 2MG BASE	N72706 001	MAY 16, 1989	JUL	DISC

PREDNICKARBATE

CREAM; TOPICAL

DERMATOP E EMOLlient

+ DERMIC LABS

0.1%

N20279 001 OCT 29, 1993 APR CTNA

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

AA	AXIOM PHARM	15MG/5ML	N40287 001	MAY 28, 1999	MAY	CAHN		
AA	HI TECH PHARMA	15MG/5ML	N40401 001	FEB 27, 2003	FEB	NEWA		
>D>	AA	KV PHARM	5MG/5ML	N40423 001	OCT 22, 2001	JUL	CRLD	
>A>	+		5MG/5ML	N40423 001	OCT 22, 2001	JUL	CRLD	
>D>	AA		15MG/5ML	N40364 001	APR 10, 2002	JUL	CRLD	
>A>	AA	+	15MG/5ML	N40364 001	APR 10, 2002	JUL	CRLD	
	AA	PHARM ASSOC	15MG/5ML	N40399 001	MAR 05, 2003	MAR	NEWA	
		PRENONE						
>D>	AA	+	MURO	5MG/5ML	N89654 001	JAN 17, 1989	JUL	DISC
>A>		@		5MG/5ML	N89654 001	JAN 17, 1989	JUL	DISC
>D>	AA	+	TEVA	15MG/5ML	N89081 001	FEB 04, 1986	JUL	CRLD
>A>	AA			15MG/5ML	N89081 001	FEB 04, 1986	JUL	CRLD
	AA	+		15MG/5ML	N89081 001	FEB 04, 1986	MAY	CAHN

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

ECONOPRED

@ ALCON

0.125%

N17468 001 JUN DISC

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

CETAPRED

@ ALCON

0.25%;10%

N87771 001 AUG 06, 1993 JUN DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA

HI TECH PHARMA

EQ 5MG BASE/5ML

N75183 001 MAR 26, 2003 MAR NEWA

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT

ALCON

EQ 0.23% PHOSPHATE;10%

N73630 001 MAY 27, 1993 APR CAHN

PREDNISONE

TABLET; ORAL

PREDNISONE

AB

VINTAGE PHARMS

20MG

N40392 001 FEB 12, 2003 FEB NEWA

PRIMIDONE

TABLET; ORAL					
MYSOLINE					
>D>	AB	XCEL PHARMS	50MG	N09170 003	JUL CRLD
>A>	AB	+	50MG	N09170 003	JUL CRLD
>D>	AB	+	250MG	N09170 002	JUL CRLD
>A>	AB		250MG	N09170 002	JUL CRLD

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION				
PROCAINAMIDE HCL				
@ ELKINS SINK		100MG/ML	N89029 001	APR 17, 1986 JUN DISC
@		500MG/ML	N89030 001	APR 17, 1986 JUN DISC

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION				
PROCHLORPERAZINE EDISYLATE				
AP	GENSIA SICOR PHARMS	EQ 5MG BASE/ML	N40505 001	MAY 30, 2003 MAY NEWA

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION				
PHENERGAN				
@ WYETH AYERST		25MG/ML	N08857 002	JUN DISC
@		50MG/ML	N08857 003	APR DISC
PROMETHAZINE HCL				
AP	BAXTER HLTHCARE	25MG/ML	N83312 001	JUN CAHN
AP		50MG/ML	N83312 002	JUN CAHN
AP +	GENSIA SICOR PHARMS	25MG/ML	N40454 001	AUG 22, 2002 APR CRLD
AP +		50MG/ML	N40454 002	AUG 22, 2002 APR CRLD
AP	PHARMAFORCE	25MG/ML	N40515 001	MAR 19, 2003 MAR NEWA
SUPPOSITORY; RECTAL				
PHENERGAN				
AB +	WYETH AYERST	50MG	N11689 001	FEB CTEC
AB	WYETH PHARMS INC	12.5MG	N10926 002	MAR CAHN
AB +		25MG	N10926 001	MAR CAHN
AB +		50MG	N11689 001	MAR CAHN
PROMETHAZINE HCL				
AB	ABLE	12.5MG	N40504 001	APR 11, 2003 APR NEWA
AB		25MG	N40504 002	APR 11, 2003 APR NEWA
AB		50MG	N40449 001	FEB 27, 2003 FEB NEWA
AB	CLAY PARK	12.5MG	N40500 001	JUN 30, 2003 JUN NEWA
AB		25MG	N40500 002	JUN 30, 2003 JUN NEWA
AB	G AND W LABS	12.5MG	N40428 002	MAR 31, 2003 MAR NEWA
AB	PADDICK	12.5MG	N40479 001	JUN 24, 2003 JUN NEWA
AB		25MG	N40479 002	JUN 24, 2003 JUN NEWA
SYRUP; ORAL				
PHENERGAN PLAIN				
@ WYETH AYERST		6.25MG/5ML	N08381 004	APR 18, 1984 JUN DISC
PROMETH PLAIN				
AA +	ALPHARMA	6.25MG/5ML	N85953 001	JUN CRLD

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL

PHENERGAN

WYETH PHARMS INC	12.5MG	N07935 002	MAR	CAHN
BP	25MG	N07935 003	MAR	CAHN
BP +	50MG	N07935 004	MAR	CAHN

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

LARGON

@ BAXTER HLTHCARE CORP	20MG/ML	N12382 002	MAY	CAHN
------------------------	---------	------------	-----	------

>D> PROPOXYPHENE NAPSYLATE

>D> SUSPENSION; ORAL

>D> DARVON-N

>A> @ AAIPHARMA LLC	50MG/5ML	N16861 001	JUL	DISC
>D> + NEOSAN PHARMS	50MG/5ML	N16861 001	JUL	DISC

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERAL LA

WYETH PHARMS INC	60MG	N18553 004	MAR 18, 1987	MAR	CAHN
BX	80MG	N18553 002	APR 19, 1983	MAR	CTEC
BX	120MG	N18553 003	APR 19, 1983	MAR	CTEC
+ @	160MG	N18553 001	APR 19, 1983	MAR	CAHN

INNOPRAN XL

BX RELIANT PHARMS	80MG	N21438 001	MAR 12, 2003	MAR	NEWA
BX	120MG	N21438 002	MAR 12, 2003	MAR	NEWA

INJECTABLE; INJECTION

INDERAL

AP + BAXTER HLTHCARE CORP	1MG/ML	N16419 001		MAY	CAHN
---------------------------	--------	------------	--	-----	------

PROPRANOLOL HCL

AP SABEX 2002	1MG/ML	N76400 001	FEB 26, 2003	FEB	NEWA
---------------	--------	------------	--------------	-----	------

TABLET; ORAL

INDERAL

AB + WYETH PHARMS INC	10MG	N16418 001		MAR	CAHN
AB	20MG	N16418 003		MAR	CAHN
AB	40MG	N16418 002		MAR	CAHN
AB	60MG	N16418 009	OCT 18, 1982	MAR	CAHN
AB + @	80MG	N16418 004		MAR	CAHN
@	90MG	N16418 010	OCT 18, 1982	MAR	CAHN

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

@ ELKINS SINK	10MG/ML	N89474 001	NOV 05, 1986	JUN	DISC
@	10MG/ML	N89475 001	NOV 05, 1986	JUN	DISC

>D>	<u>PROTIRELIN</u>						
>D>	INJECTABLE; INJECTION						
>D>	THYREL TRH						
>D>	+ FERRING	0.5MG/ML		N18087 001	JUL	DISC	
>A>	@	0.5MG/ML		N18087 001	JUL	DISC	
<u>PYRIDOSTIGMINE BROMIDE</u>							
INJECTABLE; INJECTION							
REGONOL							
@ ORGANON		5MG/ML		N17398 001	MAY	DISC	
@ SABEX 2002		5MG/ML		N17398 001	JUN	CAHN	
TABLET; ORAL							
PYRIDOSTIGMINE BROMIDE							
AB	IMPAK LABS	60MG		N40502 001	APR 24, 2003	APR	NEWA
	@ US ARMY	30MG		N20414 001	FEB 05, 2003	FEB	NEWA
<u>QUETIAPINE FUMARATE</u>							
TABLET; ORAL							
SERQUEL							
+ ASTRAZENECA		EQ 25MG BASE		N20639 001	SEP 26, 1997	MAR	CRLD
<u>QUINAPRIL HYDROCHLORIDE</u>							
TABLET; ORAL							
ACCUPRIL							
AB	PFIZER PHARMS	EQ 5MG BASE		N19885 001	NOV 19, 1991	MAY	CFTG
AB		EQ 10MG BASE		N19885 002	NOV 19, 1991	MAY	CFTG
AB		EQ 20MG BASE		N19885 003	NOV 19, 1991	MAY	CFTG
AB	+ WATSON LABS	EQ 40MG BASE		N19885 004	NOV 19, 1991	MAY	CFTG
QUINAPRIL HCL							
AB	TEVA	EQ 5MG BASE		N75504 001	MAY 30, 2003	MAY	NEWA
AB		EQ 10MG BASE		N75504 002	MAY 30, 2003	MAY	NEWA
AB		EQ 20MG BASE		N75504 003	MAY 30, 2003	MAY	NEWA
AB		EQ 40MG BASE		N75504 004	NOV 20, 1998	MAY	NEWA
<u>QUINIDINE GLUCONATE</u>							
TABLET, EXTENDED RELEASE; ORAL							
QUINAGLUTE							
@ BERLEX LABS		324MG		N16647 001	MAR	DISC	
QUINIDINE GLUCONATE							
BX	+ MUTUAL PHARM	324MG		N89338 001	FEB 11, 1987	APR	CRLD
	+	324MG		N89338 001	FEB 11, 1987	MAY	CTEC
	+ WATSON LABS	324MG		N87810 001	SEP 29, 1982	MAR	CRLD
BX		324MG		N87810 001	SEP 29, 1982	APR	CRLD
	@	324MG		N87810 001	SEP 29, 1982	MAY	DISC
<u>QUINIDINE SULFATE</u>							
TABLET; ORAL							
QUINIDINE SULFATE							
>A>	AB	CLONMEL HLTHCARE	200MG	N87011 001	JUL	CAHN	
>D>	AB	LEDERLE	200MG	N87011 001	JUL	CAHN	

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
QUINIDEX

AB + WYETH PHARMS INC	300MG	N12796 002	MAR CAHN
@	300MG	N12796 002	JUN DISC
QUINIDINE SULFATE			
+ COBLEY PHARM	300MG	N40045 001	JUN 30, 1994 JUN CTEC

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL
METATENSIN #2

@ AVENTIS PHARMS	0.1MG;2MG	N12972 001	MAY DISC
METATENSIN #4			
@ AVENTIS PHARMS	0.1MG;4MG	N12972 002	MAY DISC

RIBAVIRIN

>A>	SOLUTION; ORAL			
>A>	REBETOL			
>A>	+ SCHERING	40MG/ML	N21546 001	JUL 29, 2003 JUL NEWA

RILUZOLE

TABLET; ORAL
RILUTEK

AB + AVENTIS	50MG	N20599 001	DEC 12, 1995 JAN CFTG
RILUZOLE			
AB IMPAX LABS	50MG	N76173 001	JAN 29, 2003 JAN NEWA

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL
RIMANTADINE HCL

AB AMIDE PHARM	100MG	N76375 001	JAN 14, 2003 JAN NEWA
----------------	-------	------------	-----------------------

RISPERIDONE

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERDAL

JOHNSON AND JOHNSON	0.5MG	N21444 001	APR 02, 2003 APR NEWA
+	1MG	N21444 002	APR 02, 2003 APR NEWA
	2MG	N21444 003	APR 02, 2003 APR NEWA

ROSIGLITAZONE MALEATE

TABLET; ORAL
AVANDIA

SB PHARMCO	EQ 2MG BASE	N21071 002	MAY 25, 1999 APR CAHN
	EQ 4MG BASE	N21071 003	MAY 25, 1999 APR CAHN
+	EQ 8MG BASE	N21071 004	MAY 25, 1999 APR CAHN

SACROSIDASE

SOLUTION; ORAL
SUCRAID

+ QOL MEDCL	8,500 IU/ML	N20772 001	APR 09, 1998 MAY CAHN
-------------	-------------	------------	-----------------------

SECOBARBITAL SODIUM

INJECTABLE; INJECTION
SODIUM SECOCARBITAL
@ WYETH AYERST 50MG/ML

N83262 001

JUN DISC

SERMORELIN ACETATE

INJECTABLE; INJECTION
GEREF
@ SERONO EQ 0.5MG BASE/VIAL
@ EQ 1MG BASE/VIAL

N20443 001 SEP 26, 1997 JUN DISC
N20443 002 SEP 26, 1997 JUN DISC

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL
RENAGEL
+ GENZYME 403MG
TABLET; ORAL
GENZYME 400MG
+ 800MG

N20926 001 OCT 30, 1998 APR CAHN
N21179 001 JUL 12, 2000 APR CAHN
N21179 002 JUL 12, 2000 APR CAHN

SIROLIMUS

SOLUTION; ORAL
RAPAMUNE
+ WYETH PHARMS INC 1MG/ML
TABLET; ORAL
WYETH PHARMS INC 1MG
+ 2MG

N21083 001 SEP 15, 1999 MAR CAHN
N21110 001 AUG 25, 2000 MAR CRLD
N21110 002 AUG 22, 2002 MAR NEWA

SODIUM IODIDE, I-131

CAPSULE; ORAL
SODIUM IODIDE I 131
+ DRAXIMAGE 1-250mCi
+ 1-500mCi
SOLUTION; ORAL
SODIUM IODIDE I 131, KIT
+ DRAXIMAGE 1-250mCi/0.25ML
+ 1-500mCi/0.5ML

N21305 002 JAN 24, 2003 JAN NEWA
N21305 003 JAN 24, 2003 JAN NEWA
N21305 002 JAN 24, 2003 FEB CDFR
N21305 003 JAN 24, 2003 FEB CDFR

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
NITROPRESS
AP + ABBOTT 50MG/VIAL
SODIUM NITROPRUSSIDE
@ ELKINS SINK 50MG/VIAL

N70566 001 JUN 09, 1986 JUN CRLD
N18581 001 JUL 28, 1982 JUN DISC

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION
BIO-TROPIN
@ BIO TECH GEN 4.8MG/VIAL
NORDITROPIN
>D> @ NOVO NORDISK 4MG/VIAL
>A> BX 4MG/VIAL
>D> @ 8MG/VIAL

N19774 001 MAY 25, 1995 MAR DISC
N19721 001 MAY 08, 1995 JUL CMFD
N19721 001 MAY 08, 1995 JUL CMFD
N19721 002 MAY 08, 1995 JUL CMFD

>A>		8MG/VIAL	N19721 002 MAY 08, 1995 JUL CMFD
	TEV-TROPIN		
BX +	BIO TECH GEN	5MG/ML	N19774 002 JAN 04, 2002 FEB CTNA
<u>SOTALOL HYDROCHLORIDE</u>			
	TABLET; ORAL		
	BETAPACE AF		
@	BERLEX LABS	40MG	N21151 006 APR 02, 2003 MAY DISC
		40MG	N21151 006 APR 02, 2003 APR NEWA
@		60MG	N21151 007 APR 02, 2003 MAY DISC
		60MG	N21151 007 APR 02, 2003 APR NEWA
@		100MG	N21151 005 MAR 14, 2003 MAY DISC
		100MG	N21151 005 MAR 14, 2003 MAR NEWA
<u>STANOZOLOL</u>			
	TABLET; ORAL		
	WINSTROL		
>A>	+ OVATION PHARMS	2MG	N12885 001 MAY 14, 1984 JUL CAHN
>D>	+ SANOFI SYNTHELABO	2MG	N12885 001 MAY 14, 1984 JUL CAHN
<u>STREPTOZOCIN</u>			
	INJECTABLE; INJECTION		
	ZANOSAR		
	+ GENSIA SICOR PHARMS	1GM/VIAL	N50577 001 MAY 07, 1982 JUN CAHN
<u>STRONTIUM CHLORIDE, SR-89</u>			
	INJECTABLE; INJECTION		
	METASTRON		
AP +	AMERSHAM HLTH	1mCi/ML	N20134 001 JUN 18, 1993 JAN CFTG
	STRONTIUM CHLORIDE SR-89		
AP	BIO NUCLEONICS	1mCi/ML	N75941 001 JAN 06, 2003 JAN NEWA
<u>SUCCIMER</u>			
	CAPSULE; ORAL		
	CHEMET		
>A>	+ OVATION PHARMS	100MG	N19998 002 JAN 30, 1991 JUL CAHN
>D>	+ SANOFI SYNTHELABO	100MG	N19998 002 JAN 30, 1991 JUL CAHN
<u>SULFAMETHOXAZOLE; TRIMETHOPRIM</u>			
	INJECTABLE; INJECTION		
	SEPTRA		
@	MONARCH PHARMS	80MG/ML;16MG/ML	N18452 001 MAY DISC
<u>SULINDAC</u>			
	TABLET; ORAL		
	SULINDAC		
@	CLONMEL HLTHCARE	150MG	N73261 001 SEP 06, 1991 JUN DISC
@		200MG	N73262 001 SEP 06, 1991 JUN DISC
<u>TAMOXIFEN CITRATE</u>			
	TABLET; ORAL		
	NOLVADEX		
AB	ASTRAZENECA	EQ 10MG BASE	N17970 001 FEB CTEC

AB +	TAMOXIFEN CITRATE	EQ 20MG BASE	N17970 002	MAR 21, 1994	FEB	CTEC
AB	AEGIS PHARMS	EQ 10MG BASE	N76398 001	MAR 31, 2003	MAR	NEWA
AB		EQ 20MG BASE	N76398 002	MAR 31, 2003	MAR	NEWA
AB	ANDRX PHARMS	EQ 10MG BASE	N76179 001	FEB 20, 2003	FEB	NEWA
AB		EQ 20MG BASE	N76179 002	FEB 20, 2003	FEB	NEWA
AB	BARR	EQ 10MG BASE	N70929 001	FEB 20, 2003	FEB	NEWA
AB		EQ 20MG BASE	N70929 002	FEB 20, 2003	FEB	NEWA
AB	IVAX PHARMS	EQ 10MG BASE	N75740 001	FEB 20, 2003	FEB	NEWA
AB		EQ 20MG BASE	N75740 002	FEB 20, 2003	FEB	NEWA
AB	MYLAN	EQ 10MG BASE	N74732 002	FEB 20, 2003	FEB	NEWA
AB		EQ 20MG BASE	N74732 001	FEB 20, 2003	FEB	NEWA
AB	PHARMACHEMIE	EQ 10MG BASE	N74539 001	MAR 31, 2003	APR	CAHN
AB		EQ 20MG BASE	N74858 001	FEB 20, 2003	FEB	NEWA
AB	ROXANE	EQ 10MG BASE	N76027 001	FEB 20, 2003	FEB	NEWA
AB		EQ 20MG BASE	N76027 002	FEB 20, 2003	FEB	NEWA
AB	TEVA	EQ 10MG BASE	N74504 001	APR 28, 2003	APR	NEWA
AB		EQ 10MG BASE	N74539 001	MAR 31, 2003	MAR	NEWA
AB		EQ 10MG BASE	N75797 001	FEB 20, 2003	FEB	NEWA
AB		EQ 20MG BASE	N74504 002	APR 28, 2003	APR	NEWA

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

TECHNECAN MDP KIT

AP +	DRAIMAGE	N/A	N18035 001	MAR	CRLD
------	----------	-----	------------	-----	------

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION

PYROLITE

@ CIS

N/A

N17684 001

MAY DISC

TELMISARTAN

TABLET; ORAL

MICARDIS

>D>	+ BOEHRINGER INGELHEIM	20MG	N20850 003	APR 04, 2000	JUL	CRLD
>A>		20MG	N20850 003	APR 04, 2000	JUL	CRLD

TESTOSTERONE

GEL; TOPICAL

ANDROGEL

BX +	UNIMED PHARMS	1%	N21015 001	FEB 28, 2000	APR	CTEC
------	---------------	----	------------	--------------	-----	------

TESTIM

BX +	AUXILIUM A2	1%	N21454 001	OCT 31, 2002	APR	CTEC
------	-------------	----	------------	--------------	-----	------

TABLET, EXTENDED RELEASE; BUCCAL

STRIANT

+ COLUMBIA LABS

30MG

N21543 001 JUN 19, 2003 JUN NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

ACHROMYCIN V

@ CLONMEL HLTHCARE

250MG

N50278 003

JUN DISC

@

500MG

N50278 001

JUN DISC

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL				
SUMYCIN				
AB + APOTHECON	500MG		N60429 003	JUN CRLD
TETRACYCLINE HCL				
AB AXIOM PHARM	250MG		N60736 001	MAY CAHN
AB	500MG		N60736 002	MAY CAHN
FIBER, EXTENDED RELEASE; PERIODONTAL				
ACTISITE				
@ ALZA	12.7MG/FIBER		N50653 001 MAR 25, 1994	JUN DISC

THALIDOMIDE

CAPSULE; ORAL				
THALOMID				
CELGENE	100MG		N20785 002 JAN 17, 2003	JAN NEWA
+	200MG		N20785 003 JAN 17, 2003	JAN NEWA

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION				
THIAMINE HCL				
@ WYETH AYERST	100MG/ML		N80553 001	JUN DISC

THIETHYLPERAZINE MALEATE

SUPPOSITORY; RECTAL				
TORECAN				
@ NOVARTIS	10MG		N13247 001	JUN DISC

THIOTEPA

INJECTABLE; INJECTION				
>D> THIOPLEX				
>D> AP + IMMUNEX	15MG/VIAL		N20058 001 DEC 22, 1994	JUL DISC
>A> @	15MG/VIAL		N20058 001 DEC 22, 1994	JUL DISC
THIOTEPA				
>D> AP GENESIA SICOR PHARMS	15MG/VIAL		N75730 001 APR 20, 2001	JUL CRLD
>A> AP +	15MG/VIAL		N75730 001 APR 20, 2001	JUL CRLD

THIOTHIXENE

CAPSULE; ORAL				
NAVANE				
AB PFIZER	1MG		N16584 001	FEB CAHN
AB	2MG		N16584 002	FEB CAHN
AB +	5MG		N16584 003	FEB CAHN
AB	10MG		N16584 004	FEB CAHN
	20MG		N16584 005	FEB CAHN

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL				
AA + PFIZER	EQ 5MG BASE/ML		N16758 001	FEB CAHN
INJECTABLE; INJECTION				
@ PFIZER	EQ 2MG BASE/ML		N16904 001	FEB CAHN
+	EQ 10MG BASE/VIAL		N16904 002	FEB CAHN

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HCL

AB	BARR	EQ 2MG BASE	N76371 001	APR 09, 2003	APR	NEWA
AB		EQ 4MG BASE	N76371 002	APR 09, 2003	APR	NEWA
AB	MYLAN	EQ 2MG BASE	N76354 001	MAR 28, 2003	MAR	NEWA
AB		EQ 4MG BASE	N76354 002	MAR 28, 2003	MAR	NEWA

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

>D>	AB	CLONMEL HLTHCARE	500MG	N86926 001	JUL	DISC
>A>		@	500MG	N86926 001	JUL	DISC

TOLBUTAMIDE SODIUM

INJECTABLE; INJECTION

ORINASE DIAGNOSTIC

@ PHARMACIA AND UPJOHN EQ 1GM BASE/VIAL

N12095 001 JUN DISC

TORSEMIDE

TABLET; ORAL

TORSEMIDE

AB	PAR PHARM	5MG	N76226 001	MAY 27, 2003	MAY	NEWA
AB		10MG	N76226 002	MAY 27, 2003	MAY	NEWA
AB		20MG	N76226 003	MAY 27, 2003	MAY	NEWA
AB		100MG	N76226 004	MAY 27, 2003	MAY	NEWA
AB	PLIVA PHARM IND	5MG	N76346 001	MAY 30, 2003	MAY	NEWA
AB		10MG	N76346 002	MAY 30, 2003	MAY	NEWA
AB		20MG	N76346 003	MAY 30, 2003	MAY	NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HCL

AB	IVAX PHARMS	50MG	N75963 001	JUL 03, 2002	MAR	CAHN
----	-------------	------	------------	--------------	-----	------

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; NASAL

NASACORT

>D>							
>D>	+	AVENTIS	0.055MG/INH	N19798 001	JUL 11, 1991	JUL	DISC
>A>	@		0.055MG/INH	N19798 001	JUL 11, 1991	JUL	DISC

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	ALTANA	0.025%	N40467 001	APR 21, 2003	APR	NEWA
AT		0.1%	N40467 002	APR 21, 2003	APR	NEWA

SPRAY, METERED; NASAL

TRI-NASAL

>A>	@ COLLEGIUM	0.05MG/SPRAY	N20120 001	FEB 04, 2000	JUL	CAHN
>D>	@ MURO	0.05MG/SPRAY	N20120 001	FEB 04, 2000	JUL	CAHN

TRICHLORMETHIAZIDE

TABLET; ORAL					
METAHYDRIN					
@ AVENTIS PHARMS	2MG		N12594 001	JUN 16, 1988	MAY DISC
@	4MG		N12594 002	JUN 16, 1988	MAY DISC

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL					
ARTANE					
@ LEDERLE	2MG/5ML		N06773 009	JUN	DISC
TRIHEXYPHENIDYL HCL					
AA + PHARM VENTURES	2MG/5ML		N89514 001	APR 07, 1989	JUN CRLD
TABLET; ORAL					
ARTANE					
@ LEDERLE	2MG		N06773 005	JUN	DISC
@	5MG		N06773 003	JUN	DISC
TRIHEXYPHENIDYL HCL					
AA + WATSON LABS	2MG		N84363 001	JUN	CRLD
AA +	5MG		N84364 001	JUN	CRLD

TRIMETHOPRIM

TABLET; ORAL					
PROLOPRIM					
@ MONARCH PHARMS	200MG		N17943 003	JUL 14, 1982	MAY DISC
TRIMETHOPRIM					
+ TEVA	200MG		N71259 001	JUN 18, 1987	MAY CRLD

UREA, C-13

FOR SOLUTION; ORAL					
HELICOSOL					
@ METABOLIC SOLUTIONS	125MG/VIAL		N21092 001	DEC 17, 1999	MAY DISC
PYLORI-CHEK BREATH TEST					
@ DEVICES	100MG/VIAL		N20900 001	FEB 04, 1999	MAR CAHN

VALPROATE SODIUM

INJECTABLE; INJECTION					
VALPROATE SODIUM					
AP AM PHARM	EQ 100MG BASE/ML		N76539 001	JUN 26, 2003	JUN NEWA

VALSARTAN

TABLET; ORAL					
DIOVAN					
>A> NOVARTIS	40MG		N21283 004	AUG 14, 2002	JUL NEWA

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL					
VANCOCIN HCL					
+ LILLY	EQ 250MG BASE/5ML		N61667 002	JUL 13, 1983	JUN CTEC
VANCOLED					
@ LEDERLE	EQ 250MG BASE/5ML		N63321 002	OCT 15, 1993	JUN DISC

VECURONIUM BROMIDE

INJECTABLE; INJECTION

NORCURON

@ ORGANON

10MG/VIAL

N18776 002 APR 30, 1984 MAY DISC

VECURONIUM BROMIDE

AP + BEDFORD

10MG/VIAL

N75549 001 JUN 13, 2000 MAY CRLD

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

WYETH PHARMS INC

EQ 37.5MG BASE

N20699 001 OCT 20, 1997 MAR CAHN

EQ 75MG BASE

N20699 002 OCT 20, 1997 MAR CRLD

@

EQ 100MG BASE

N20699 003 OCT 20, 1997 MAR CAHN

+

EQ 150MG BASE

N20699 004 OCT 20, 1997 MAR CRLD

TABLET; ORAL

EFFEXOR

@ WYETH PHARMS INC

EQ 12.5MG BASE

N20151 001 DEC 28, 1993 MAR CAHN

EQ 25MG BASE

N20151 002 DEC 28, 1993 MAR CRLD

EQ 37.5MG BASE

N20151 006 DEC 28, 1993 MAR CAHN

EQ 50MG BASE

N20151 003 DEC 28, 1993 MAR CAHN

EQ 75MG BASE

N20151 004 DEC 28, 1993 MAR CAHN

+

EQ 100MG BASE

N20151 005 DEC 28, 1993 MAR CAHN

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

VERAPAMIL HCL

>D> AB CLONMEL HLTHCARE

80MG

N71880 001 APR 05, 1988 JUL DISC

>A> @

80MG

N71880 001 APR 05, 1988 JUL DISC

>D> AB

120MG

N71881 001 APR 05, 1988 JUL DISC

>A> @

120MG

N71881 001 APR 05, 1988 JUL DISC

VIDARABINE

OINTMENT; OPHTHALMIC

VIRA-A

@ PARKEDALE

3%

N50486 001

MAY DISC

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCASAR PFS

>A> AP GENESIA SICOR PHARMS

1MG/ML

N71426 001 JUL 17, 1987 JUL CAHN

>D> AP PHARMACIA AND UPJOHN

1MG/ML

N71426 001 JUL 17, 1987 JUL CAHN

VINCRISTINE SULFATE PFS

>D> AP GENESIA SICOR PHARMS

1MG/ML

N75493 001 SEP 01, 1999 JUL CAHN

>A> AP SICOR PHARMS

1MG/ML

N75493 001 SEP 01, 1999 JUL CAHN

VINORELBINE TARTRATE

INJECTABLE; INJECTION

NAVELBINE

AP + GLAXOSMITHKLINE

EQ 10MG BASE/ML

N20388 001 DEC 23, 1994 FEB CFTG

VINORELBINE TARTRATE

AP ESI LEDERLE

EQ 10MG BASE/ML

N75992 001 JUN 10, 2003 JUN NEWA

AP GENSIA SICOR PHARMS

EQ 10MG BASE/ML

N76028 001 FEB 03, 2003 FEB NEWA

XENON, XE-133

GAS; INHALATION
XENON XE 133

>D>	GEN ELECTRIC	1-2.5 CI/AMP	N17550 003	JUL	CPOT
>A>		5-100 CI/CYLINDER	N17550 001	JUL	CPOT
>A>		.25-5 CI/AMP	N17550 003	JUL	CPOT
>D>		5 CI/CYLINDER	N17550 001	JUL	CPOT

ZALEPLON

CAPSULE; ORAL
SONATA

JONES PHARMA	5MG	N20859 001	AUG 13, 1999	JUN	CAHN
+	10MG	N20859 002	AUG 13, 1999	JUN	CAHN

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)
ZOMETA

+	NOVARTIS	EQ 4MG BASE/5ML	N21223 002	MAR 07, 2003	MAR NEWA
---	----------	-----------------	------------	--------------	----------



ACETAMINOPHEN

TABLET, EXTENDED RELEASE; ORAL					
TYLENOL (CAPLET)					
+ MCNEIL CONS SPECLT	650MG		N19872 001	JUN 08, 1994	JUN CTNA
TYLENOL (GELTAB)					
+ MCNEIL CONS SPECLT	650MG		N19872 002	JAN 11, 2001	JUN NEWA

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL					
FOAMICON					
NOVARTIS	80MG;20MG		N72687 001	JUN 28, 1989	MAR CAHN

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL					
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE					
@ CENT PHARMS	8MG;120MG		N19428 001	AUG 02, 1988	MAR DISC

CIMETIDINE

TABLET; ORAL					
CIMETIDINE					
@ LEK PHARMS	100MG		N75122 001	JUN 19, 1998	MAR CAHN
	200MG		N75122 002	JUN 19, 1998	MAR CAHN

EPINEPHRINE

AEROSOL, METERED; INHALATION					
BRONKAID MIST					
@ STERLING	0.25MG/INH		N16803 001		MAY DISC

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL					
MUCINEX					
ADAMS LABS	600MG		N21282 001	JUL 12, 2002	JAN CRLD
+	1.2GM		N21282 002	DEC 18, 2002	JAN NEWA

IBUPROFEN

TABLET; ORAL					
JUNIOR STRENGTH MOTRIN					
MCNEIL	100MG		N20602 001	JUN 10, 1996	JUN CRLD

LOPERAMIDE HYDROCHLORIDE

TABLET; ORAL					
LOPERAMIDE HCL					
LNK	2MG		N76497 001	JUN 10, 2003	JUN NEWA

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL					
IMODIUM ADVANCED					
+ MCNEIL CONS SPECLT	2MG;125MG		N21140 001	NOV 30, 2000	JAN CRLD

LORATADINE

SYRUP; ORAL					
CLARITIN					
+ SCHERING	1MG/ML	N20641 002	NOV 27, 2002	APR	CRLD
	1MG/ML	N20641 002	NOV 27, 2002	MAR	NEWA
TABLET; ORAL					
+ SCHERING	10MG	N19658 002	NOV 27, 2002	APR	CRLD
	10MG	N19658 002	NOV 27, 2002	MAR	NEWA
LORATADINE					
GENEVA PHARMS	10MG	N75209 001	JAN 21, 2003	JAN	NEWA
TABLET, ORALLY DISINTEGRATING; ORAL					
ALAVERT					
WYETH CONS	10MG	N21375 001	DEC 19, 2002	APR	CRLD
CLARITIN REDITABS					
+ SCHERING	10MG	N20704 002	NOV 27, 2002	APR	CRLD
	10MG	N20704 002	NOV 27, 2002	MAR	NEWA
LORATADINE					
WYETH CONS	10MG	N75822 001	FEB 10, 2003	FEB	NEWA

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL					
CLARITIN-D					
+ SCHERING	5MG;120MG	N19670 002	NOV 27, 2002	APR	CRLD
	5MG;120MG	N19670 002	NOV 27, 2002	MAR	NEWA
CLARITIN-D 24 HOUR					
+ SCHERING	10MG;240MG	N20470 002	NOV 27, 2002	APR	CRLD
	10MG;240MG	N20470 002	NOV 27, 2002	MAR	NEWA
LORATADINE AND PSEUDOEPHEDRINE HCL					
ANDRX PHARMS	10MG;240MG	N75706 001	FEB 21, 2003	FEB	NEWA
LORATADINE AND PSEUDOEPHEDRINE SULFATE					
IMPAK LABS	5MG;120MG	N76050 001	JAN 30, 2003	JAN	NEWA

MICONAZOLE NITRATE

CREAM; TOPICAL, VAGINAL					
MONISTAT 3 COMBINATION PACK					
+ PERSONAL PRODS	2%,4%	N21261 003	JUN 17, 2003	JUN	NEWA
MONISTAT 3 COMBINATION PACK (PREFILLED)					
+ PERSONAL PRODS	2%,4%	N21261 001	FEB 02, 2001	JUN	CTNA

MINOXIDIL

SOLUTION; TOPICAL					
MINOXIDIL EXTRA STRENGTH (FOR MEN)					
MORTON GROVE	5%	N75438 001	FEB 27, 2003	FEB	NEWA

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE; ORAL					
PRILOSEC					
+ ASTRAZENECA	EQ 20MG BASE	N21229 001	JUN 20, 2003	JUN	NEWA

PERMETHRIN

LOTION; TOPICAL

NIX

+ INSIGHT PHARMS

1%

N19918 001 MAY 02, 1990 MAR CAHN



**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 7 JULY '03

NO JULY 2003 APPROVALS



**This data is provided to the Office of Generic Drugs from
the Office of Orphan Products Development and it is not edited prior to publication.**

Orphan Products Designations and Approvals List

July 2003

Generic Name/ Trade Name (if present):	Date Designated = DD Date Approved= MA	Indication Designated:	Sponsor and Address
(+/-)-7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	DD: 3/31/2003 MA:	Prevention of serious adverse events associated with vascular leak syndrome caused by Interleukin-2 therapy	BioMedicines, Inc. 2000 Powell Street Suite 1640 Emeryville CA 94608
(R)-N-[2-(6-Chloro-methoxy-1H-indol-3yl)propyl]acetamide	DD: 7/3/2003 MA:	Treatment of neuroleptic-induced tardive dyskinesia in schizophrenia patients	Phase 2 Discovery, Inc. 3130 Highland Ave. Third Floor Cincinnati OH 45219
1,1'-[1,4-phenylenebis(methylene)-bis-1,4,8,11-tetraazacyclotetradecan	DD: 7/10/2003 MA:	For combination use with filgrastim to improve the yield of progenitor cells in the apheresis product for subsequent stem cell transplantation following myelosuppressive or myeloablative	AnorMED Inc. 200-20353 64th Avenue Langley, BC, V2Y 1N5 CANADA
2',3',5'-tri-o-acetyluridine	DD: 1/13/2003 MA:	Treatment of mitochondrial disease	Repligen Corporation 41 Seyon Street Building 1, Suite 100 Waltham MA 02453
4,5-dibromorhodamine 123 Theralux Irradiation Device	DD: 4/10/2003 MA:	Treatment of chronic myelogenous leukemia	Celmed BioSciences Inc. 2310 boul Alfred-Nobel 2310 boul Alfred-Nobel Saint-Laurent, Quebec Canada H4S 2A4
a-(3-aminophthalimido) Actimid	DD: 1/15/2003 MA: MA:	Treatment of multiple myeloma	Celgene Corporation 7 Powder Horn Drive Warren NJ 07059
a-Galactosidase A Corporation Plant-Produced Human a-Galactosidase	DD: 1/21/2003 MA:	Treatment of Fabry's disease	Large Scale Biology 3333 Vacaville Parkway Suite 1000 Vacaville CA 95688

Orphan Products Designations and Approvals List

July 2003

alendronate	DD: 3/31/2003	Treatment of osteogenesis imperfecta in pediatric patients 4 years of age and older	Merck & Co., Inc. 126 East Lincoln Ave. 126 East Lincoln Ave. Rahway NJ 07065-0900
Fosamax	MA:		
alteplase	DD: 1/27/2003	Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage	Daniel F. Hanley, MD Johns Hopkins
University Activase University	MA:		Johns Hopkins
Jefferson 1-109			600 N. Wolfe St., Baltimore MD 21287
AMG 531	DD: 3/27/2003	Treatment of immune thrombocytopenic purpura.	Amgen, Inc. One Amgen Center
Drive 91320-1799	MA:		Thousand Oaks CA
anti-CD23 IgG1, kappa monoclonal Inc. antibody	DD: 2/12/2003	Treatment of chronic lymphocytic leukemia	IDECC Pharmaceuticals, 3030 Callan Road San Diego CA 92121
MA:			
Anti-CEA Sheep-human chimeric monoclonal antibody labeled Court w/iodine-131 (KAb201)	DD: 5/21/2003	Treatment of pancreatic cancer	KS Biomedix Ltd Ground Floor, 1 Occam
7HJ UK	MA:		Surrey Research Park Guilford, Surrey, GU2
antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA] GTI-2040	DD: 3/12/2003	Treatment for renal cell carcinoma	Lorus Therapeutics, Inc 2 Meridan Road
MA:			
MA:			
arsenic trioxide Trisenox	DD: 6/13/2003	Treatment of liver cancer	Cell Therapeutics, Inc. 501 Elliott Avenue West Suite 400 Seattle WA 98119
MA:			

Orphan Products Designations and Approvals List
July 2003

arsenic trioxide Trisenox	DD: 5/13/2003 MA:	Treatment of chronic lymphocytic leukemia	Cell Therapeutics, Inc. 501 Elliott avenue West 501 Elliott avenue West Suite 400 Seattle WA 98119
bifidobacterium longum infantis Limited 35624	DD: 1/16/2003 MA:	Treatment of pediatric Crohn's disease	Alimentary Health Guardwell, Kinsale County Cork, Ireland
bortezomib Pharmaceuticals, Inc. VELCADE	DD: 1/15/2003 MA:	To treat multiple myeloma	Millennium 75 Sidney Street Cambridge MA 02139
Capsaicin Park 4117	DD: 5/2/2003 MA:	Treatment of painful HIV-associated neuropathy	NeurogesX, Inc. San Carlos Business 981F Industrial Road San Carols CA 94070-
cholic acid (3 alpha, 7 alpha, 12 alpha trihydroxy 5-beta cholanolic acid) Falkochol	DD: 7/18/2003 MA: MA:	Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism	Dr. Falk Pharma Leinenweberstrasse 5 Postfach 6529 9041 Freiburg
GERMANY			
cinacalcet Drive 91320-1799	DD: 5/12/2003 MA:	Treatment of hypercalcemia in patients with parathyroid carcinoma	Amgen, Inc. One Amgen Center Thousand Oaks CA
Combretastatin A4 Phosphate	DD: 7/23/2003 MA: MA:	Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer	OXiGENE, Inc 321 Arsenal Street Watertown MA 02472
conjugated bile acids COBARTin 4317	DD: 7/18/2003 MA:	Treatment of steatorrhea in patients with short bowel syndrome	Jarrow Formulas, Inc. 1824 S. Robertson Blvd. 1824 S. Robertson Blvd. Los Angeles CA 90035-

Orphan Products Designations and Approvals List
July 2003

Defibrotide (CO)	DD: 5/21/2003 MA:	For the treatment of hepatic veno-occlusive disease	Gentium SpA Piazza XX Settembre, 2 22079 Villa Guardia ITALY
dextran 1 3B5	DD: 3/21/2003 MA:	Treatment of cystic fibrosis	BCY LifeSciences Inc. 160 Eglinton Ave. East Suite 600 Toronto, Ontario M4P
DHA-paclitaxel Boulevard Taxoprexin Boulevard 19406	DD: 5/1/2003 MA:	Treatment of adenocarcinoma of the stomach or lower esophagus	Protarga, Inc. 2200 Renaissance 2200 Renaissance Suite 450 King of Prussia PA
diferuloylmethane LLC	DD: 6/13/2003 MA:	Treatment of cystic fibrosis	Seer Pharmaceuticals, P. O. Box 138 Southport CT 06890
diphenylcyclopenone	DD: 6/13/2003 MA: MA:	Treatment of chronic severe forms of alopecia areata (Alopecia Totalis [AT]/Alopecia Universalis [AU])	Lloyd E. King, Jr. 1900 Patterson Street Suite 104 Nashville TN 37203
Erlotinib Hydrochloride Tarceva 94080-4990	DD: 7/18/2003 MA:	Treatment of malignant gliomas	Genentech, Inc 1 DNA Way South San Francisco CA
Factor XIII [A2] homodimer, recombinant DNA origin East	DD: 5/21/2003 MA:	Treatment of congenital FXIII deficiency	ZymoGenetics, Inc. 1201 Eastlake Avenue Seattle WA 98102
ferric hexacyanoferrate (II) "Prussian Blue"	DD: 6/26/2003 MA:	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Degussa AG Weissfrauenstr.9 D-60287 Frankfurt GERMANY

Orphan Products Designations and Approvals List
July 2003

HepeX-B Biopharmaceuticals, Ltd.	DD: 7/15/2003 MA: MA:	For the prevention of hepatitis B virus (HBV) reinfection in patients who have received a liver transplantation	XTL Kiryat Weizmann Science Park Bldg 3 Rehovot 76100 ISRAEL
Human Anti-tumor Necrosis factor alpha monoclonal antibody Parkway	DD: 1/16/2003 MA:	Treatment of uveitis of the posterior segment of non-infectious etiology, and uveitis of the anterior segment of non-infectious etiology and refractory to conventional therapy	Centocor, Inc. 200 Great Valley Malvern PA 19355-
1307			
infliximab Remicade Parkway	DD: 5/21/2003 MA:	Treatment of chronic sarcoidosis	Centocor, Inc. 200 Great Valley Malvern PA 19355-
1307			
infliximab Remicade Parkway	DD: 5/6/2003 MA:	Treatment of giant cell arteritis	Centocor, Inc. 200 Great Valley Malvern PA 19355-
1307			
INGN 201 Inc. ADVEXIN	DD: 1/27/2003 MA: MA:	Treatment of head and neck cancer	Introgen Therapeutics, 2250 Holcombe Blvd Houston TX 77030
iron(III)-hexacyanoferrate(II) Pharmzeutische KG	DD: 5/1/2003 MA: MA:	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Heyl Chemisch-Fabrik GMBH & Co, Goerzallee 253 Goerzallee 253 D-14167 Berlin, Federal Germany
Radiogardase-Cs / Antidotum Republic of			
Mafosfamide (formerly Oncology)	DD: 1/21/2003 MA:	Treatment of neoplastic meningitis	Baxter Oncology GmbH ASTA Medica Daimlerstrasse 40 60314 Frankfurt/Main Germany

Orphan Products Designations and Approvals List

July 2003

MaxAdFVIII Corporation	DD: 3/3/2003 MA:	Treatment of Hemophilia A	GenStar Therapeutics 10865 Altman Row Suite 200 San Diego CA 92121-
1113 motexafin gadolinium	DD: 1/27/2003 MA: MA:	For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors	Pharmacyclics, Inc. 999 East Arques Avenue 999 East Arques Avenue Sunnyvale CA 94085-
Xcytrin			
4521			
myristoylated recombinant SCR1-3 of human complement reseptor Pk, type I	DD: 5/21/2003 MA: MA:	Prevention of delayed graft function in solid organ transplant	Adprotech, Ltd. Chesterford Research
APT070			
Saffron Walden,			Little Chesterford, Essex, CB10 1XK UK
polyinosinic-polycytidilic acid infections		including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses	DD: 3/3/2003 Treatment of flavivirus Ribopharm, Inc. 3203 Cleveland Ave.,
NW Poly-ICLC NW	MA:		3203 Cleveland Ave.,
3450	MA:		Washington DC 20008-
Protaxel cancer			Treatment of ovarian
Court	MA:		3333 North Torrey Pines Suite 100 La Jolla CA 92037
recombinant adeno-associated Technologies Corp. virus alpha 1-antitrypsin vector rAAV-AAT	DD: 1/27/2003 MA: MA:	Treatment of alphal-antitrypsin deficiency	Applied Genetic 12085 Research Drive Suite 110 Alachua FL 32615
recombinant inhibitor of human plasma kallikrein	DD: 2/4/2003 MA:	Treatment of angioedema	Dyax Corp 300 Technology Square Cambridge MA 02139

Orphan Products Designations and Approvals List

July 2003

Recombinant T-cell receptor Square Road	DD: 5/2/2003 MA: MA:	Treatment of multiple sclerosis patients who are both HLA-DR2 positive and glycoprotein residues 35-55 autoreactive to myelin oligodendrocyte	Virogenomics, Inc. 9020 SW Washington Suite 380 Tigard, OR 97223-4332
repertaxin	DD: 1/27/2003 MA:	Prevention of delayed graft function in solid organ transplant	Dompe s.p.a. Via Campo di Pile 67100 - L'Aquila Italy
repository corticotropin or Pharmaceuticals, Inc. adrenocorticotrophic hormone H.P. Acthar Gel 1217	DD: 5/21/2003 MA: MA:	Treatment of infantile spasms	Questcor 3260 Whipple Road Union City CA 94587-
resiniferatoxin	DD: 5/13/2003 MA: DASS/PPCS/NIDCR/NIH	Treatment of intractable pain at end-stage disease	Andrew J. Mannes, Md Bldg 10/Rm 2N236 - 10 Convent Drive Bethesda MD 20892
Ribavirin USP Road REBETOL Road	DD: 4/4/2003 MA:	Treatment of chronic hepatitis C in pediatric patients	Schering Corporation 2000 Galloping Hill 2000 Galloping Hill Kenilworth NJ 07033
SGN-30 (anti-CD30 mAb) Southeast	DD: 7/18/2003 MA:	Treatment of Hodgkin's disease	Seattle Genetics, Inc 21823 30th Drive, Bothell WA 98021
sipilizumab Inc. Road	DD: 7/15/2003 MA:	Treatment of T-cell lymphomas	MedImmune Oncology, 35 W. Watkins Mill Gaithersburg Md 20878
sodium dichloroacetate	DD: 7/3/2003 MA: MA:	Use as an antidote in the management of systemic monochloroacetic acid poisoning	EBD Group 6120 Paseo del Norte Suite J2 Carlsbad CA 92009

Orphan Products Designations and Approvals List July 2003

Sodium pyruvate	DD: 3/31/2003	Treatment of cystic fibrosis	Cellular Sciences, Inc. 84 Park Avenue P. O. Box 968 Flemington NJ 08822
	MA:		
suberoylanilide hydroxamic acid	DD: 6/12/2003	Treatment of multiple myeloma	Aton Pharma, Inc. 777 Old Saw Mill River
Road	MA:		Tarrytown NY 10591-
6717			
Tezacitabine			DD: 1/27/2003
adenocarcinoma of the		esophagus and stomach	Treatment of Chiron Corporation 4560 Horton Street Emeryville CA 94608-
	MA:		
2916			
Tretinoin	DD: 4/11/2003	Treatment of T-cell non-Hodgkin's lymphoma	Antigenics, Inc. 34 Commerce Way 34 Commerce Way Woburn MA 01801
ATRA-IV	MA:		

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JULY 2003 ADDITIONS



PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCLUS EXPIRES
020977 001	ABACAVIR SULFATE;ZIAGEN	5034394	DEC 18, 2011			
020978 001	ABACAVIR SULFATE;ZIAGEN	5034394 * PED	JUN 18, 2012			
020213 001	ACETYLCHOLINE CHLORIDE;MIPOCHOL-E ACYCLOVIR;ZOVIRAX	5034394	DEC 18, 2011			
021478 001	ALBUMIN HUMAN;OPTISON	5034394 * PED	JUN 18, 2012			
020560 001	ALENDRONATE SODIUM;FOSAMAX	6261546	APR 29, 2019			U-506
020899 001		4963555	OCT 16, 2007			
		5573751	APR 25, 2012			
		5529766	JUN 25, 2013			U-505
		5558094	FEB 28, 2012			U-505
		5358941	DEC 02, 2012			I-309
		4621077	AUG 06, 2007			SEP 29,
		5681590	DEC 02, 2012			MAR 29,
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015			
		6090410	DEC 02, 2012			
		6194004	DEC 02, 2012			
		4621077 * PED	FEB 06, 2008			
		5358941 * PED	JUN 02, 2013			
		5681590 * PED	JUN 02, 2013			
		5849726 * PED	DEC 06, 2015			
		6008207 * PED	DEC 06, 2015			
		6090410 * PED	JUN 02, 2013			
		6194004 * PED	JUN 02, 2013			
		5358941	DEC 02, 2012			
		4621077	AUG 06, 2007			
		5681590	DEC 06, 2015			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015			
		6090410	DEC 02, 2012			
		5358941 * PED	JUN 02, 2013			
		5681590 * PED	JUN 02, 2013			
		5849726 * PED	DEC 06, 2015			
		6008207 * PED	DEC 06, 2015			
		6090410	DEC 02, 2012			
		4621077 * PED	FEB 06, 2008			
		5358941 * PED	JUN 02, 2013			
		5681590	DEC 02, 2012			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015			
		6090410	DEC 02, 2012			
		4621077 * PED	FEB 06, 2008			
		5358941 * PED	JUN 02, 2013			
		5681590 * PED	JUN 02, 2013			
		5849726 * PED	DEC 06, 2015			
		6008207 * PED	DEC 06, 2015			
		6090410 * PED	JUN 02, 2013			

**PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity**

PREScription AND oTC DRUG PRODUCT
 PATENT AND EXCLUSIvITY DATA
 * PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCLUSIvE CODE	EXCLUSIvE EXPIRES
020364 002	AMLODIPINE BESTYLATE; LOTREL	4410520	AUG 11, 2003				
020364 003	AMLODIPINE BESTYLATE; LOTREL	4410520*PED	FEB 11, 2004				
020364 004	AMLODIPINE BESTYLATE; LOTREL	4410520	AUG 11, 2003				
020364 005	AMLODIPINE BESTYLATE; LOTREL	4410520	AUG 11, 2004				
>ADD>	0 21303 001	AMPHETAMINE ASPARTATE; ADDERALL XR 10	4410520*PED	FEB 11, 2004			
>ADD>	0 21303 006	AMPHETAMINE ASPARTATE; ADDERALL XR 15	4410520	AUG 11, 2004			
>ADD>	0 21303 002	AMPHETAMINE ASPARTATE; ADDERALL XR 20	4410520*PED	FEB 11, 2004			
>ADD>	0 21303 004	AMPHETAMINE ASPARTATE; ADDERALL XR 25	6605300	OCT 21, 2018			
>ADD>	0 21303 003	AMPHETAMINE ASPARTATE; ADDERALL XR 30	6605300	OCT 21, 2018			
>ADD>	0 21303 005	AMPHETAMINE ASPARTATE; ADDERALL XR 5	6605300	OCT 21, 2018			
040422 005	AMPHETAMINE ASPARTATE; DEXTROAMP SACCHARATE	6322819	OCT 21, 2018				
040422 006	AMPHETAMINE ASPARTATE; DEXTROAMP SACCHARATE	6322819	OCT 21, 2018				
040422 007	AMPHETAMINE ASPARTATE; DEXTROAMP SACCHARATE	6322819	OCT 21, 2018				
021549 001	APREPITANT; EMEND	6605300	OCT 21, 2018				
021549 002	APREPITANT; EMEND	6322819	OCT 21, 2018				
021436 001	ARIPIPRAZOLE; ABILIFY	5719147	JUN 29, 2012				
021436 002	ARIPIPRAZOLE; ABILIFY	5538982	JUL 23, 2013				
021436 003	ARIPIPRAZOLE; ABILIFY	60488859	JUN 29, 2012				
021436 004	ARIPIPRAZOLE; ABILIFY	6096742	JUL 01, 2018				
021436 005	ARIPIPRAZOLE; ABILIFY	6235735	JUN 29, 2012				
021436 006	ARIPIPRAZOLE; ABILIFY	5719147	JUN 29, 2012				
021436 009	ARIPIPRAZOLE; ABILIFY	5538982	JUL 23, 2013				
021436 011	ARIPIPRAZOLE; ABILIFY	60488859	JUN 29, 2012				
021436 012	ARIPIPRAZOLE; ABILIFY	6235735	JUN 29, 2012				
021436 013	ARIPIPRAZOLE; ABILIFY	4734416	MAR 29, 2005				
021436 014	ARIPIPRAZOLE; ABILIFY	5006528	OCT 20, 2009				
021436 015	ARIPIPRAZOLE; ABILIFY	4734416	MAR 29, 2005				
021436 016	ARIPIPRAZOLE; ABILIFY	5006528	OCT 20, 2009				
021436 017	ARIPIPRAZOLE; ABILIFY	4734416	MAR 29, 2005				
021436 018	ARIPIPRAZOLE; ABILIFY	5006528	OCT 20, 2009				
021436 019	ARIPIPRAZOLE; ABILIFY	4734416	MAR 29, 2005				
021436 020	ARIPIPRAZOLE; ABILIFY	5006528	OCT 20, 2009				

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

* PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME ; TRADE NAME NUMBER	PATENT NUMBER	PATENT/PED	EXCL	USE	EXCLUS	EXCLUS
			EXPIRES	CODE	CODE	EXPIRES	
021387 001	ASPIRIN; PRAVIGARD PAC (COPAC	4346227 4346227*PED	OCT 20, APR 20,	2005 2006			
		5030447 5030447*PED	JUL 09, JAN 09,	2008 2009			
		5180589 5180589*PED	JUL 09, JAN 09,	2208 2009			
		5622985 5622985*PED	APR 22, OCT 22,	2014 2014	U-335 U-335		
021387 002	ASPIRIN; PRAVIGARD PAC (COPAC	4346227 4346227*PED	OCT 20, APR 20,	2005 2006			
		5030447 5030447*PED	JUL 09, JAN 09,	2008 2009			
		5622985 5622985*PED	APR 22, OCT 22,	2014 2014	U-335 U-335		
		5180589 5180589*PED	JUL 09, JAN 09,	2008 2009			
021387 003	ASPIRIN; PRAVIGARD PAC (COPAC	4346227 4346227*PED	OCT 20, APR 20,	2005 2006			
		5030447 5030447*PED	JUL 09, JAN 09,	2008 2009			
		5180589 5180589*PED	JUL 09, JAN 09,	2008 2009			
		5622985 5622985*PED	APR 22, OCT 22,	2014 2014	U-335 U-335		
021387 004	ASPIRIN; PRAVIGARD PAC (COPAC	4346227 4346227*PED	APR 20, APR 20,	2005 2006			
		5030447 5030447*PED	JUL 09, JAN 09,	2008 2009			
		5622985 5622985*PED	OCT 22, OCT 22,	2014 2014	U-335 U-335		
021387 005	ASPIRIN; PRAVIGARD PAC (COPAC	4346227 4346227*PED	APR 20, APR 20,	2005 2006			
		5180589 5180589*PED	JUL 09, JAN 09,	2008 2009			
		5622985 5622985*PED	APR 22, OCT 22,	2014 2014	U-335 U-335		
021387 006	ASPIRIN; PRAVIGARD PAC (COPAC	4346227 4346227*PED	APR 20, APR 20,	2005 2006			
		5030447 5030447*PED	JUL 09, JAN 09,	2008 2009			
		5180589 5180589*PED	JUL 09, JAN 09,	2008 2009			
		5622985 5622985*PED	APR 22, OCT 22,	2014 2014	U-335 U-335		

PRESCRIBPTION AND OTC DRUG PRODUCT

**INDOXYL AND SIC DRUG PRODUCTS
PATENT AND EXCLUSIVITY DATA**
* PED and PED represent Pediatric Exclusivity

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/ PED EXPIRES	EXCL CODE	USE CODE	EXCLUS EXPIRES
>ADD>	021567 001	ATAZANAVIR SULFATE; REYATAZ	5849911 APR 09, 2017	NCE	JUN 20,	
>ADD>	021567 002	ATAZANAVIR SULFATE; REYATAZ	6087383 DEC 21, 2018	NCE	JUN 20,	
>ADD>	021567 003	ATAZANAVIR SULFATE; REYATAZ	5849911 APR 09, 2017	NCE	JUN 20,	
>ADD>	021411 001	ATOMOXETINE HYDROCHLORIDE; STRATTERA	5849911 APR 09, 2017	NCE	JUN 20,	
>ADD>	021411 002	ATOMOXETINE HYDROCHLORIDE; STRATTERA	6087383 DEC 21, 2018	NCE	JUN 20,	
>ADD>	021411 003	ATOMOXETINE HYDROCHLORIDE; STRATTERA	5658590 JAN 11, 2015	U-494	NCE	NOV 26,
>ADD>	021411 004	ATOMOXETINE HYDROCHLORIDE; STRATTERA	5658590 * PED JUL 11, 2015	U-494	PED	MAY 26,
>ADD>	021411 005	ATOMOXETINE HYDROCHLORIDE; STRATTERA	5658590 * PED JAN 11, 2015	U-494	NCE	NOV 26,
>ADD>	021411 006	ATOMOXETINE HYDROCHLORIDE; STRATTERA	5658590 * PED JUL 11, 2015	U-494	PED	MAY 26,
>ADD>	021078 001	ATOVAQUONE; MALARONE	5658590 * PED JAN 11, 2015	U-494	PED	MAY 26,
>ADD>	021078 002	ATOVAQUONE; MALARONE PEDIATRIC	5658590 * PED JUL 11, 2015	U-494	PED	MAY 26,
>ADD>	020259 001	ATOVAQUONE; MEPRON	6166046 NOV 25, 2013	U-406	NC	JUL 14, 2016
>ADD>	020500 001	ATOVAQUONE; MEDRON	5053432 OCT 01, 2008	PED	JAN 14,	2014
>ADD>	021470 001	AZELAIC ACID; FINACEA	6166046 * PED MAY 25, 2014	U-406	NC	JUL 14, 2014
>ADD>	019851 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	6166046 * PED MAY 25, 2014	U-406	NC	JUL 14, 2014
>ADD>	019851 002	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	6166046 * PED MAY 25, 2014	U-406	NC	JUL 14, 2014
>ADD>	019851 003	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	6166046 * PED MAY 25, 2014	U-406	NC	JUL 14, 2014
>ADD>	019851 004	BENAZEPRIL HYDROCHLORIDE; LOTENSIN	6166046 * PED MAY 25, 2014	U-406	NC	JUL 14, 2014
>ADD>	020033 001	BENAZEPRIL HYDROCHLORIDE; LOTENSIN HCT	6166046 * PED MAY 25, 2014	U-406	NC	JUL 14, 2014

PREScription AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 * PED and PED represent Pediatric Exclusivity

APL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCL CODE	EXCLUS CODE	EXCLUS EXPIRES	
021392 002	DILTAZEM HYDROCHLORIDE; CARDIZEM LA	5288505	JUN 26, 2011	NDF	FEB 06,	2006		
021392 003	DILTAZEM HYDROCHLORIDE; CARDIZEM LA	5529791	JUN 25, 2013	NDF	FEB 06,	2006		
021392 004	DILTAZEM HYDROCHLORIDE; CARDIZEM LA	5288505	JUN 26, 2013	NDF	FEB 06,	2006		
021392 005	DILTAZEM HYDROCHLORIDE; CARDIZEM LA	5529791	JUN 25, 2013	NDF	FEB 06,	2006		
021392 006	DILTAZEM HYDROCHLORIDE; CARDIZEM LA	5288505	JUN 26, 2011	NDF	FEB 06,	2006		
020401 006	DILTAZEM HYDROCHLORIDE; TIAZAC	5529791	JUN 25, 2013	NDF	FEB 06,	2006		
021168 001	DIVALPROEX SODIUM; DEPAKOTE ER	5529791	JUN 25, 2013	NDF	FEB 06,	2006		
021168 002	DIVALPROEX SODIUM; DEPAKOTE ER	6511678	DEC 18, 2018	DEC 18,	2018			
020941 001	DOCOSANOL; ACREVA	4874794	APR 28,	2014	U-248			
020972 001	EFAVIRENZ; SUSTIVA	6555133	APR 06,	2019	U-248			
020972 002	EFAVIRENZ; SUSTIVA	6555133	APR 06,	2019	U-248			
020972 003	EFAVIRENZ; SUSTIVA	5663169	SEP 02,	2014	U-248			
021360 001	EFAVIRENZ; SUSTIVA	5210085	MAY 11,	2010	NCE	JUL 02,	2008	
021500 001	EMTRICITABINE; EMTRIVA	5814639	SEP 29,	2015				
>ADD>		5914331	SEP 29,	2015				
>ADD>		5464933	JUN 07,	2013	NCE	MAR 13,	2008	
021481 001	ENUVIRTIDE; FUZEON	6133418	JUN 07,	2013	U-248			
		6475491	JUN 07,	2015				
		6500867	JUN 29,	2020				
		5112861	MAY 12,	2009				
>ADD>	020164 007	ENOXAPARIN SODIUM; LOVENOX	4692435	DEC 24,	2004	I-315	NOV 17,	2003
>ADD>	020164 008	ENOXAPARIN SODIUM; LOVENOX	5389618	FEB 14,	2012	I-315	NOV 17,	2003
>ADD>	020164 009	ENOXAPARIN SODIUM; LOVENOX	6534093	DEC 08,	2019	U-3		
>ADD>		EPLERENONE; INSPIRA	6534093	DEC 08,	2019	U-3		
021437 001	EPLERENONE; INSPIRA	6534093	DEC 08,	2019	U-3			
021437 002	EPLERENONE; INSPIRA	6528540	JAN 12,	2021				
021437 003	ESMOLYL HYDROCHLORIDE; BREVIBLOC	4593119	JUN 03,	2003				
019386 004		6310094	JAN 12,	2021				
019386 006	ESMOLYL HYDROCHLORIDE; BREVIBLOC	6528540	JAN 12,	2021				
		4593119	JUN 03,	2003				
>ADD>	019386 007	ESMOLYL HYDROCHLORIDE; BREVIBLOC	6310094	JAN 12,	2021			
>ADD>		4593119	JUN 03,	2003				
>ADD>	019386 005	ESMOLYL HYDROCHLORIDE; BREVIBLOC DOUBLE STR	6310094	JAN 12,	2021			
		4593119	JUN 03,	2003				
		6310094	JAN 12,	2021				

PED and PED represent Pediatric Exclusivity
PATENT AND EXCLUSIVITY DATA
PRESCRIPTION AND OTC DRUG PRODUCT

* PED and PED represent Pediatric Exclusivity

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVE
DISTRIBUTOR

* PED and PED represent Pediatric Exclusivity
EXCLUSIVITY AND EXCLUSIVITY DATA

APPL / PROD INGREDIENT NAME; TRADE NAME

PREScription AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

*PED and PED represent Pediatric Excl

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	USE CODE	EXCLUS IVE CODE	EXCLUS IVE EXPIRES
019958 001	FLUTICASONE PROPIONATE; CUTIVATE	4 335121	NOV 14, 2003			
020121 001	FLUTICASONE PROPIONATE; FLONASE	4 335121*PED	MAY 14, 2004	D-76	MAY 23, 2005	
		4 335121	NOV 14, 2003	PED	NOV 23, 2005	
		4 335121*PED	MAY 14, 2004	M-24	MAY 01, 2006	
				PED	NOV 01, 2006	
020548 001	FLUTICASONE PROPIONATE; FLOVENT	4 335121	NOV 14, 2003			
020548 002	FLUTICASONE PROPIONATE; FLOVENT	4 335121*PED	MAY 14, 2004			
020548 003	FLUTICASONE PROPIONATE; FLOVENT	4 335121	NOV 14, 2003			
020549 001	FLUTICASONE PROPIONATE; FLOVENT	4 335121*PED	MAY 14, 2004			
020549 002	FLUTICASONE PROPIONATE; FLOVENT	4 335121*PED	MAY 14, 2004			
020549 003	FLUTICASONE PROPIONATE; FLOVENT	4 335121*PED	MAY 14, 2004			
020833 001	FLUTICASONE PROPIONATE; FLOVENT DISKUS 50	4 335121	NOV 14, 2003			
020833 002	FLUTICASONE PROPIONATE; FLOVENT DISKUS 100	4 335121*PED	MAY 14, 2004			
020833 003	FLUTICASONE PROPIONATE; FLOVENT DISKUS 250	4 335121	NOV 14, 2003			
020261 001	FLUVASTATIN SODIUM; LESCOL	4 335121*PED	MAY 14, 2004			
020261 002	FLUVASTATIN SODIUM; LESCOL	5354772	OCT 11, 2011	U-409	U-409	
021192 001	FLUVASTATIN SODIUM; LESSCOL XL	5354772	OCT 11, 2011	U-413	U-409	
>ADD>	020961 001	5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-413	I-394	MAY 27, 2006
>ADD>		5354772	OCT 11, 2011	U-109	I-394	MAY 27, 2006
>ADD>	019915 002	FOSINOPRIL SODIUM; MONOPRIL	MAR 08, 2019		I-397	JUN 17, 2006
>ADD>	021345 001	FONDAPARINUX SODIUM; ARIXTRA FORMOTEROL FUMARATE; FORADIL			I-342	SEP 25, 2004
>ADD>	020831 001				NPP	MAY 27, 2006
>ADD>	019915 003	FOSINOPRIL SODIUM; MONOPRIL			PED	NOV 27, 2006
>ADD>						

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD> >ADD> >ADD>	019915 004 POSINOPRIL SODIUM; MONOPRIL	4337201 5006344 5006344*PED	DEC 04, JUL 10, JUN 04,	2002 2009 2010	NPP PED	MAY 27, NOV 27,	2006 2006
020286 001	POSINOPRIL SODIUM; MONOPRIL-HCT	4337201*PED 4337201 5006344 5006344*PED	JUN 04, DEC 04, JUL 10, JAN 10,	2003 2002 2009 2010			
020286 002	POSINOPRIL SODIUM; MONOPRIL-HCT	4337201*PED 4337201 5006344 5006344*PED	JUN 04, DEC 04, JUL 10, JAN 10,	2003 2002 2009 2010			
>ADD> >ADD> >ADD> >ADD> >ADD> >ADD>	021061 001 GATIFLOXACIN; TEQUIN 021061 002 GATIFLOXACIN; TEQUIN 021062 001 GATIFLOXACIN; TEQUIN 021062 002 GATIFLOXACIN; TEQUIN 021062 003 GATIFLOXACIN; TEQUIN 021062 004 GATIFLOXACIN; TEQUIN 021493 001 GATIFLOXACIN; ZYMAR	5880283 4980470 5457105 5616582 5707059 6262071 6331550 6340689 6455540 5633262 5716944 5962468 5091190 5545413 5091190 5545413 4612008 5024843 5082668 5091190 5545413 5591454 5952340 5952340 6372252 5616599	DEC 05, DEC 15, JAN 19, JAN 19, APR 26, SEP 21, SEP 21, SEP 14, SEP 21, JUN 15, JUN 15, JUN 15, SEP 05, SEP 05, JUL 21, SEP 05, JUL 21, SEP 16, SEP 05, SEP 16, JUL 21, JUL 21, JAN 07, SEP 14, SEP 14, APR 28, APR 01,	2015 2009 2013 2013 2016 2019 2019 2019 2019 2015 2015 2015 2003 2003 2009 2008 2014 2016 2016 2020 2014	I-329 I-329 OCT 17, OCT 17, I-329 OCT 17, I-329 OCT 17, NDF NCE NCE NCE APR 04,	OCT 17, OCT 17, 2005 2005 2005 2005 2005 2006 2004 2004 2008	
>ADD> >ADD>	021399 001 GEFITINIB; IRESSA						
021158 001	GEMIFLOXACIN MESYLATE; FACTIVE						
020329 001	GLIPIZIDE; GLUCOTROL XL						
020329 002	GLIPIZIDE; GLUCOTROL XL						
020329 003	GLIPIZIDE; GLUCOTROL XL						
>ADD> >ADD>	020239 001 GRANISETRON HYDROCHLORIDE; KYTRIL 020239 002 GRANISETRON HYDROCHLORIDE; KYTRIL 021282 002 GUAIFENESIN; MUCINEX 021532 002 HYDROCHLOROTHIAZIDE; BENICAR HCT						

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	PATENT/PED EXCL USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021532 003	HYDROCHLOROTHIAZIDE; BENICAR HCT	5616599	APR 01, 2014	U-500 NCE	JUN 05, 2006	
021532 005	HYDROCHLOROTHIAZIDE; BENICAR HCT	5616599	APR 01, 2014	U-500 NCE	APR 25, 2007	
020818 003	HYDROCHLOROTHIAZIDE; DIOVAN HCT	5399578	MAR 21, 2012	U-3	JUN 05, 2006	
>ADD>		6294197	JUN 18, 2017	U-3	APR 25, 2007	
>ADD>		6599531	JUN 10, 2017			
020716 001	HYDROCODONE BITARTRATE; VICOPROFEN	4794106	AUG 28, 2006			
020453 001	HYDROCORTISONE PROBUTATE; PANDEL	4927814	JUL 09, 2007	U-520 NCE	MAY 16, 2008	
021455 001	IBANDRONATE SODIUM; BONIVA	6143326	APR 21, 2017	U-520		
>ADD>		6294196	OCT 07, 2019			
>ADD>		6248726	JUN 19, 2018	U-495		
021321 001	ICODEXTRIN; EXTRANEAL	4761237	AUG 02, 2005	U-495		
		4886789	DEC 12, 2006	U-495		
		6077836	JUN 20, 2017	U-495		
021335 001	IMATINIB MESYLATE; GLEEVEC	5521184	MAY 28, 2013		I-392	MAY 20, 2006
021335 002	IMATINIB MESYLATE; GLEEVEC				I-392	MAY 20, 2006
021588 001	IMATINIB MESYLATE; GLEEVEC				NCE	MAY 10, 2006
021588 002	IMATINIB MESYLATE; GLEEVEC				I-376	DEC 20, 2005
					ODE	FEB 01, 2009
					ODE	FEB 01, 2009
					ODE	MAY 10, 2008
					ODE	MAY 20, 2006
					I-392	MAY 20, 2006
					NCE	MAY 10, 2006
					I-376	DEC 20, 2005
					ODE	FEB 01, 2009
					ODE	FEB 01, 2009
021081 001	INSULIN GLARGINE; LANTUS	4364921	MAR 06, 2005	U-498		
021425 001	IOPROMIDE; ULTRAVIST (PHARMACY	4364921	MAR 06, 2005	U-498		
021425 002	IOPROMIDE; ULTRAVIST (PHARMACY	5110493	MAY 05, 2009	NP	MAY 30, 2006	
021528 001	KETOROLAC TROMETAMINE; ACULAR LS	5110493* PED	NOV 05, 2009			
020857 001	LAMIIVUDINE; COMBIVIR	5047407* PED	MAY 17, 2010			
		5047407	NOV 17, 2009			
021003 001	LAMIIVUDINE; EPIVIR-HBV	5047407	NOV 17, 2009			
021004 001	LAMIIVUDINE; EPIVIR-HBV	5047407	NOV 17, 2009			
		5047407* PED	MAY 17, 2010			
020241 001	LAMOTRIGINE; LAMICTAL				I-387	JAN 17, 2006
020241 002	LAMOTRIGINE; LAMICTAL				I-387	JAN 17, 2006
020241 003	LAMOTRIGINE; LAMICTAL				I-387	JAN 17, 2006
020241 004	LAMOTRIGINE; LAMICTAL				I-387	JAN 17, 2006
020241 005	LAMOTRIGINE; LAMICTAL				I-387	JAN 17, 2006
020241 006	LAMOTRIGINE; LAMICTAL				I-387	JAN 17, 2006

PRESCRIPTION AND OTC DRUG PRODUCTION

PATENT AND EXCLUSIVITY DATA

*BED and BED represent Bediatric Evaluation Index.

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCLUS EXPIRES
020764 001	LAMOTRIGINE ; LAMICTAL CD			I-387	JAN 17,	2006
020764 002	LAMOTRIGINE ; LAMICTAL CD			I-387	JAN 17,	2006
020764 003	LAMOTRIGINE ; LAMICTAL CD			I-387	JAN 17,	2006
020764 004	LAMOTRIGINE ; LAMICTAL CD			I-387	JAN 17,	2006
021281 001	LANSOPRAZOLE ; PREVACID >ADD>	46228098	MAY 10, 2009			
>ADD>		4689333	JUL 29, 2005			U-126
>ADD>		5013743	FEB 12, 2010			U-452
>ADD>		5026560	JUN 25, 2008			
>ADD>		5045321	SEP 03, 2008			
>ADD>		5093132	SEP 03, 2008			
>ADD>		5433959	SEP 03, 2008			
>ADD>		4628098	MAY 10, 2009			
>ADD>		4689313	JUL 29, 2005			U-126
>ADD>		5013743	FEB 12, 2010			U-452
>ADD>		5026560	JUN 25, 2008			
>ADD>		5045211	SEP 03, 2008			
>ADD>		5093132	SEP 03, 2008			
>ADD>		5433959	SEP 03, 2008			
021281 002	LANSOPRAZOLE ; PREVACID >ADD>	4938763	OCT 03, 2008			
>ADD>		527801	JAN 11, 2011			
>ADD>		5324719	OCT 20, 2011			
>ADD>		5599552	FEB 04, 2014			
>ADD>		5733950	OCT 03, 2008			
>ADD>		5739176	OCT 03, 2008			
>ADD>		5362755	NOV 08, 2011			
>ADD>		4941639	JUN 06, 2006			
>ADD>		4943639	JUN 06, 2006			
>ADD>		4941639	JUN 06, 2006			
>ADD>		4943639	JUN 06, 2006			
>ADD>		4837223	JUN 06, 2006			
020905 001	LEFLUNOMIDE ; ARAVA 020905 002			I-395	JUN 13,	2006
020905 003	LEFLUNOMIDE ; ARAVA LEUPROLIDE ACETATE ; ELIGARD >ADD>			I-395	JUN 13,	2006
021488 001				I-395	JUN 13,	2006
>ADD>				NP	FEB 13,	2006
020905 001	LEFLUNOMIDE ; ARAVA 020905 002			I-395	JUN 13,	2006
020905 003	LEFLUNOMIDE ; ARAVA LEUPROLIDE ACETATE ; ELIGARD >ADD>			I-395	JUN 13,	2006
021488 001						
020837 001	LEVABUTEROL HYDROCHLORIDE ; XOPENEX >ADD>			I-332		
021035 001	LEVETIRACETAM ; KEPRA >ADD>					
021035 002	LEVETIRACETAM ; KEPRA >ADD>					
021035 003	LEVETIRACETAM ; KEPRA LEVETIRACETAM ; KEPRA >ADD>					
021505 001	LEVETIRACETAM ; KEPRA >ADD>					
020634 001	LEVOFLOXACIN ; LEVAQUIN 020634 002			I-393	MAY 23,	2006
020634 003	LEVOFLOXACIN ; LEVAQUIN LEVOFLOXACIN ; LEVAQUIN >ADD>			I-393	MAY 23,	2006
020635 001	LEVOFLOXACIN ; LEVAQUIN 020635 002			I-393	MAY 23,	2006
020635 003	LEVOFLOXACIN ; LEVAQUIN IN DEXTROSE 021199 001			I-393	MAY 23,	2006
021301 001	LEVOFLOXACIN SODIUM ; LEVOXYL 021301 002			I-393	MAY 23,	2006
021301 003	LEVOFLOXACIN SODIUM ; LEVOXYL LEVOFLOXACIN SODIUM ; LEVOXYL LEVOFLOXACIN SODIUM ; LEVOXYL >ADD>			I-393	MAY 23,	2006
021301 004						
5503407	DEC 20, 2010					
6555581	FEB 15, 2022					
6555581	FEB 15, 2022					
6555581	FEB 15, 2022					
6555581	FEB 15, 2022					

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

*BED and BED represent Pediatric Exclusion

*PED and PED represent Pediatric Exclusivity

INGREDIENT NAME; TRADE NAME

PATENT / PED EXCL USE EXCLUS
EXPIRES CODE CODE EXPIRES

PATENT
NUMBER

APPL/PROD
NUMBER

021301 005 LEVOTHYROXINE SODIUM; LEVOXYL
 021301 006 LEVOTHYROXINE SODIUM; LEVOXYL
 021301 007 LEVOTHYROXINE SODIUM; LEVOXYL
 021301 008 LEVOTHYROXINE SODIUM; LEVOXYL
 021301 009 LEVOTHYROXINE SODIUM; LEVOXYL
 021301 010 LEVOTHYROXINE SODIUM; LEVOXYL
 021301 011 LEVOTHYROXINE SODIUM; LEVOXYL
 021301 012 LEVOTHYROXINE SODIUM; LEVOXYL
 LIDOCAINE; LIODERM
 020612 001

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

* PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCLUSIVITY CODE	EXCLUSIVITY EXPRIES
020641 002	LORATADINE; CLARITIN	4659716 4659716*PED 4863931 4863931*PED	APR 21, 2004 OCT 21, 2004 SEP 15, 2008 MAR 15, 2009			U-142 U-142 U-142	
020704 002	LORATADINE; CLARITIN REDITABS	6132758 4659716 4863931	JUN 01, 2018 APR 21, 2004 SEP 15, 2008			U-142 U-142	
019670 002	LORATADINE; CLARITIN-D	4863931*PED 4659716*PED 4863931 4863931*PED	MAR 15, 2009 APR 21, 2004 SEP 15, 2008 MAR 15, 2009			U-142 U-142 U-142	
020470 002	LORATADINE; CLARITIN-D 24 HOUR	4863931*PED 4659716*PED 4863931*PED 5314697	APR 21, 2004 OCT 21, 2004 SEP 15, 2008 OCT 23, 2012			U-142 U-142	
075209 001	LORATADINE; LORATADINE	5210079 5210079*PED 5210079 5210079*PED	MAY 11, 2010 NOV 11, 2010 MAY 11, 2010 NOV 11, 2010			U-496 U-496 U-496 U-496	
075822 001	LORATADINE; LORATADINE	5210079 5210079*PED 5210079 5210079*PED	MAY 11, 2010 NOV 11, 2010 MAY 11, 2010 NOV 11, 2010			I-383 I-383 I-383 I-383	
075706 001	LORATADINE; LORATADINE AND PSEUD	5210079 5210079*PED 5210079 5210079*PED	MAY 11, 2010 NOV 11, 2010 MAY 11, 2010 NOV 11, 2010			SEP 17, 2005	
076050 001	LORATADINE; LORATADINE AND PSEUD	5210079 5210079*PED 5210079 5210079*PED	MAY 11, 2010 NOV 11, 2010 MAY 11, 2010 NOV 11, 2010				
020386 001	LOSARTAN POTASSIUM; COZAR	5210079 5210079*PED 5210079 5210079*PED	MAY 11, 2010 NOV 11, 2010 MAY 11, 2010 NOV 11, 2010				
020386 002	LOSARTAN POTASSIUM; COZAR	5210079 5210079*PED 5210079 5210079*PED	MAY 11, 2010 NOV 11, 2010 MAY 11, 2010 NOV 11, 2010				
020386 003	LOSARTAN POTASSIUM; COZAR	5210079 5210079*PED 5210079 5210079*PED	MAY 11, 2010 NOV 11, 2010 MAY 11, 2010 NOV 11, 2010				
021410 001	METFORMIN HYDROCHLORIDE; AVANDAMET	5210079 5210079*PED 5210079 5210079*PED	MAY 11, 2010 NOV 11, 2010 MAY 11, 2010 NOV 11, 2010				
021410 002	METFORMIN HYDROCHLORIDE; AVANDAMET	5210079 5210079*PED 5210079 5210079*PED	MAY 11, 2010 NOV 11, 2010 MAY 11, 2010 NOV 11, 2010				
021202 004	METFORMIN HYDROCHLORIDE; GLUCOPHAGE XR	6475521 6344215 6344215 6344215	MAR 19, 2018 OCT 27, 2020 OCT 27, 2020 OCT 27, 2020				
021259 002	METHYLPHENIDATE HYDROCHLORIDE; METADATE CD	4927640 5472969 5525616	MAY 22, 2007 MAY 13, 2013 JUN 11, 2013				
021259 003	METHYLPHENIDATE HYDROCHLORIDE; METADATE CD	4927640 5472969 5525616	MAY 22, 2007 MAY 13, 2013 JUN 11, 2013				
>ADD>	019962 003	METOPROLOL SUCCINATE; TOPROL-XL					
>ADD>	021348 001	MIGLUSTAT; ZAVESCA					
>ADD>	076119 001	MIRTAZAPINE; MIRTAZAPINE					
	076119 002	MIRTAZAPINE; MIRTAZAPINE					
	076204 001	MOEXIPRIL HYDROCHLORIDE; MOEXIPRIL HCL					
	076204 002	MOEXIPRIL HYDROCHLORIDE; MOEXIPRIL HCL					
	021085 001	MOXIFLOXACIN HYDROCHLORIDE; AVELOX					
	021277 001	MOXIFLOXACIN HYDROCHLORIDE; AVELOX IN SODIUM CHL	4990517 5607942 5849752	JUN 30, 2009 MAR 04, 2014 DEC 05, 2016		U-298 I-385 U-298	

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

* PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	EXCL USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021598 001	MOXIFLOXACIN HYDROCHLORIDE; VIGAMOX	4990517	JUN 30, 2009			
		5607942	MAR 04, 2014			
		5849752	DEC 05, 2016			
		4990517*PED	DEC 30, 2009			
		5607942*PED	SEP 04, 2014			
		5849752*PED	JUN 05, 2017			
021204 001	NATEGLINIDE; STARLIX	6559188	SEP 17, 2019			
021204 002	NATEGLINIDE; STARLIX	6559188	SEP 17, 2019			
020636 001	NEVIRAPINE; VIRAMUNE	5366972	NOV 22, 2011			
020933 001	NEVIRAPINE; VIRAMUNE	5366972*PED	MAY 22, 2012			
021330 001	NICOTINE; POLACRILEX; COMMIT	5366972*PED	MAY 22, 2012			
021330 002	NICOTINE; POLACRILEX; COMMIT	5110605	AUG 21, 2010			
020076 004	NICOTINE; HABITROL	5110605	AUG 21, 2010			
020076 005	NICOTINE; HABITROL	4597961	JAN 23, 2005			
020076 006	NICOTINE; HABITROL	5016652	MAY 21, 2008			
019983 003	NICOTINE; PROSTEP	5016652	MAY 21, 2008			
019983 004	NICOTINE; PROSTEP	4946853	AUG 07, 2007			
021498 001	NITAZOXANIDE; ALINIA	5387598	FEB 07, 2012			
>ADD>		5578621	SEP 08, 2014			
>ADD>		5965590	JUL 03, 2017			
>ADD>		5968961	MAY 07, 2017			
>ADD>		6020353	SEP 08, 2014			
>ADD>		6117894	MAY 07, 2017			
>ADD>		5006158	APR 09, 2008			
>ADD>		5550165	AUG 27, 2013			
>ADD>		5006158	APR 09, 2008			
>ADD>		5550165	AUG 27, 2013			
>ADD>		5006158	APR 09, 2008			
>ADD>		5550165	AUG 27, 2013			
>ADD>		5873359	JAN 23, 2013			
>ADD>		5873359	U-297			
>ADD>		4382892	SEP 02, 2003			
>ADD>		4551456	NOV 14, 2003			
>ADD>		4382892*PED	MAR 02,			
>ADD>		4551456*PED	MAY 14,			
>ADD>		5616599	APR 01,			
>ADD>		5616599	APR 01,			
>ADD>		4738974	APR 19,			
>ADD>		5900424	MAY 04,			
>ADD>		4786505	APR 20,			
>ADD>		4853230	APR 20,			
>ADD>		5690960	NOV 25,			
>ADD>		5817338	OCT 06,			
>ADD>		5753265	JUN 07,			
>ADD>		6403616	NOV 15,			
>ADD>		6428810	NOV 03,			
		4786505*PED	OCT 20,			

**PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

* PED and PED represent Pediatric Exclusivity

* PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020007 003	ONDANSETRON HYDROCHLORIDE; ZOFRAN PRESERVATIVE	4853230*PED 2007	OCT 20,'2007				
020776 001	OXAPROZIN POTASSIUM; DAYPRO ALTA	4695578	JAN 25,'2005				
017577 001	OXYBUTYNIN CHLORIDE; DITROPAN	4753789	JUN 24,'2006	U-44			
018211 001	OXYBUTYNIN CHLORIDE; DITROPAN	6030643	MAY 16,'2017	U-497	NPP	APR 15,	
020897 001	OXYBUTYNIN CHLORIDE; DITROPAN XL				PED	OCT 15,	
020897 002	OXYBUTYNIN CHLORIDE; DITROPAN XL				NPP	APR 15,	
020897 003	OXYBUTYNIN CHLORIDE; DITROPAN XL				PED	OCT 15,	
>ADD>	OXYBUTYNIN; OXYTROL				NPP	APR 15,	
>ADD>					PED	OCT 15,	
021372 001	PALONOSETRON HYDROCHLORIDE; ALOXI	5164190	DEC 11,'2010				
020936 001	PAROXETINE HYDROCHLORIDE; PAXIL CR	5601839	APR 26,'2015				
020936 002	PAROXETINE HYDROCHLORIDE; PAXIL CR	5834010	APR 26,'2015				
020936 003	PAROXETINE HYDROCHLORIDE; PAXIL CR	5202333	APR 13,'2010				
>ADD>	PAROXETINE MESYLATE; PAROXETINE MESYLATE	6548084	JUL 19,'2016				
>ADD>		6548084*PED	JAN 19,'2017				
>ADD>		6548084	JUL 19,'2016				
021299 001	PAROXETINE MESYLATE; PAROXETINE MESYLATE	6548084	JAN 19,'2017				
>ADD>	PAROXETINE MESYLATE; PAROXETINE MESYLATE	6548084	JUL 19,'2016				
>ADD>		6548084*PED	JAN 19,'2017				
>ADD>		6548084	JUL 19,'2016				
021299 002	PAROXETINE MESYLATE; PAROXETINE MESYLATE	5874447	JUN 10,'2017				
>ADD>		5874447	JUN 10,'2017				
>ADD>		5874447	JUN 10,'2017				
>ADD>		5874447	JUN 10,'2017				
021299 003	PAROXETINE MESYLATE; PAROXETINE MESYLATE	5874447	JUN 10,'2017				
>ADD>		5874447	JUN 10,'2017				
>ADD>		5874447	JUN 10,'2017				
>ADD>		5874447	JUN 10,'2017				
021299 004	PAROXETINE MESYLATE; PAROXETINE MESYLATE	5874447	JUN 10,'2017				
>ADD>		5874447	JUN 10,'2017				
>ADD>		5874447	JUN 10,'2017				
>ADD>		5874447	JUN 10,'2017				
021106 001	PEGVISOMANT; SOMAVERT	6583115	SEP 27,'2011				
>ADD>		6583115	SEP 27,'2011				
>ADD>		6057292	SEP 21,'2015				
>ADD>		5849535	SEP 21,'2015				
>ADD>		5958879	SEP 27,'2011				
>ADD>		5350836	SEP 27,'2011				
>ADD>		5681809	SEP 27,'2011				
>ADD>		6583115	SEP 27,'2011				
>ADD>		6057292	SEP 21,'2015				
>ADD>		5849535	SEP 21,'2015				
>ADD>		5958879	SEP 27,'2011				
>ADD>		5350836	SEP 27,'2011				
>ADD>		5681809	SEP 27,'2011				
>ADD>		6583115	SEP 27,'2011				
>ADD>		6057292	SEP 21,'2015				
>ADD>		5849535	SEP 21,'2015				
>ADD>		5958879	SEP 27,'2011				
>ADD>		5350836	SEP 27,'2011				
>ADD>		5681809	SEP 27,'2011				
>ADD>		6583115	SEP 27,'2011				
>ADD>		6057292	SEP 21,'2015				
>ADD>		5849535	SEP 21,'2015				
>ADD>		5958879	SEP 27,'2011				
>ADD>		5350836	SEP 27,'2011				
>ADD>		5681809	SEP 27,'2011				
>ADD>		6583115	SEP 27,'2011				

PREScription AND OTC DRUG PRODUCT
 PATENT AND EXCLUSIVITY DATA
 * PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCL CODE	EXCLUS EXPIRES
>ADD> 021106 003	PEGVISOMANT; SOMAVERT	6583115 6057292 5849535 598879 5350836 5618015 6469015 6573378 6579981	SEP 27, 2011 SEP 21, 2015 SEP 21, 2015 SEP 27, 2011 SEP 27, 2011 SEP 27, 2011 OCT 22, 2019 SEP 24, 2010 JUN 17, 2020	U-507 U-507 U-507 U-507 U-507 U-507 U-501 U-501	NCE	MAR 25, 2008	
020629 001	PENCICLOVIR SODIUM; DENAVIR						
076061 001 076061 002 076061 003	PERGOLIDE MESYLATE; PERGOLIDE MESYLATE PERGOLIDE MESYLATE; PERGOLIDE MESYLATE PERGOLIDE MESYLATE; PERGOLIDE MESYLATE	4687777 4687777 6150384 4687777	JAN 17, 2011 JAN 17, 2011 JUN 19, 2016 JAN 17, 2011				
021073 001 021073 002 021073 003	PIOGLITAZONE HYDROCHLORIDE; ACTOS PIOGLITAZONE HYDROCHLORIDE; ACTOS PIOGLITAZONE HYDROCHLORIDE; ACTOS	6500454 6500454 5403856 5403856 5403856 5403856 6524570 6524570*	DEC 31, 2022 DEC 31, 2022 APR 04, 2012 APR 01, 2012 APR 01, 2012 APR 04, 2012 NOV 01, 2016 MAY 01,				
>ADD> 020451 001	PORFIMER SODIUM; PHOTOFIN						
074726 003 021438 001 021438 002	POTASSIUM CHLORIDE; KLOR-CON M15 PROPRANOLOL HYDROCHLORIDE; INNOPRAN XL PROPRANOLOL HYDROCHLORIDE; INNOPRAN XL	6500454 6500454 5403856 5403856 5403856 5403856 6524570 6524570*	DEC 31, 2022 DEC 31, 2022 APR 04, 2012 APR 01, 2012 APR 01, 2012 APR 04, 2012 NOV 01, <td></td> <td></td> <td></td> <td></td>				
019901 001 019901 002 019901 003 019901 004 020903 001	RAMIPRIL; ALTACE RAMIPRIL; ALTACE RAMIPRIL; ALTACE RAMIPRIL; ALTACE RIBAVIRIN; REBETOL	6472373 6472373*PED 6461605 6461605*PED 6172046 6172046*PED 6063772 6063772*PED 5767097 5767097*PED 6096342 6096342	SEP 21, 2017 SEP 21, 2017 NOV 01, 2016 MAY 01, 2017 SEP 21, 2017 MAR 21, 2018 JAN 23, 2016 JUL 23, 2016 JAN 23, 2016 JUL 23, 2016 NOV 22, 2011 NOV 22, 2011				
020903 002 021546 001	RIBAVIRIN; REBETOL RIBAVIRIN; REBETOL						
>ADD> >ADD> >ADD> >ADD> >ADD> >ADD> >ADD> >ADD>		6472373*PED 6461605 6461605*PED 6172046 6172046*PED 6063772 6063772*PED 5767097 5767097*PED 6096342 6096342					
020835 001 020835 002 020835 003	RISEDRONATE SODIUM; ACTONEL RISEDRONATE SODIUM; ACTONEL RISEDRONATE SODIUM; ACTONEL	5583122 6096342 6165513 4804663 5648093 6224905	DEC 10, 2013 NOV 22, 2011 JUN 10, 2018 DEC 29, 2007 JUL 15, 2004 JUN 10, 2017				
021444 001	RISPERIDONE; RISPERDAL						

PREScription AND OTC DRUG PRODUCT
PATIENT AND EXCLUSIVITY DATA
* PED and PED represent Pediatric Exclusivity

*PED and PED represent Pediatric Exclusivity

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

* PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME ; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020231 001	SODIUM FLUORIDE;COLGATE TOTAL	5288480	JUL 16, 2008	ODE	OCT 31,	2004
020280 007	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT			ODE	OCT 31,	2004
020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT			ODE	OCT 31,	2004
020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT			ODE	OCT 31,	2004
020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT			ODE	OCT 31,	2004
020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT			ODE	OCT 31,	2004
020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT			ODE	OCT 31,	2004
020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT			ODE	OCT 31,	2004
020280 010	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT			ODE	OCT 31,	2004
020280 011	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT			ODE	OCT 31,	2004
020280 012	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT			ODE	OCT 31,	2004
020280 013	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT			I-398	JUL 25,	2006
>ADD>	SOMATROPIN RECOMBINANT;HUMATROPE			I-398	JUL 25,	2006
>ADD>	SOMATROPIN RECOMBINANT;HUMATROPE			I-398	JUL 25,	2006
>ADD>	SOMATROPIN RECOMBINANT;HUMATROPE			I-398	JUL 25,	2006
>ADD>	SOMATROPIN RECOMBINANT;HUMATROPE			I-398	JUL 25,	2006
019640 005	SOMATROPIN RECOMBINANT;HUMATROPE	5633352	MAY 27,	2014		
019640 006	SOMATROPIN RECOMBINANT;HUMATROPE	5633352	MAY 27,	2014		
019640 007	SOMATROPIN RECOMBINANT;HUMATROPE	5633352	MAY 27,	2014		
021148 001	SOMATROPIN RECOMBINANT;NORDITROPIN	5849700	DEC 15,	2015	U-340	
021148 002	SOMATROPIN RECOMBINANT;NORDITROPIN	5849700	DEC 15,	2015	U-340	
021148 003	SOMATROPIN RECOMBINANT;NORDITROPIN	5849700	DEC 15,	2015	U-340	
021151 005	SOTALOL HYDROCHLORIDE;BETAPACE AF	4978655	JUN 24,	2008		
021151 006	SOTALOL HYDROCHLORIDE;BETAPACE AF	4978655	JUN 24,	2008		
021151 007	SOTALOL HYDROCHLORIDE;BETAPACE AF	4978655	JUN 24,	2008		
020413 001	STAVUDINE;ZERIT	4978655*PED	DEC 24,	2008	U-248	NDF
021453 001	STAVUDINE;ZERIT XR	4978655	JUN 24,	2008	U-248	PED
021453 002	STAVUDINE;ZERIT XR	4978655*PED	DEC 24,	2008	U-248	NDF
021453 003	STAVUDINE;ZERIT XR	4978655	JUN 24,	2008	U-248	PED
021453 004	STAVUDINE;ZERIT XR	4978655*PED	DEC 24,	2008	U-248	NDF
020600 001	TAZAROTENE;TAZORAC	5914334	JUN 07,	2014	U-517	
		6258830	JUN 07,	2014	U-517	

PRESCRIPTION AND OTC DRUG PRODUCT

* PED and PED represent Pediatric Exclusivity

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

* PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021108 001 020550 001	TRETINOIN; RENOVA VALACYCLOVIR HYDROCHLORIDE; VALTREX	6531141	MAR 07, 2020			I-381	SEP 09, 2005
020550 002	VALACYCLOVIR HYDROCHLORIDE; VALTREX					I-389	APR 01, 2006
020699 001 020699 002 020699 003 020699 004 020552 001	VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR VENLAFAXINE HYDROCHLORIDE; EFFEXOR XR VERAPAMIL HYDROCHLORIDE; COVERA-HS					I-381	SEP 09, 2005
020552 002 >ADD> >ADD> >ADD> >ADD> >ADD> >ADD> >ADD> >ADD> >ADD> >ADD>	VERAPAMIL HYDROCHLORIDE; COVERA-HS VORICONAZOLE; VFEND VORICONAZOLE; VFEND VORICONAZOLE; VFEND VORICONAZOLE; VFEND ZALEPLON; SONATA ZALEPLON; SONATA ZOLEDRONIC ACID; ZOMETA ZOLMITRIPTAN; ZOMIG-ZMT	4612008 6146662 4612008 6146662 5116844 5364938 5567817 5773443 5116844 5364938 5567817 5773443 5773443 5116844 5364938 5567817 5773443 4626538 4626538 4777163 4939130 5466699	SEP 16, 2003 AUG 14, 2007 SEP 16, 2003 AUG 14, 2007 AUG 11, 2009 NOV 15, 2011 OCT 22, 2013 JAN 25, 2011 AUG 11, 2009 NOV 15, 2011 OCT 22, 2013 JAN 25, 2011 AUG 11, 2009 NOV 15, 2011 OCT 22, 2013 JAN 25, 2011 JUN 06, 2008 JUN 06, 2008 JUL 24, 2007 NOV 13, 2007 NOV 14, 2012			I-389	APR 01, 2006
021266 001 >ADD> >ADD> >ADD> >ADD>	VORICONAZOLE; VFEND					I-389	APR 01, 2006
021267 001 >ADD> >ADD> >ADD> >ADD>	VORICONAZOLE; VFEND					I-261	FEB 11, 2006
020859 001 >ADD> >ADD> >ADD>	ZALEPLON; SONATA ZALEPLON; SONATA ZOLEDRONIC ACID; ZOMETA					I-261	FEB 11, 2006
020859 002 >ADD> >ADD>	ZOLMITRIPTAN; ZOMIG-ZMT					I-261	FEB 11, 2006
021223 002 >ADD>						U-53	
021231 002 >ADD>							

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 23RD EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

PATENT & EXCLUSIVITY ABBREVIATIONS

RTO RX TO OTC SWITCH OR OTC USE

EXCLUSIVITY DOSING SCHEDULE

- D-78 USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
- D-79 NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
- D-80 CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
- D-81 NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-82 USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS

EXCLUSIVITY INDICATION

- I-380 TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
- I-381 TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
- I-382 FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
- I-383 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
- I-384 USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES
- I-385 MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD "INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN \geq 2MCG/ML" TO STREPTOCOCCUS PNEUMONIAE
- I-386 RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
- I-387 ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE
- I-388 TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
- I-389 SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS
- I-390 USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI & STROKE.....
- I-391 INTENTIONALLY LEFT BLANK
- I-392 TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL
- I-393 CHRONIC BACTERIAL PROSTATITIS
- I-394 USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES
- I-395 TO IMPROVE PHYSICAL FUNCTION

- I-396 EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION
- I-397 EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY
- I-398 IDIOPATHIC SHORT STATURE
- I-399 TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSSES, PERITONITIS AND PLEURAL SPACE INFECTIONS


EXCLUSIVITY MISCELLANEOUS

- M-23 INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
- M-24 INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
- M-25 ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT
- M-26 INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01

PATENT USE

- U-494 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
- U-495 PERITONEAL DIALYSIS SOLUTION
- U-496 METHOD FOR TREATING CHRONIC RENAL FAILURE
- U-497 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
- U-498 INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
- U-499 METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
- U-500 USE AS AN ANTIHYPERTENSIVE AGENT
- U-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
- U-502 PITYRIASIS VERSICOLOR
- U-503 GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR
- U-504 TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS
- U-505 ULTRASOUND CONTRAST AGENT
- U-506 PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAM PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE, BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..
- U-507 ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
- U-508 METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
- U-509 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
- U-510 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
- U-511 USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
- U-512 USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA
- U-513 METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA
- U-514 PREVENTION OF OVULATION IN A WOMAN
- U-515 TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
- U-516 METHOD OF TREATING A PSYCHOTIC DISEASE
- U-517 STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
- U-518 OBSESSIVE COMPULSIVE DISORDER
- U-519 POST OPERATIVE NAUSEA AND VOMITING
- U-520 PREMENOPAUSAL OSTEOPOROSIS
- U-521 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
- U-522 TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA
- U-523 METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED

- U-524 METHOD OF TREATING DIARRHEA
- U-525 METHOD OF TREATING PARASITIC INFECTIONS
- U-526 METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION
- U-527 METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE
- U-528 PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING





Approved Drug Products, ADP SUBSCRIPTION ORDER FORM

Order Processing
Code: **8392**

Easy Secure Internet:
bookstore.gpo.gov
Toll Free: 866 512-1800
Phone: 202 512-1800
Fax: 202 512-2250
Mail: Superintendent of Documents
PO Box 371954
Pittsburgh, PA 15250-7954

YES, enter my subscription(s) as follows:

_____ subscription(s) of the **Approved Drug products with Therapeutic Equivalence Evaluations, ADP**, and the monthly Cumulative Supplements, for \$108.00 per year. The total cost of my order is \$ _____. Price includes regular shipping and handling and is subject to change. International customers please add 40%.



Check method of payment:

- (Please type or print)
- Personal name _____
- Company name _____
- Street address _____
- City, State, Zip code _____
- Daytime phone including area code _____
- Purchase Order Number _____
- Authorizing signature _____
- Expiration date _____ (expiration date)
- Check payable to Superintendent of Documents
 SOD Deposit Account _____ - _____
 VISA MasterCard Discover/Novus American Express

Thank you for your order!

02/03